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ABSTRACT  
Liquid biopsy, based on the analysis of blood constituents, and more in particular, the 
study of circulating nucleic acids (CNAs) in plasma, is a less-invasive alternative to tissue 
biopsy which is showing great potential in the diagnosis and monitoring of cancer and 
other pathologies.  Sample preparation is one of the bottlenecks that prevents the wider 
applicability of CNAs based technologies in clinical settings.  Current methods for CNAs 
sample preparation involve bulky equipment and trained staff, non-compatible with near 
patient blood processing.  This thesis describes the development of a microfluidic 
platform for the fast, user-friendly and reproducible sample preparation of CNAs from 
whole blood in a single step, deployable near patient.  A fast-prototyping method 
developed to ease the iterative design of the disposable cartridges is described together 
with the design process that led to the final device.  Finally, the characterisation of clinical 
samples within the microfluidic platform, on either microRNA or cell-free DNA 
extraction, is benchmarked against the gold standard benchtop protocol, currently used in 
molecular biology laboratories.  The device is deemed to reduce sample preparation cost 
and allow analyses of samples before aging phenomena occur, thus showing the true state 
of disease. 
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CHAPTER 1: INTRODUCTION  
Circulating biomarkers, comprising fragmented DNA and RNA, miRNA, circulating 
tumour cells (CTC) and extracellular vesicles (EVs), including exosomes, have generated 
increasing interest in the past years in the scientific community.  Circulating nucleic acids 
(CNAs) enable the diagnosis, prognosis and monitoring of a range of pathologies 
including, among others, cancer, cardiac and neural diseases.  These blood-based analyses 
have been named liquid biopsy.  Liquid biopsy is a less invasive alternative to more 
intrusive solutions, such as tissue biopsy, for cancer diagnosis, and amniocentesis, for 
prenatal diagnosis.  One of the greatest sources of variability in the analysis of these 
biomarkers and, according to most, the bottleneck to overcome for the effective 
introduction into clinical practice of their potential, is sample preparation.  Blood reaches 
virtually the whole body, potentially carrying information concerning all the tissues it 
enters in contact with.  Nonetheless, to obtain clear readings of medical significance from 
the analysis of circulating biomarkers in blood, a number of steps are necessary before 
amplification or detection.  All sample preparation methods still rely on centralised 
laboratories, equipped with bulky instruments, and time-consuming procedures, handled 
by trained staff.  These requirements impair the deployment of new, CNAs based, 
diagnostic technologies near patient, at the point-of-care (POC), and in all other situations 
where there is lack of equipment or specialised staff.  This thesis describes the 
development of an integrated and automated microfluidic platform, which overcomes 
these issues and allows the standardisation of sample preparation for CNAs analysis from 
whole blood.  We hope that this approach will soon offer a real alternative in actual 
clinical settings.  
Chapter 2 covers an overview on the nature of circulating biomarkers and their clinical 
potential for early diagnostics and for monitoring conditions or treatment response.  
Additionally, it includes a review on the most recent advancement in the field obtained 
with both bench and microfluidic tools, highlighting their potential and pointing at the 
improvements that would lead to their employment in POC applications. 
Chapter 3 describes the design of microfluidic protocols and disposable microfluidic 
cartridges as well as the technical problems that were overcome during the project.  Two 
types of cartridge types are described in detail.  This chapter also describes the design and 
purpose of the automation platform that controls the NAs extraction protocol within the 
disposable cartridges. In this thesis, is not included the fluid dynamic characterisation of 
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the systems developed; indeed, for time constraints, I only focused on biological 
validation of CNAs extraction performances. 
Chapter 4 describes a method for the rapid prototyping of microfluidic cartridges in the 
context of translational research.  A rapid solvent-assisted thermal bonding method was 
developed during this project allowing manufacturing of multi-layer prototypes, from 
CAD drawing to prototype in less than 15 minutes.  The work described has been 
published in 2016 in Microfluidics and Nanofluidics and is herein introduced by a general 
introduction to microfluidic prototyping.  
Chapter 5 describes the biological validation and benchmarking of the two cartridge 
designs presented in Chapter 3 using two miRNA panels. 
Chapter 6 describes the optimisation of the microfluidic protocol for cfDNA by 
manipulating parameters such as drying conditions and physical characteristics of the 
adsorption module.  
Chapter 7 draws conclusions and final remarks and suggest future work. 
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CHAPTER 2: STATE OF THE ART 
2.1 Introduction 
The human circulatory system is the major network for cells to obtain nutrients, dispose 
of waste, receive signals and exchange information with other cells; therefore it contains 
different functional and non-functional molecular “packages”1.  Blood has virtual access 
to the whole human body and these packages can be used as a source of information on 
the tissues it soaks.  The blood liquid phase, plasma, constituted for about 90% out of 
water, carries circulating nucleic acids (CNAs), extracellular vesicles (EVs), proteins and 
molecules that can potentially be used as biomarkers for the monitoring of the clinical 
conditions of the patient.  In Figure 1 is proposed a simplified scheme of blood 
components.  
 
 
Figure 1 Blood composition and circulating biomarkers.  
The analysis of different blood constituents, also known as liquid biopsy, can be relevant 
to diverse clinical areas.  For example, serum proteins were used as biomarkers to 
characterise cancer progression2.  Likewise, the concentration levels of small molecules 
such as metabolites could help the assessment of the health status of patients, as used in 
diabetes cases with glucose, but to a broader extent3.  CNAs mostly include fragmented 
DNA, RNA and microRNA (miRNA)4.  Genetic and epigenetic alterations in DNA 
biomarkers have been identified over the past decades in several diseases such as cancer, 
immune system disorders and neurological diseases.  They can also play an important 
role when deciding personalised treatment5.  It has been shown that patients suffering 
from several pathologies have levels of CNAs higher than healthy individuals do.  Viral 
or bacterial NAs can be found in saliva at comparable concentrations as in nasal swabs6.  
In cancer patients, due to the spatial and temporal heterogeneity of tumours, a single tissue 
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biopsy might not capture the complete genomic profile of the tumour, and liquid biopsy 
on circulating tumour DNA (ctDNA) might give more reliable information7.  Tissue 
biopsy is often inconvenient and sometimes just not physically possible.  It does not allow 
for longitudinal assessment, over regular intervals of time, for treatment monitoring and 
is usually not performed in specific cases, such as when metastatic tissue is present8.  On 
the other hand liquid biopsy in metastatic diseases allows for serial assessments, including 
follow-up during remission, characterisation of treatment effect and clonal evolution9.  
Also, after radiotherapy CNAs levels in cancers patients drop by 60-90%10.  CNAs can 
also be used as rejection marker after organ transplant.  Indeed it was shown that a small 
amount of graft genomic material can be found circulating in the host plasma11.  Non-
invasive prenatal testing is another important application, avoiding the risk of 
miscarriages and infections caused by invasive procedures such as amniocentesis or 
chorionic villus sampling12.  Circulating tumour cells (CTC), are another critical source 
of biomarker that can be found through liquid biopsy in blood, and whose monitoring can 
determine guidelines for personalised treatment13.  EVs and in particular exosomes, are 
another carrier for biomarkers and raised a growing interest in the last five years.  Grail, 
a spin-out from Illumina, is investing 1 billion dollars, into blood tests detection of early 
stage cancer, financing a study which involves 7000 early diagnosed patients and 3000 
healthy volunteers14.  Other companies, such as Guardant, are working on prognostic 
tools to monitor recurrence in high risk patients.  Liquid biopsy is expected to grant 
flexibility in the interrogation of cancer molecular drivers, thus giving patients and 
clinicians a better chance at making the most efficient treatment decision in a timely 
fashion14.  Still several issues need to be addressed before the introduction of blood based 
circulating biomarkers analysis becomes a routine in critical practice.  In line with the 
statement that 70% of clinical errors are due to pre-analytical variables15, one of the 
greatest issues is the inconsistency and variability between results obtained in different 
studies, and the different time lapses at which blood is processed and shipped after blood 
draw8.  In the next sections, we are going to analyse in more detail the clinical relevance 
of CNAs on different clinical conditions, the current bench technology that deal with them 
and, finally, the microfluidic alternatives. 
2.2 Circulating Biomarkers origin and use 
2.2.1 cfDNA 
Deoxyribonucleic acids, commonly known as DNA, are macromolecules that carry the 
genomic information in all living organisms and are constituted by the repetition of 
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nucleotides.  Each nucleotide is composed by one of four nucleobases, cytosine (C), 
guanine (G), adenine (A), or thymine (T), a sugar, the deoxyribose, and a phosphate.  
Nucleotides are bonded together by sugar/phosphate covalent bonding, which forms the 
phosphate backbone of DNA, and usually arranged in a double helix by hydrogen bonding 
between the nucleobases of two paired DNA strands.  
With cell-free DNA (cfDNA) we refer to 500 bp to 30 kb double stranded DNA 
circulating in bodily fluid16 containing both genomic and mitochondrial, coding and 
noncoding, fragmented DNA8. Its presence in plasma has been noted in 1948 by Mandel 
and Metais in both healthy and sick individuals17.  The interest in cfDNA was renewed in 
the 60s and 70s in context of Lupus and cancer research and in 1997 foetal DNA was first 
discovered in plasma samples from pregnant women18.  The concept of “plasma DNA 
chimerism”, the presence of genetic differences in the plasma of an individual, soon 
prompted researchers to look, successfully, into analogous situations, such as scanning 
for donor DNA in the plasma of organ transplant recipients or DNA from infectious 
agents in several viral/bacterial diseases patients19.  Although cfDNA origin is still 
debated, many speculate it lies into apoptotic and necrotic cells20, and active secretion is 
being investigated as well21.  The advances in genomic sequencing technologies, allowed 
different approaches to the study of cfDNA7.  It was recently showed that, in spite of the 
fact that fragmentation of cfDNA follows patterns biased towards some genomic features, 
such as transcription start sites, it still represents comparably the whole genome and 
potential mutations22. 
A plethora of clinical conditions has been related to dysregulation of cfDNA, including 
autoimmune disorders23, chromosomal anomalies in foeti24, several cancer types20, tissue 
trauma, stroke25, myocardial infarction26, DNA methylation, and in some cases, such as 
for breast cancer7, cfDNA has been proposed as biomarker to monitor disease progression 
and therapy response. 
Levels in circulating tumour DNA (or ctDNA, the tumour derived fraction of cfDNA) in 
plasma have been related to overall survival for patients suffering from different cancer 
types27, while in a study on colorectal cancer patients, undetectable ctDNA after surgery 
were related to 100% relapse free survival28 (although in the patients cohort only 4 exhibit 
this behaviour). 
cfDNA clearing from blood is a relatively fast process, thus suggesting the importance of 
blood-draw timing in the context of liquid biopsy.  After child delivery, fetal DNA in 
maternal plasma has a mean half-life (the time required for the total amount of fetal DNA 
11 
 
to be half of the initial value) of 16 minutes29, while half-life of ctDNA after complete 
resection of tumour tissues was calculated to be 114 minutes28. Incomplete resection 
caused only mild decrease or even increase in ctDNA levels.  Clearance from blood has 
been suggested to proceed through organ-based related mechanism30 (mostly the liver in 
mouse models). Fast clearance of plasma cfDNA, might implicate that cfDNA is less 
likely to give false positive results due to carryover cfDNA, from previous clinical 
conditions29. 
In 2015, high concordance between cfDNA and tissue biopsy derived analysis was shown 
for 157 tumour patients.  Furthermore, the analysis of cfDNA revealed the emergence of 
new mutations in some patients, potentially explaining the resistance to gene targeting 
therapy of those individuals27.  Other studies showed a much lower concordance between 
the ctDNA and tDNA derived from tissues, and suggested the complementary analysis of 
both markers7 for a more thorough characterisation of the health status. 
The lack of standardisation of cfDNA assays and sample preparation has been advanced 
as a detrimental factor for the evaluation and direct comparison of cfDNA related studies, 
ultimately thus slowing down the introduction of cfDNA markers in medical practice20,31. 
 
2.2.2 miRNA 
Ribonucleic acid, or RNA, is similar to DNA but contains ribose sugar instead of 
deoxyribose and uracil (U) instead of thymine as nucleobase.  It is usually found in single 
stranded form and is involved in several biological processes such as protein translation.  
Due to the low amount of circulating RNA and the efficient activity of RNase in 
extracellular space, research of using RNA as circulating biomarkers was limited until 
the discovery, in 200832, of stable microRNA (miRNA) in bodily fluids.  Firstly 
discovered in 1993, miRNA is a class of naturally occurring non-coding RNA, 19-25 bp 
long33.  miRNA is involved in the inhibition of messenger RNA, thus controlling 
translation phenomena34 and other biological processes, including carcinogenesis35.  
There are three class of small regulatory RNAs, differentiated for their biogenesis and 
role: small interfering RNA (siRNA), piwi interacting RNA (piRNA) and miRNA36.  
Small RNAs mediate gene silencing creating RNA-induced silencing complex with 
Argonaute proteins.  Over 25000 different miRNAs were found in over 200 species37.  
The evolutionary conservation of some miRNA sequences, along multiple species, 
suggests the key role that they play in biological processes, while the different targeting 
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method between plant and animals seems to indicate a double evolution from a common 
gene silencing process in ancestral eukaryotic cells38.  An increasing number of papers in 
the scientific literature relates miRNAs to several biological processes, including cell 
proliferation, maintenance, lineage differentiation, development and apoptosis, regulating 
both healthy status and diseases39,40.  Circulating miRNAs have been detected in several 
biological fluids, comprising blood, urine, saliva, cerebrospinal fluid (CSF), seminal fluid 
and even tears34.  miRNA stability, higher than that of RNA, suggests protective 
packaging such as protein complexes (e.g. high density lipoproteins41,42Argonaute243,44, 
Nucleophosmin45) and micro-vesicles, including exosomes and apoptotic bodies. miRNA 
has been proposed as an effective biomarker for liquid biopsy, indeed it has several 
advantages with respect to currently used protein markers which present technical 
difficulties, e.g. in the realisation of high affinity capture reagents34.  Many miRNAs have 
been related to specific pathologies or tissues of origin46,47.  Besides their use for 
screening purposes, some miRNA seems to be actively involved in drug resistance33. 
While the first connection of miRNA involvement in cancer, in Croce’s lab48, dates back 
to 2002, in 2008 the expression of a five-microRNAs panel ((hsa-let-7a, hsa-miR-221, 
hsa-miR-137, hsa-miR-372, and hsa-miR-182) from tissue biopsy was found to have 
predictive capability on overall/relapse free survival on 112 non-small cell lung cancer 
(NSCLC) patients49. In the same year, miRNA was first found to be stable in serum and 
plasma, and dysregulation expression patterns were related to several cancers50,32,51.  
Currently, blood derived miRNAs expressions has been studied in relation to several 
cancers including, breast, pancreatic, colorectal34, hepatocellular carcinoma52. Showing 
its potential for personalised treatment, miRNA was used to monitor the response of 
breast cancer patients to chemotherapy.  The latter is a particularly detrimental treatment 
and the understanding of whether or not it is useful can greatly benefit patients and the 
development of new therapeutic strategies33.  Finally, the tumour suppressor role of 
miR15-miR16 is well documented and these miRNAs are downregulated in several 
cancers53 (leukaemia, colorectal, bladder, and other solid tumours). 
miRNAs are also involved in other clinical conditions and diseases, such as diabetes54, 
psychiatric disorders55 and organ rejection after transplant56. Various, organ-specific 
miRNA have consistent patterns, the dysregulation of which is directly attributable to 
organ’s health.  Hence, monitoring these patterns can be related to toxicological responses 
and drug induced damages34 (examples are miR122 for liver, miR21 for kidney, miR208 
for myocardium etc.). The outcomes of interferon therapy on hepatitis C patients was 
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shown to be related to miR122 expression57.  miRNAs analysis has been proposed as 
prognostic marker, in a complementing strategy with the standard methods, for risk 
prediction after acute myocardial infarction58 (AMI).  The involvement of miRNAs has 
been shown also for other cardiovascular diseases, such as atherosclerosis59 (miR126-5p), 
atrial fibrillation60 (miRNA-328), Hypertension61, etc.  
Expression or miRNAs depends on several factors, both related to the patient, such as 
sex, exercise, circadian cycle, and to external factors such as sample type and storage 
conditions11.  It was shown that serum has higher mRNA content then plasma, probably 
due to the release of miRNAs during blood coagulation and platelet activation62.  
Haemolysis has a similar effect, as was shown on miR-1663.  Studies on miRNA stability 
in blood64 showed significant variation in miRNA expression after 48h incubation in 
blood and even after only 8h in plasma in the presence of physical disturbances.  
Freeze/thaw cycles were shown to have an effect as well and the most stable miRNA 
storage conditions seems to be in plasma stored at -80°C.  Also different extraction 
methods showed significantly different extraction yields1.  The direct comparison among 
different studies is therefore not feasible before a thorough standardisation in sample 
preparation protocol.  In spite of the growing number of publications on the topic (Figure 
2), still no miRNA based method is being introduced in standard medical practice. 
 
 
Figure 2. Number of miRNA publications from 2002 to 2016 according to Thompson Reuters Searching Engine 
(Web of Science, topic-based research, keyword “miRNA”). 
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2.2.3 Exosomes  
With the term exosome we refer to a particular subset of EVs, with diameter ranging 
between 20 and 100 nm65, and which stands out from other EVs for their intracellular 
biogenesis66.  The fact that they carry around a tissue specific cargo67 and have been found 
in most biological fluids, greatly increased the interest around them in the past years. 
Exosomes were shown to be able to deliver mRNA and miRNA to different cells68.  The 
uptake of exosomes can have highly significant biological impact on the recipient cells, 
for example increasing invasiveness of breast cancer cells69 or enhancing growth of 
neurons and astrocytes70.  Research on G13D mutant KRAS alleles indicated a feedback-
like behaviour, in which mutations in KRAS change exosomes content, which changes 
composition of the tumour microenvironment, thus affecting the tumour71,72. 
 
2.3 CNAs isolation on the bench  
CNAs extraction protocols can be subdivided in two main steps: (1) plasma or serum is 
extracted from whole blood, (2) circulating cell-free nucleic acids are isolated.  Here each 
step is detailed and discussed in the context of the project. 
2.3.1 Blood plasma separat ion  
In blood processing, the first step in CNAs isolation include the removal of the principal 
source of amplification inhibitors and contaminants from the source material.  
Haemoglobin, in erythrocytes, and lactoferrin, in leukocytes, were proved to act as PCR 
inhibitors73.  Haemolysis is the most common cause for rejection of clinical samples by 
laboratories, accounting for 40-70% of the total rejected samples74.  When the desired 
biomarkers are contained within CTCs it is necessary to isolate them from leukocytes and 
other sources of genomic contamination, usually much more abundant than these rare 
cells.  Similarly, when looking for cfNAs circulating in plasma, the first step is the 
isolation of plasma, usually accomplished by centrifugation (single or multiple steps) or 
filtration.  Centrifugation is the most widespread method for plasma isolation and requires 
a centrifuge.  Centrifugation is usually performed in a centralised lab by trained 
technicians.  Most CNAs workflows employ a double centrifugation protocols between 
sequential steps.  The first, slower, spin (~ 1’600 g) is used to remove the cells while the 
second and faster one (~ 12-16,000 g) eliminates small cell debris.  It is therefore a batch 
procedure and requires manual pipetting of the supernatant plasma, thus increasing the 
risk of genomic contamination.  This is mostly due to the so called “buffy coat”, a 
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leukocyte layer placed between the liquid phase and the red blood cells layer, which can 
be erroneously withdrawn while drawing plasma with a pipette.  Filtration is another 
plasma isolation technique which can entail cells damage75, thus implicating genomic 
contamination and haemolysis.  It is also a batch procedure and the size of filter has to be 
adequate for the blood volume to treat, so as to avoid clogging.  
Variants of centrifugation and filtration, together with other techniques, have been 
implemented also for the separation of exosomes from cells and other micro-vesicles 
present in blood.  These methods are treated in a focused review that I wrote and published 
in Lab on a Chip in 2015.  As this treats primarily microfluidic techniques, it was included 
in section 2.4 of this thesis, together with other microfluidic approaches to CNAs 
isolation.  
 
2.3.2 NAs Isolat ion and purif icat ion  
After plasma isolation, a lysis step is performed on the sample.  Lysis is usually carried 
out so as to disrupt cells, carrier vesicles and nucleus membrane and, in the case of CNAs, 
unbinding any proteins attached to NAs76,77.This has been accomplished in different 
ways, including chemical, acoustic, electrical and mechanical based methods76.  
Following lysis, NAs are isolated.  This is often accomplished by binding them to a 
substrate, by solid phase extraction (SPE), although several other techniques can be used.  
SPE is performed with or without a chaotropic agent depending on the substrate used.  
Chaotropic methods owe their popularity to the simplicity of the materials required, e.g. 
binding NAs to a silica membrane in presence of ethanol as a chaotropic agent.  The exact 
mechanism of DNA-silica membrane bonding is not entirely clear and several 
simultaneous, short range interactions are deemed to play a role in it78.  These include 
primarily hydrophobic interactions and phosphate-silanol binding, but also polar 
interactions and surface-sugar hydroxyl interactions, according to parameters such as the 
pH of the solution and if the DNA is double or single stranded78.  Chaotropic agents act 
as Polymerase Chain Reaction (PCR) inhibitors, and therefore require more careful 
washing steps.  Therefore, non-chaotropic methods for SPE are recently getting more 
attention.  All SPE methods require high surface area; this can be achieved thanks to high-
density multichannel microchip, nanoporous membranes, sol-gel immobilized silica 
particles and micro/nano pillars sieves5.  Thanks to the facility in their handling and the 
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possibility to modify their surface properties to satisfy different needs, in the past few 
years magnetic beads based extraction are gaining increasing interest79. 
The NA binding step is usually followed by a step aimed to increase the purity of the 
extracted sample.  Proteins are washed away by means of one or more washing buffers 
and a final elution step, sometimes performed simply with deionised water, is used to 
recover the NAs sample as a concentrated eluate. 
The processes described above enable the non-specific total recovery of all cfNAs.  NA 
fragments of different size can be separated with techniques such as electrophoresis, 
which can be advantageous for example to separate tumour circulating DNA (90-150 bp) 
from apoptosis derived cfDNA80 (peak of the distribution ~166 bp). 
Although some techniques can be used for both DNA and RNA (as we show in Chapter 
5, extracting miRNA with a technique aimed at cfDNA extraction) due to their differences 
in chemistry and stability the latter is usually processed differently.  RNA extraction 
methods can be divided in three categories according to if their chemistry is based on 
organic phenol-chloroform separation, chaotropic SPE or iso-pycnic gradient81.  Besides 
the chemistry of the extraction method, the main goals of an ideal sample preparation are 
maintaining RNAs intactness and purity, keeping it as close as possible to its native state, 
but the clear specifics depends closely on sample source, quantity and type of downstream 
application81. 
 
 
CNAs isolation challenges and some current solutions 
As described, in the previous sections, CNAs isolation techniques are time consuming 
and require trained staff and a centralised lab.  In order to accelerate the process and 
prevent human handling mistakes, several companies developed automated protocols, 
usually relying on automatic pipetting robots.  Among them are QIAgen, ThermoFisher, 
Beckman-Coulter life sciences, Stratec Biomedical, BioChain, Cynvenio.  These 
machines allow for the processing of several (usually between 12 and 96) samples at a 
time and some of them are compatible with in line amplification or detection.  On the 
other hand, due to their bulky size and the need of off-platform operator steps, they do 
not offer a viable alternative at the point-of-care.  Figure 3 shows six examples of such 
systems.  A cost-effective alternative to these expensive machines was recently proposed 
by Chan et al. who modified a low cost 3D printer to move magnets on reagents filled 
tubes, achieving the same performances as their commercial competitors82. 
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Figure 3 Automated systems for nucleic acids extraction example of six commercially available platforms. 
 
2.3.3 Amplif icat ion  and Detect ion  of  CNAs 
Downstream operations often involve an amplification step, such as Polymerase Chain 
Reaction (PCR) or a direct detection step such as sequencing or electrochemical detection.  
Some of these steps can also be combined77.  The extraction of CNAs on an automated 
platform cannot be designed without considering the requirements of the downstream 
operations; therefore in this section I briefly introduce the most common techniques for 
the amplification and detections of CNAs. 
Most PCR devices require high purity DNA samples to perform amplification 
effectively76.  Before PCR based RNA amplification, it is necessary to perform a reverse 
transcriptase (RT) to translate RNA chains into amplifiable DNA strands, although it has 
been shown that inhibition due to the RT process might impair calibration curves during 
PCR step and lead to overestimated results83.  Real time PCR or qPCR, first developed in 
199684, is the most widely used method for NAs amplification, but it is an expensive and 
time consuming method85, which prompted research towards alternative methods16.  
Variants of PCR have been proposed over the past 25 years.  Another isothermal 
amplification step, first used in 199286, isothermal strand displacement amplification 
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(SDA), works with two primers cleaving a nick in a DNA double strand and duplicating 
it in one direction, while displacing the cleaved strand.  Using primers in both direction, 
so that the strand duplicated in a sense reaction serves as a target for anti-sense reaction, 
leads to exponential amplification (108 folds in 2 hours87).  Isothermal rolling-circle 
amplification (RCA), allowed in 1998 to amplify, in a few minutes, hundreds of copies 
from a single primer88.  Loop mediated isothermal amplification (LAMP) was first 
developed in 200089 and uses 6 primers, to produce in 1h 109 fold increase of the targeted 
strand, arranged in a multi-stems structure.  This method was coupled with a simple 
fluorescent detection method which makes LAMP an attractive detection method90.  It 
has some limitations however, related to tedious primer design91 and its final product, 
which makes multiplexing difficult and is not suitable for cloning and other applications.  
Single molecule detection has shown promising results.  Digital PCR, in which a sample 
is diluted and divided in partitions each one virtually containing either one or no molecule, 
allows for a much more accurate and reproducible quantification than standard qPCR at 
a lower cost than NGS92 making it particularly helpful in detecting low abundant cfDNA.  
A locked nucleic acids molecular beacon (LNA-MB) method was specifically developed 
to identify a cfDNA target in breast cancer patients with good results in terms of 
specificity and rapidity16 (1h).  Molecular beacon sensitivity was increased by 2 order of 
magnitude by Huang et al. using a bimolecular beacon sensing strategy93, reaching 10 pM 
sensitivity.  It was developed a liposome Quantum-Dots (LQ-D) based method, in which 
a LQ-D forms a complex with a target DNA molecule.   Magnetic beads fitted with a 
probe complementary to the one present in the LQ-D, were used to obtain attomolar (10-
18M) detection of multiple targets without any amplification, by detecting the LQ-D 
disruption occurring when the beads are invested by a magnetic fields94.  
Genomic sequencing was first introduced by Sanger’s95 and Gilbert’s96 groups in 1977 
and successively evolved in different variants, such as shotgun sequencing in 1981 and 
others.  In 2005, the introduction in the market of next generation sequencing, forewarned 
by the development of pyrosequencing in 199697, had a drastic impact in the scientific 
community98, reducing time and cost of the procedure.  The over 2 orders of magnitude 
cost drop, democratised massively paralleled DNA sequencing allowing individual 
investigators to benefit from it99.  Currently, the method is still the most expensive and 
time consuming, but also the one able to give the most thorough answers.  Alternatives, 
such as the Oxford Nanopore Technology sequencing100, in which single stranded DNA 
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chains are read linearly, base by base, through the disturbance they cause on an electric 
field while passing through a nanopore, might soon offer a solution at a more affordable 
price and with nearly the same accuracy as NGS. Melting curve (MC) analysis on PCR 
product was shown to be more precise than Sanger’s Sequencing (still considered the gold 
standard) in KRAS mutation detection101.   
Finally, electrochemical biosensors, such as electrochemical impedance spectroscopy, 
can enable label free detection, sometimes without the need of amplification102, and due 
to their low cost and specificity, hold great potentials in in point of care diagnostics for 
infectious diseases or cancer markers103.  
 
2.4 Microfluidic technologies for CNA extraction 
As shown in the previous section, benchtop NAs isolation with macroscale devices are 
routinely performed with a range of different techniques.  One commonality between 
these techniques is that they all usually involve the use of expensive, bulky equipment 
and specialised staff which results in the need for centralised, well-equipped, 
laboratories77.  The use of microfluidic integrated platforms could allow the isolation to 
be performed in a quicker and more reliable way, free from human errors and, above all, 
near the patient.  Several methods for NAs isolation, amplification or detection have been 
implemented into microfluidics devices for several purposes, including microbial 
detection and DNA methylation epigenetic analysis104.  However, none has yet been 
reported for use with CNAs, which motivated this project.  Among the challenges of this 
task, the possibility to integrate in a microfluidic platform a plasma extraction module 
compatible with the volume required (> 0.2 ml) plays an important role.   
Microfluidics is generally considered to be advantageous for lower volume consumption 
of sample and reagents, speed of analysis, higher accuracy and fluid control, ability to 
multiplex, portability and compatibility with other protocols105. Beside the 
aforementioned benefits, the most remarkable advantages of miniaturising NAs based 
assays are: sensitivity, lower risk of contamination and possibility to be automated77.  
These characteristics are furtherly accentuated when several operations are integrated in 
a single microfluidic platform. The miniaturisation of existing procedures, allowing 
multiplexed analysis close to the patient, using minimal equipment, for example a simple 
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smartphone, is deemed to have extreme potential in fields such as infectious diseases, 
where similar symptoms can have drastically different causes106. 
The following sections give an overview of microfluidic devices designed for performing 
blood plasma separation, NAs isolation, amplification/detection and also include a 
discussion on current integrated approaches in which several of these steps are included 
on the same device.  
 
 
2.4.1 Microfluidic Blood plasma separat ion (BPS) 
Blood plasma separation microfluidic devices can be categorised according to different 
parameters.  Concerning their format, we can divide them into the more classic 
microfluidic chip format, disk format or paper format.  In the latter two formats, 
separation is usually driven by centrifugal forces and capillary action respectively.  In 
chip format, separation has been accomplished through passive, or fluidic-only, and 
active methods, based on an external force field.  Passive methods include those based on 
sedimentation, microfiltration or cell deviation, obtained by different means, such as 
deterministic lateral displacement and various hydrodynamic focus strategies.  Active 
methods may benefit from the use of an acoustic, electrical or magnetic field, for the 
focusing of cells and their sorting to different outlets3.  Figure 4 shows examples of 
different approaches. Microfluidic BPS showed several advantages, although a few 
important issues still need to be addressed.  One of them concerns the blood dilution, 
often required for the correct operability of these devices.  Diluted analytes will be harder 
to analyse and separation time per unit of actual plasma will be proportionally increased.  
Also, high purity or high plasma yield were achieved by mean of microfluidic devices, 
but never both of them at the same time107.  Also some of the methods developed work 
with bench equipment comparable to the standard bench protocols.  For example, a chip 
working within a tube, inside a centrifuge, relies on a stepper motor and its geometry to 
avoid the pipetting steps of the procedure108, although still needing the piece of equipment 
itself and batch processing typical of the original method.  In 3.2 the hydrodynamic 
focusing based BPS chip used in this project is described. 
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Figure 4 Microfluidic plasma separation device examples. i) Passive separation109 ii) Compact Disk microfluidic 
chip110  iii) Active separation: dielectrophoretic and capillary forces111 iv) Microfluidic paper-based analytical 
device112 
2.4.2 Microfluidic exosome i solat ion 
Exosomes are circulating microvesicles which carry a tissue specific cargo, mostly 
constituted by RNA and proteins.  This content makes them important circulating targets, 
which have been the subject of a large body of scientific studies.  
This section includes a review written in 2015 in our group.  Since 2015, other work has 
been performed on the microfluidic isolation of exosomes and clinical application, e.g. 
their usefulness as diagnostics for cancer113.  A few new devices were developed in these 
two years: a nanostructured graphene oxide/polydopamine coating was used on chip, on 
Y-shaped nano-posts, to isolate exosomes from diluted plasma and perform ELISA114.  
Another device, named ExoSearch115, coupled continuous flow mixing and immuno-
magnetic isolation with multiplexed detection of markers combination.  Promisingly, the 
device showed diagnostics accuracy on ovarian cancer comparable to the standard 
Bradford protein assay but requiring only 40 mins against the 12 hours of the latter.   
Viscoelastic microfluidics, which uses size-based lift forces differences to separate 
particles in a continuous, label-free, field-free manner, was successfully applied to the 
separation of exosomes from a suspension of micro-vesicles116.  The device obtained 90% 
purity with a recovery of 80% (against 5-25% of the standard ultracentrifugation) at a 
flow rate of 200 l/h.  
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In spite of these new developments, the premises and conclusions of our review still stand.  
As other microfluidic techniques, those applied to exosome isolation offer promising 
results at the expense of complicated procedures and off-chip steps handled by trained 
staff.  
Herein we report the full paper. 
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Exosome isolation: a microfluidic road-map†
A. Liga,a A. D. B. Vliegenthart,b W. Oosthuyzen,b J. W. Dearb
and M. Kersaudy-Kerhoas*a
Exosomes, first isolated 30 years ago, are nanoscale vesicles shed by most types of cells. The nucleic acid
rich content of these nanoparticles, floating in virtually all bodily fluids, has great potential for non-invasive
molecular diagnostics and may represent a novel therapeutic delivery system. However, current isolation
techniques such as ultracentrifugation are not convenient and do not result in high purity isolation. This
represents an interesting challenge for microfluidic technologies, from a cost-effective perspective as well
as for enhanced purity capabilities, and point-of-care acquisition and diagnosis. In this frontier review, we
present the current challenges, comment the first microfluidic advances in this new field and propose a
roadmap for future developments. This review enables biologists and clinicians familiar with exosome
enrichment to assess the performance of novel microfluidic devices and, equally, enables microfluidic
engineers to educate themselves about this new class of promising biomarker-rich particles and the chal-
lenges arising from their clinical use.
1 Introduction
Extracellular vesicles (EVs) are membrane-bound structures
that are released by most, if not all, cell types. Due to their
“cargo” of protein, RNA and DNA from their cell of origin,
EVs offer a minimally-invasive ‘window’ into the intra-cellular
world.1,2 In the literature, differing nomenclature and classifi-
cation of EVs has been used based on size, density, morphol-
ogy, lipid composition, protein composition, and subcellular
origin.3 Exosomes are distinguished from other EV subtypes
by their unique intra-cellular biogenesis, in contrast with
other EVs, such as microparticles, that are shed directly from
the cell membrane.3 Exosomes are reported to measure 20–
100 nm and appear cup-shaped when visualized by transmis-
sion electron microscopy. Exosomes are first formed as intra-
luminal vesicles by budding into early endosomes and multi-
vesicular bodies (MVBs). Subsequently, the MVBs either fuse
with lysosomes or with the plasma membrane and the endo-
somes are released into the extra-cellular milieu to become
exosomes.4 Due to this specific formation process, exosomes
contain a cargo that, to some extent, mirrors the cell of
origin.
The observation that the proteome and transcriptome of
exosomes changes according to the cell of origin5,6 and the
ability to access exosomes from virtually any biological
fluid (including saliva, lymph, urine, milk, blood, synovial
and amniotic fluids7) forms the rationale for the use of
exosomes as non-invasive biomarkers for disease and
toxicity.8–10
Exosomes can also behave as inter-cellular signals by
transferring functional mRNA and microRNA between cells
in vitro.2,11 The importance of exosomal signalling in vivo
remains to be determined. This signalling capacity may
enable exosomes to be used as a non-immunogenic RNA
delivery system that can cross natural divisions such as the
blood–brain barrier.12,13
2. Conventional exosome capturing
Current methods for exosome ‘capturing’ concentrate exo-
somes, but do not isolate them. Contamination of exosome
preparations with non-exosomal proteins and other EV sub-
types can lead to spurious biomarker discovery studies and
incorrect conclusions about exosome biological activity.14
The isolation of a pure population of exosomes would facili-
tate studies in exosome biology, in particular regarding their
physiological functions and their roles in various pathologies.
While next-generation deep sequencing (NGS) provides
fast profiling of miRNA or other biomarkers in biological
fluids, including from exosomes, liquid biopsy sample prep-
aration is sometimes crucial to reliably differentiate between
diseased and healthy patients.15,16 In this case, the isolation
of exosomes can improve the sensitivity of biomarker ampli-
fication and reduce the number of false-negative results.16
The most common method used for concentrating exosomes
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is ultracentrifugation, a method that includes differential
centrifugation steps reaching speeds of up to 200 000 × g.
However, this procedure is time consuming (4–5 hours),17
requires specialist laboratory equipment that is not available
in routine hospital laboratories, and is inefficient with
regard to exosome yield (5–25% recovery).18 Variations on
this method, such as adding in a sucrose gradient centrifu-
gation step, lead to higher purity of extracted exosomes.
However, the more complicated the sample processing the
longer the time from sample to exosome preparation. The
capital cost of an ultracentrifuge is typically around $50–
100k and the running cost is around $3k per year. Addition-
ally it requires training and a dedicated team. Exosomes can
be isolated in as little as two hours but isolation time ranges
from 2 to 10 hours depending on the biofluid and protocol.
It may be difficult for standard hospital laboratories and
resource-poor countries to acquire and maintain such equip-
ment, thus denying exosome-based diagnostics to a substan-
tial part of the population. A promising method for EV
selective concentration relies on antibody-coated magnetic
beads. This technique results in higher recovery and purity –
at least two-fold more exosome markers and proteins mea-
sured in the exosome concentrate compared to ultracentrifu-
gation.19 The use of magnetic beads also facilitates the use
of standard analysis methods, such as flow cytometry,
immuno-blot and electron microscopy on exosome-bead
complexes.20 However, it is important to highlight that the
magnetic beads only attach to exosomes that contain the
targeted protein that might not be present in all the exo-
somes in the sample resulting in a biased analysis. Recently,
commercial precipitation kits like ExoQuick™ and Total
Exosome Isolation™ precipitation solution have become
available. The advantages of these kits are that they are easy
to use with only 1 or 2 steps and do not require any expen-
sive equipment or advanced technical know-how. The disad-
vantage is that they commonly require a lengthy overnight
incubation step and their mode-of-action has not been
disclosed. The purity of the acquired exosomes has been
reported to be inferior compared to OptiPrep density gradi-
ent centrifugation, as demonstrated by lower enrichment of
exosomal marker proteins and more contaminating proteins
such as extra-cellular argonaute 2 complexes.21 Chemicals
originating from the precipitation kit may contaminate the
prep and these commonly undisclosed chemicals may affect
the apparent biological activity of the exosomes. Micro-
filtration techniques and other size exclusion methods can
suffer from clogging and vesicle trapping issues and often
entail shear stress-induced damages. This paper focuses on
the potential of microfluidic devices to concentrate, and
even isolate, exosomes, describing the most recent techno-
logical developments and highlighting pro and cons of each
of these methods that promise to deliver rapid and easy iso-
lation. In this review we have chosen to focus on the diag-
nostics rather therapeutic use of exosomes, as microfluidic
solutions will be most beneficial, or at least of immediate
benefit, in the diagnostic area.
3. Microfluidic technologies for
exosome isolation
The advent of microfluidic technologies has allowed the
development of new exosome manipulation techniques
which, though still at an early stage of development (most of
these were developed between 2012 and 2015), are proving
themselves extremely convenient in terms of reagent vol-
umes, product purity and isolation time (cf. ESI† Table for
detailed comparison of techniques). The techniques devel-
oped so far for microfluidic-based exosomal purification can
be classified in three categories including (i) trapping exo-
somes with an immune-affinity approach, (ii) sieving (e.g.
nanoporous membranes) or (iii) trapping exosomes on
porous structures (e.g. nanowire-on-micropillars). Sieving
approach differs from the others by the possibility to start
from whole blood without previous treatment. However, all
methods require further off-chip additional steps for sample
preparation, such as plasma extraction, or reagent mixing.22
3.1 Immunological separation
Immuno-chip. Chen et al. demonstrated the first immune
affinity approach for the capture of exosomes within a micro-
fluidic device.23 The separation principle relies on receptors
on the exosome outer surface which enable specific collection
according to their origin and function, and allow their isola-
tion from other shed membrane particles and lipid struc-
tures. The device features a planar structure with herring-
bone engravings to enhance mixing (cf. Fig. 1a). Collected
exosomes are characterised in situ, after several washing
steps, or lysed for DNA extraction.23 Chen et al. demonstrated
a faster method (~1 h), with respect to the traditional tech-
nologies, that used smaller amounts of reagents (100–400 μl).
Total RNA amount, extracted from exosomes captured on-
chip using CD63 antibodies (common exosomal marker)
from 400 μL serum samples, was around 30 ng for non-small
cell lung cancer patients. Further analyses demonstrated the
quality and quantity of on-chip exosomal RNA was sufficient
for the evaluation of tumor-derived RNA.
Immuno-chips and on-chip fluorescent characterisation.
Kanwar et al.22 used the same principle, modifying the prior
design so as to carry out “on chip” exosome quantification by
a fluorescent assay method on a standard read-out plate
reader. The device, called Exochip, features several circular
wells connected by narrow channels, in order to enhance
mixing (Fig. 1b–d). Additionally, the extended retention time
leads to a stronger interaction between the exosomes and the
functionalised surface. Besides being specially adapted for
further analysis, the device can also be easily scaled up, sim-
ply adding more rows of wells in the same chip. The protein
yield of the ExoChip exosomes was 15–18 μg of total protein
and 10–15 ng of total nucleic acid from 400 μL serum sam-
ples. A higher level of fluorescence on the chip was measured
in exosomes obtained from patients with pancreatic cancer
compared to healthy volunteers. This was in line with the
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relatively higher protein expression of CD63 and Rab5 mea-
sured in the exosomes from the cancer patients (western
blot). A panel of miRNAs measured in the extracted exosomes
was also able to distinguish between cancer patients and
healthy volunteers. He et al.24 developed a cascading chip
where exosome isolation and enrichment, chemical lysis, pro-
tein immuno-precipitation and sandwich immunoassay
assisted by chemi-fluorescence detection are integrated in a
microfluidic circuit. The on-chip isolation protocol takes less
than 1.5 hours and only requires 30 μl of human plasma
premixed with antibody-labelled magnetic beads. The analy-
sis of type 1 insulin growth factor receptor (IGF-1R) concen-
tration in on-chip exosomes, though 100 times lower than
that recovered from ultracentrifugation, showed a clear
overexpression of the marker in 5 non-small-cell lung cancer
patients compared to 6 healthy volunteers confirming the
diagnostic potential of this approach. As mentioned in
section 2, one of the main limitations of immunological anal-
ysis is its focus on only one particular surface protein at a
time.
Immuno-chips and sensing. Several groups are proposing
to use immunological techniques in combination with differ-
ent techniques, allowing for better separation, or detection,
or both. In this regard, Im et al.25 devised an on-chip nano
plasmonic exosome sensor (nPLEX), in which surface
plasmon resonance (SPR, a technique based on the oscilla-
tions of electrons at an interface stimulated by incident light)
is used through nanohole arrays patterned on a metal film.
Each array is functionalised with different affinity ligands
specific for a particular surface protein, which overcomes the
issue highlighted in the previous section. In the first chip
generation each of 12 microfluidic channels were coupled
with 3 arrays (12 × 3), giving the possibility to monitor and
display bonds with 36 different proteins. A second generation
of chips is being developed, implementing 33 × 33 arrays
thus allowing increased data collection from 1089 sites.
Thanks to the high sensitivity of the plasmonic sensors, it is
possible to display in real time the intensity of exosome-site
bonds, and “map” the activity of each array, thus leading to a
quantitative analysis of exosome content. Exosomes were
present in large quantities (>109 exosomes per mL) in ascitic
fluid from 20 ovarian cancer patients and 10 non-cancer
patients. Therefore the nPLEX device could function with
samples simply collected through a 0.2 μm membrane filter.
Receiver operator characteristic curve analysis of exosomes
using paired protein levels per exosome of epithelial cell
adhesion markers (EpCAM) and CD24 resulted in a promis-
ing area under the curve of 0.97. This device performs well
with exosome-rich ascites samples, but due to its sensitivity
and high-throughput has potential as a point-of-care diagnos-
tic tool on more conventional liquid biopsies such as blood,
if combined with an integrated sample preparation. Further-
more, its use could be broadened to diagnose a range of ill-
nesses or even to monitor treatment response. Another exam-
ple of enhanced on-chip immunological separation followed
by detection was proposed by Vaydianathan et al. with an
original approach named “nanoshearing” aimed at reducing
non-specific fouling as well as providing inline detection.26
The use of this electrodynamic anti-fouling technique led to
a 3-fold enrichment in detection sensitivity relatively to a nor-
mal hydrodynamic flow.
Immuno-binding and inertial solution exchange. Finally,
Dudani et al.,27 used an off-chip immunological approach to
bind exosomes to 20 μm polystyrene beads followed by on-
chip inertial focusing to enrich the bead-exosome complex
from the original sample into a buffer. The device was tested
with blood samples (after RBC lysis) spiked with centrifuged
melanoma and breast cancer culture supernatant. This
mixture was incubated for 4 h with polystyrene beads
functionalised with exosome-specific antibodies and then
processed through the chip. There, inertial lift forces push
the beads toward the centre of a channel with multiple out-
lets, transferring them into a wash buffer and allowing their
selective separation. A single centrifugation step removed the
larger cell debris and the exosomes can then be eluted from
the beads and characterized. The device features a relatively
high throughput (70 μl min−1, five-fold higher than most
other microfluidic techniques) and demonstrated the enrich-
ment of exosomes but still needs a thorough molecular char-
acterisation of the retrieved material. The 4 h needed for
Fig. 1 (a) The first chip realised for microfluidic exosome isolation
featured a 19 mm × 20 μm × 4.5 cm chamber with herringbone groves
10 μm deep to enhance contact between microparticles and chip
surface. The device is pictured here is filled with supernatant fluid and
attached to a syringe pump. Reproduced from ref. 23 with the
permission of the Royal Society of Chemistry. (b) A modified version of
the same scheme: single channel Exochip, the device has the same
dimensions of a standard glass-side (W = 0.75 mm, L = 73 mm, P = 9
mm, H = 100 μm). Up to 12 channels could fit within the dimensions of
a microtiter-plate. (c) Experimental setup using a 3 channels Exochip (d)
Exochip working scheme: exosomes counting is made possible through
a simple 3 steps procedure involving: (i) blood serum infusion within the
chip (pre-coated with exosome-specific capture antibodies, anti-CD63),
(ii) staining with specifically functionalised (Di-O) fluorescent dye, (iii)
on chip analysis through conventional counting methods. Reproduced
from ref. 22 with the permission of the Royal Society of Chemistry.
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bead incubation makes it unsuitable for acute care
applications.
In conclusion, it is important to highlight that immuno-
logical methodologies are the only ones, so far developed,
which can be directed towards the isolation of a pure exo-
some population. Other methods relying on physical proper-
ties (size, density, surface charge) lead to higher percentages
of contaminants (similar micro-particles with different origin,
proteins).
3.2 Sieving
Davies et al.28 developed a different approach to exosome col-
lection, by sieving EVs directly from whole blood through a
membrane and driving filtration either by pressure or electro-
phoresis (cf. Fig. 2). The pressure-driven solution leads to a
shorter separation time while the electric field produces a
higher purity of the extracted vesicles, proteins being less
affected by electric fields than phospholipidic vesicles, due to
their lower negative charge.29 In the authors' opinion, the
non-selectivity of this device with respect to vesicle type can
be seen as an advantage compared to the over-specific collec-
tion offered by immune-affinity related methods, which can
lead to biased data analysis. A significant drawback is the
low exosome recovery (unspecified in the text but shown to
be next to 2% in a graph) while the device seems to perform
well regarding separation time. The device reached a satura-
tion point after 3–4 μL of filtrate was extracted when pressure
driven filtration was used. However this volume was enough
to assess the exosomal cargo by western blot and RT-PCR.
When electro-driven filtration was used, the average yield was
79 ng RNA per 100 μg of protein from a 100 μL sample, com-
pared to 187 ng of RNA per 100 μg of proteins from a 5 mL
sample obtained by centrifugation.
3.3. Trapping on porous structures
Wang et al.7 devised a third approach consisting of trapping
EVs through a porous microstructure. They designed a
ciliated micropillar structure forming a microporous silicon
nano-wire which was able to selectively trap particles in
the range of 40–100 nm (Fig. 3). According to Wang et al.
this method allows the selective collection of intact
phospholipidic “exosome-like” vesicles. Though the trapping
step is relatively fast (~10 min), to proceed with imaging and
characterisation, it is necessary to dissolve the silicon nano-
wire in PBS buffer overnight, thus making the recovery proce-
dure time consuming. This device was tested with a solution
containing 83 nm and 120 nm lipid vesicles and 500 nm
nanoparticles. The highest retention (60%) was obtained for
83 nm vesicles when up to 30 μL of sample was injected
(based on fluorescent intensity measured with a plate reader,
starting concentration undisclosed), followed by 120 nm vesi-
cles (45%), while the retention of 500 nm bead was only
10%. The retention rate of 83 and 120 nm lipid vesicles
decreased when more sample volume was injected, probably
due to a saturation effect. The device was not validated with
clinical samples, and no analysis of cargo protein or RNA was
performed.
4. Road map for microfluidic
exosomal isolation
The increased interest in the role of exosomes in biomarker
discovery and diagnostics has highlighted the pressing need
for new technologies to isolate exosomes in biofluids rapidly
and accurately with minimal sample preparation. Here we
discuss 5 areas of consideration for future developments.
Fig. 2 Schematics for two sieving modes for exosome filtration. The
membrane is realised by in situ photopatterning of a porous polymer
monolith. Sieving can be performed by (a) applying pressure on an
on-chip dead end filter or (b) by applying an electric field to drive the
exosomes through the porous membrane in a hybrid solution of cross
flow and electrophoresis sorting. Vesicles damage through the device
was shown to be undetectable by analysing haemolysis and DNA was
not contaminated by intracellular proteins. Adapted from ref. 28 with
the permission of the Royal Society of Chemistry.
Fig. 3 Ciliated structures for exosome isolation and capture by Wang
et al. The hierarchical geometry of the device does not allow cells
larger than 1 μm to access the wired area, due to the distance
between the pillars (b) being too narrow (900 nm). Smaller cell debris
can enter the micropillar area but are excluded by the ciliated nano
structure (a), which forms pores with diameters ranging between 30
and 200 nm, in order to selectively trap exosomes and small EVs.
Smaller proteins and molecules are free to pass through the device
without being captured. Reproduced from ref. 7 with the permission of
the Royal Society of Chemistry.
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4.1. From research to clinical setting: increased speed and
lower cost
Ultracentrifugation is currently used in the research setting,
but not yet regularly used in the clinical setting. If an
exosome-based diagnostic was to be used in real-life clinical
medicine, one could envisage that in a non-urgent situation,
such as the diagnosis of cancer, the use of a centralised labo-
ratory with an ultracentrifugation unit could be feasible, pro-
viding the extraction is reproducible. However if standardised
performance is demonstrated using microfluidic chips, it
would open the door for faster, reliable, cost-effective exo-
some-based diagnostics for emergencies in acute care set-
tings (e.g., myocardial infections and drug toxicity) as well as
non-emergency illnesses (cancer diagnostics). Furthermore,
this could allow a more accurate exosomes analysis, since
studies have indicated that there is a significant loss in exo-
somes number from biofluids such as urine, even when
frozen at −80 °C30 and within 2 h.31 If exosomes are to be
used for acute care, the device would ideally allow the biolo-
gist or clinician to rapidly and confidently isolate exosomes
from biofluids within a 30 minute time frame after sample
collection.
4.2. Future directions, technological considerations and
potential challenges for the development of microfluidic
technologies
All prototypes presented in this review have used a single
isolation strategy and none are free from issues. Future
microfluidic devices might therefore benefit from hybrid
approaches using two or more isolation techniques, for
example, a first separation based on size could eliminate the
largest blood cells from a blood samples, followed by an
immunological separation to access a specific exosome pop-
ulation. The challenge, as with all microfluidic development,
is to provide a solution to a real clinical question. Two
routes are likely to emerge: the first will explore the exo-
some biology in the research area, and will require refined
isolation. For this route, the advantage of microfluidics will
be to provide cheaper alternative to ultracentrifugation with
low capital investment. The second route will focus on the
development of tools to facilitate liquid biopsy preparation
for next generation sequencing. The challenge will lie in the
rapid extraction from complex matrices. To fit in a clinical
work flow the devices will need to be more robust and cost-
effective as their current counterparts. The challenges in the
development will lie in (i) reducing the cost of the devices,
a consideration which will need to be taken into account at
the design stage, and which might involve alleviating the
need for structures below 80 μm, at which point photoli-
thography might be replaceable by rapid-prototyping and
high volume manufacturing processes. (ii) Secondly,
achieving the right throughput will be crucial and might
necessitate stacking several microfluidic units on the same
device.
4.3. Achieving specificity and reproducibility
As discussed above, in some cases, devices will need to reli-
ably provide an exosome preparation specific to an organ of
origin. If a device has on-chip technologies such as protein
specific markers for sorting exosomes from specific organs it
allows the clinician access to a relevant exosome population
specifically to his site of interest. Current methods of isola-
tion are not delivering on reproducibility of exosome recov-
ery, arguably due to variations in sample handling. Ideally,
microfluidic chips should be tested by different laboratories
to assess reproducibility and consistency and demonstrate
standardised performance.
4.5. Characterisation and biological validation
At present, the methods of quantifying exact or ideal exo-
somal yield are still very semi-quantitative. There is an unmet
need for quantitative and qualitative assessment of exosomes
and the definition of clear biological controls.32 We have
demonstrated that nanoparticle tracking analysis is a promis-
ing method for quantifying exosomes in biofluids, such as
urine31 and it would therefore be interesting to compare the
yield of current and future devices using this method. How-
ever, there is no “one fits all” solution for the characterisa-
tion of exosomes. The characterisation required will depend
on the clinical application. Spiking-in labelled exosomes
offers a reliable method to determine the yield, either via
fluorescence measuring or RT-PCR. Furthermore, it is
recommended to assess not only the presence of the selected
markers (yield) but also the absence of contaminants
(specificity).32
5. Conclusion
Through highly precise fluid control and high surface to vol-
ume ratios, microfluidics has the power to differentiate, cap-
ture, enrich and isolate particles of very similar sizes and
shapes. Despite being in its infancy, several microfluidic
developments have demonstrated effective exosome separa-
tion, leading to robust clinical diagnostics. However none of
the first prototypes are free from issues, in particular they
often require prior sample preparation based on macro-scale
procedures. Among the aforementioned methods, immuno-
logical separation leads to high specificity, and can be
performed in a fairly short time in most cases (~1.5 h). Trap-
ping exosomes in porous structure, such as ciliated micro-pil-
lars, seemingly leads to high purity exosomes recovery, but
the recovery procedure is currently time consuming (over 1
day). Sieving is a particularly interesting method as it can be
performed directly on whole blood, without any treatment
before the separation, but it is not exempt from drawbacks,
such as low recovery and the possibility of damage to vesicles
due to shear stress. Some isolation techniques demonstrated
for microvesicles (typically of diameter above 100 nm) might
also be suitable for exosome recovery.33,34 For example, Rho
et al. have demonstrated a rapid and sensitive microvesicle
Lab on a ChipFrontier
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
8 
A
pr
il 
20
15
. D
ow
nl
oa
de
d 
on
 1
4/
02
/2
01
8 
11
:3
2:
33
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Lab Chip, 2015, 15, 2388–2394 | 2393This journal is © The Royal Society of Chemistry 2015
detection in packed red blood cell units using filter-assisted
filtration, magnetic labelling and target-specific detection via
miniaturised nuclear magnetic resonance system.33 Detection
and characterisation are an essential part of the capture-to-
diagnosis path, and some microfluidic researchers have
focused all, or part, of their efforts towards the development
of detection techniques which could be the subject of
another focused review.25,35–37 Some of these techniques pro-
pose the direct (preparation free) detection of exosomal RNA
from raw cell medium, which could be potentially applicable
to bodily fluids.37 The applications of microfluidic technology
to bodily fluids for exosome isolation have not been
described extensively with few devices using clinical samples,
and microfluidic engineers should seek to establish strong
collaboration with biologists and clinicians to demonstrate
the full potential of the technology. While current ultracentri-
fugation techniques require significant capital and mainte-
nance costs, microfluidic-based exosome isolation techniques
are promising and cost-effective, and could be deployed in a
large number of clinics and hospitals, as well as in resource-
scarce settings.
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2.4.3 Microfluidic nucleic acids  purif icat ion  
NAs isolation has been performed on-chip using different methods, including techniques 
based on functionalised paramagnetic beads, silica based surfaces, oligonucleotide-
modified polymer surfaces, pH dependent charged surfaces, Al2O3 membranes and 
liquid-phase isolation77.  In alternative to the common chemical process, lysis can be 
performed by mechanical action through magnetic beads beating117; these methods may 
be sufficient as sample preparation for some samples, such as cell culture medium. 
Some techniques developed specifically for microfluidics purposes were applied to the 
problem as well.  For example inertial focusing of CTC has been achieved on chip for 
CTC concentration before genomic analysis13.  Some methods explored more original 
techniques.  The next sections describe some of the most relevant microfluidic 
applications for the isolation of DNA or RNA. 
 
Microfluidic DNA extraction 
Shin et al. developed a silicon device which uses dimethyl adipimidate (DMA), as non 
chaotropic agent for DNA bonding, and pH change, to reverse the bonding reaction, 
starting from 2 l of whole blood.  DMA form a high surface crosslinked structure which 
binds DNA.  The complex is then captured at microchannel surfaces (activated with 
aminosilane groups)5. 
Also isotachophoresis (ITP), a separation method based on ion mobility, was integrated 
on chip for DNA isolation.  Without involving centrifugation, buffer exchange, pumping 
or toxic chemicals it was possible to extract, and amplify off chip, nucleic acids from 
salmon sperm and whole blood lysate36. 
Magnetic beads were implemented in an unconventional way in a microfluidic system by 
Yamaguchi et al. using a disposable cassette composed of a bottle, a capillary tube and a 
chamber, placed on a moving support featured with magnets.  Reagents for NA extraction 
are contained in the capillary tube and separated by silicon oil.  A zig-zag motion is forced 
on the beads by the oscillation of the external magnets.  The device performed better than 
standard protocols starting from 100 ml of cell culture, although it required several hand-
driven steps118.  
Plasmid DNA was isolated on a motor assisted microfluidic chip working within a 
centrifuge tube108.  The centrifuge rotation speed regulates the intensity of the force which 
drives fluid motion within the device while a stepper motor, internal to the tube, turns the 
chip to guide force direction.  Only a few steps require manual intervention. 
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Microfluidic RNA extraction 
Purification of miRNA has been accomplished from kidney cell lysates by on-chip 
isotachophoresys in as short as 3-5 mins119.  Thermoelectric lysis of cells followed by 
microgel electrophoresis in the same device can be performed in around 10 minutes and 
extract miRNAs from cell culture suspensions120.  
Functionalised needle tips, able to bind specific messenger RNAs once inserted in bio-
tissues, have been used as an elegant sample preparation method, allowing the reverse 
transcription to be performed within 10 mins from needle-specimen contact121. 
 
2.4.4 Microfluidic NA Amplif icat ion and Detect ion  
Nucleic acid amplification and detection has been implemented in microfluidic format 
and have demonstrated several advantages over their macroscopic counterpart.  For 
example on chip PCR was shown to be more sensitive, and not to suffer from the issues 
of technical variability, encountered with conventional PCR performed in different 
laboratories122. 
Microfluidic DNA detection 
A microfluidic droplet approach was successfully applied to DNA sequencing starting 
from a 64bp DNA template solution123.  The system is designed similarly to an array, in 
which each position tests for a 15 bp long sequence, but the reactions are performed 
sequentially with the droplets flow, instead of in spatially fixed positions.  
A self-priming fractal branching microchannel net microfluidic approach, inspired by 
circulatory and respiratory systems in mammalians, was used for effective dPCR on chip.  
The device performs as conveniently as the bench standard, avoiding sample and reagent 
loss, although it still requires all of the reacting steps to be performed off chip, before the 
final mixture is divided in the branched compartments for thermal cycling124.  
In another example, adsorption on chitosan over a nylon membrane was implemented on 
microfluidic circuits to capture small amount of NAs from diluted solution.  Using Nylon 
allows for amplification on the adsorption site, without the need of an elution step. The 
method allows for 5000 fold concentration of NAs from high volume of pre-diluted NA 
solution125.   Nonetheless, its use was demonstrated only on pure elution of DNA and it 
is left to wonder whether it would prove useful after an actual NAs extraction, where, 
with the rare molecules, a much greater amount of unwanted material is present as well. 
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Isothermal DNA amplification on a digital microfluidic platform was shown to be 100 
times more sensitive than on the bench.  The device controls multiple droplets operation 
through an “active matrix electrowetting-on-dielectric” (AM-EWOD) system featuring 
16800 electrodes, designed to perform recombinase polymerase amplification (an 
isothermal alternative to PCR) and tested on antibiotic resistant genes in E.coli126.   
Microfluidic RNA detection 
Quantification of miRNA in elution was performed on-chip with different technologies, 
e.g. digital droplet PCR127, isothermal circular-strand-displacement polymerization128 
(used in a digital microfluidic device to amplify miRNA-210) or qRT-PCR129, which was 
integrated on chip for miRNA detection from total RNA extracted from serum for prostate 
cancer prognostic.  
Multiplexed microRNA detection on a microfluidic chip was performed in 20 mins from 
miRNA elution, showing  detection limits as low as the femto to pico molar scale130. 
Microfluidic, bead-based, enzymatic amplification for miRNA detection using quantum 
dot labels was tested on total RNA elution samples from lung cancer cells131. 
Finally, flow cytometry in combination with fluorescent in situ hybridization (flow-FISH) 
and locked nucleic acids probes were integrated on chip for the detection of miRNA 
within single cells132.  
 
2.4.5 Integrated platforms  
Integrated and disposable microfluidic platforms have already been used for genomic 
material handling, including nuclei acids isolation133 and genome segments 
purification134.  A common application is the extraction of genomic material from bacteria 
or viruses present in blood or other bodily fluids such as joint fluid135 and peritoneal 
dialysis fluid136.  Most of these integrated platforms require external equipment, such as 
pumping systems, optical readers or centrifuges, although a small number of platforms 
were developed as “self-contained” technology. 
Prototypes, or commercial platforms can be passive, hand-powered or active, according 
to the way fluid flow is controlled137.  Examples of commercially available, passive, self-
contained, integrated microfluidic platforms include home pregnancy tests, in which urine 
is driven by capillary effect on the test channel where the hormone is detected, and other 
lateral flow tests138 (e.g. glucose, HIV1).  In spite of overcoming some of the limitations 
of passive systems, hand-powered systems are the ones that offer the lowest 
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reproducibility, due to their intrinsic nature, which delegates control to the end-user.  
Active systems offer more flexibility than the previous methods although, to be 
commercially viable, they are still required to be inexpensive.  Ideally, active platforms 
should be battery powered, so as to increase their portability and minimise their footprint.  
The following two sections describe in more details integrated microfluidic platforms for 
the treatment of DNA and RNA respectively.   
Integrated microfluidic-based platforms for DNA manipulation.  
An integrated DNA extraction platform was realised at the Fraunhofer Institute for 
Microengineering and Microsystems (IMM) in order to isolate bacterial and viral 
genomic material from swabs for efficient diagnostics on lower respiratory tract 
infections133.  Nucleic acids were extracted after elution and lyses of cells collected by 
mean of nasopharyngeal swabs on a solid matrix.  The device performed statistically 
better than the corresponding benchtop protocol.  In addition, it was demonstrated, for the 
first time, the successful on-chip integration of a thin (80 m) porous membrane for 
nucleic acid extraction.   
A particularly handy microfluidic tool is the “all-in-one” syringe tip membrane developed 
by So et al., able to lyse cells mechanically through ultra-sharp tips of nanowires prior to 
membrane isolation of NAs76.  Washing and elution buffers are then used in two different 
steps to finalise the extraction of nucleic acids.  The process is fast (isolation takes about 
5 minutes) and does not require an energy source (the syringe can be used simply by 
hand) nonetheless it was only tested with cells suspended in PBS. 
Shin et al. devised a microfluidic device where silica coated magnetic beads are used 
together with droplets of reagents in aqueous phase separated by oil compartments139. 
Beads are moved through the reagent chambers using a permanent magnet and finally 
exposed to thermal cycling.  The device performs isolation, amplification and melting 
curve analysis of NAs starting from 10 l of whole blood.  This allows for detection of 
mutations in specific genomic strands, thus spotting the presence of single nucleotide 
polymorphisms.  An integrated paper device, overcoming the common paper-related 
problems of off-chip reagent storage, by using dried reagents, and dependency on other 
equipment, was tested on salmonella bacteria cultures140.  The device was able to isolate 
and detect, by mean of lateral flow assay, salmonella concentrations down to 103 CFU 
ml-1 in 30 l of fluids such as fruit juice, egg and milk.   
34 
 
An integrated cartridge, working without any support platform, was developed with the 
aim to make pathogen detection tests as easy as pregnancy tests141.  The cassette performs 
sample preparation from a nasal swab, isothermal amplification and detection without 
any external action, after the loading of the sample.  This is achieved by integrating paper 
microfluidics, dried reagents, temperature controllers and lateral flow assay, all within 
the cartridge, making the instrument particularly suitable when cheaper and simpler 
cartridges would not balance the initial cost for an external automation platform by 
frequent use.   
GeneXpert, a commercially available integrated system for nucleic acids extraction from 
cells, was developed by Cepheid (Sunnyvale, CA) and includes cell filtration before lysis, 
NA extraction and multiplexed detection in disposable cartridges, completing the process 
automatically in about 2 hours. The issues related to the device are the cost and the need 
for maintenance but the fact that it works with lyophilised reagents gives the cartridges 
the advantage of a good shelf life142,143. Q-POC, another commercially available platform 
based on microfluidics, was developed by Quantum MDx and allows for integrated blood 
cell lyses, DNA extraction and multiplexed detection on microarray. Two model devices 
are shown in Figure 5. 
 
 
Figure 5 Microfluidic, self-contained systems for nucleic acids analysis. Two examples of commercially available 
platforms. 
RNA 
Integration of several tasks in one device was applied to the study of RNA as well.  One 
example by Slouka et al. saw extraction, concentration and sensing of miRNA from lysate 
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of oral cancer cell lines in one chip, using various electrokinetic phenomena exhibited by 
ion-exchange membranes subjected to a DC electric field144.   
Another integrated microfluidic device was designed to isolate mRNA from 
Cryptosporidium Parvum (a waterborne pathogen) and amplify the signal through an 
isothermal, primer-dependent technique (Nucleic acid sequence-based amplification 
(NASBA)).  Isolation is achieved through specific binding to the same material of which 
the chip is made, poly methyl methacrylate (PMMA), with surface modification 
addressed to improve immobilization efficiency and avoid nonspecific capturing.  The 
procedure is sensitive and effective and, though still not automated, represents a 
promising proof of concept145.  
Messenger RNA was detected for hepatotoxicity studies, from tissues, in a semi-
integrated device developed by Lim et al146. A fist device performs the tissue lysis and 
mRNA extraction on paramagnetic beads before multiplex RT-PCR and real time 
fluorescent detection on a second chip.  In spite of the good biological results, and 
although the method is presented as a POC, the several syringe pumps needed to drive 
the various reagents, and the manual handling required in several steps, would still 
prevent the actual deployment in clinical set ups without further improvements.   
Hepatitis B virus (HBV) genotyping was successfully accomplished on chip through the 
integration of loop mediated isothermal amplification (LAMP), for amplification of 
genomic material, line probes assay (LiPA), for genotyping, and giant magneto-resistance 
(GMR), a method based on a quantomechanic effect, which was used to build sensors. 
Combining LAMP and Lipa, shortened reaction time to about 1 h, while the use of GMR 
brought the limit of detection down to only 10 copies per ml.  The device highlights the 
advantages of integration, although LAMP and LiPA were conducted in a different chip 
than GMR.  Also, tests were performed starting from clone plasmids of HBV DNA, so 
did not require any additional sample prep step that would be necessary when starting 
from clinical samples147.   
 
2.5 Final remarks 
2.5.1 State of  the art  in  convent ional  (bench) NA platforms  
Current methods for CNA isolation are expensive and require trained staff operating 
cumbersome and expensive pieces of equipment, such as centrifuges or liquid handling 
robots.  The reagents used in the different protocols are expensive as well and often need 
to be transported and stored below room temperature148, besides being handled by 
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experienced hands.  These make current technologies not suitable for the point of care, 
not to mention for remote, resource-poor settings, where some of these applications, 
including those on infectious diseases, are needed the most148. The obvious solution is the 
integration of the systems into miniaturised portable devices, although this task was 
proven not to be straightforward.  Although microfluidics was applied several times to 
the isolation or detection of NA from plasma or other bodily fluid, several applications 
have focused on genomic NA, rather than circulating nucleic acid, thereby not requiring 
a cell separation step prior to the purification of NAs.  
2.5.2 State of  the art  in  NA microfluidic platforms  
All the methods described in section 2.4 highlight the advantages of microfluidics 
integration (speed, high sensitivity, accuracy, low sample and reagent consumption, 
possibility to integrate several steps in one device) and its promising, but still not fully 
developed, potential for clinical applications. 
The examples shown in the previous sections, show a consistent effort from the scientific 
and industrial community to miniaturise existing procedures into lab-on-a-chip devices.  
Nonetheless, most of these studies, likewise others relating to proteins and cells149, 
involve off-chip processing for sample preparation (such as plasma isolation or bead 
incubation), and reactive steps (such as lysis).  A recent review on miRNAs34 states that 
in spite of the much deeper knowledge of these biomarkers acquired in the last 10 years, 
still no candidate made it to the clinical development.  In the opinion of the authors this 
is mostly due to the lack of consistency in findings, caused by the lack of standardisation 
in sample preparation and measurements platforms.  This opinion is backed by several 
reviews on the topic of CNAs in clinical practice1,63,148,150.  The lack of an integrated 
sample preparation is considered the greatest obstacle to overcome before microfluidics 
could represent a viable tool for diagnostics and clinical monitoring, in real hospital 
applications150. 
2.5.3 Lack of  solut ions for  CNAs 
While all the platforms described in the previous section focus on isolation of NAs, 
sometimes followed by amplification or bio-sensing or both, so far sample preparation is 
done off-chip, increasing the possibility of human error and making procedures longer.  
Blood plasma separation was tackled by several microfluidic devices but never integrated 
in a complete workflow except for applications requiring very low volumes, for example 
retrievable with a filter, not compatible with circulating nucleic acids quantification.  As 
37 
 
shown in the previous section, most microfluidic solutions deal with pre-treated inlet 
samples, therefore they require an upstream processing in the hands of experienced 
staff151. Most methods achieving high purity samples, require off chip sample preparation 
such as centrifugation, cell lysis, incubation with beads etc. making unsuitable for 
deployment at the point of care152.  Also, the common belief that working with 
microfluidics will reduce lab footprint is, besides a few exception, unfortunately untrue 
and for the correct working of a small chip several bulky and expensive pieces of 
equipment are required137, including pumps, microscopes, actuators, just to mention a 
few.  This requirement confines most of the technologies developed within the lab walls.  
One reason to explain the current situation is that research on POC testing, has generally 
focused either on real time detection or miniaturised multiplexed detection148, leaving 
aside sample preparation.  Another issue is probably the attitude of several academic 
groups to develop microfluidic technologies just as proofs of concept.  A peculiar 
example sees a microfluidic device153, designed for the on-chip separation of magnetic 
beads, when the same result could be obtained simply with a magnet off-chip. This 
tendency to overcomplicate simple systems for publication scopes, clearly points at one 
of the most common mistakes in academia, unfortunately quite widespread in the 
microfluidic community. 
2.5.4 Lack of  solut ions for  commercial  translat ion.   
Although microfluidic technologies often entail technologically advanced features, it is 
deemed that this is not the main problem to the development of these technologies and, 
while the proof of concept is generally straightforward, their introduction to the market 
presents more hurdles.  Among the specific challenges to overtake there is the need of an 
open discussion between interdisciplinary branches and the need for product design 
aimed at the large scale manufacture or, in the pre-commercial step, at the fast 
prototyping/batch production154. These manufacturing requirements are not easily 
compatible with PDMS, which is used often as a material of choice for academic 
microfluidic research.  
Standardisation of procedures for microfluidic equipment should be performed as for any 
other pieces of equipment, thus involving the periodic calibration of the machines to 
ensure they are working on their specifications.  Similarly, as sample volume has an 
impact on chip-performances, due to the fixed amount of reagents, adsorption capacity of 
membranes etc. having a metering system at the interface between the microfluidic 
component and the outside world becomes crucial154. The lack of understanding of these 
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problems, during the technological development, is therefore a great obstacle to 
commercial translation. 
 
2.6 Aim of this project and objectives 
It is worth to point out that the issues described for efficient sample preparation from 
blood have no universally applicable solution: isolation methods must be chosen 
specifically, according to the sample type, target of NAs to isolate, sensitivity required 
and downstream application.  Additionally, while in highly specialised centres the most 
valued traits are extraction yield, specificity and speed, at the point of care and low 
resource settings, ease of use and shelf life are invaluable requirements154.   
The aim of this project is the development of an integrated microfluidic platform, able to 
perform the isolation of CNAs, from whole blood, straight after blood-draw.  In order to 
fulfil this scope, the extraction protocol needs to be fast whilst guarantee robust results.  
Most importantly, the system needs to overcome the need for “off-chip” steps, which is 
the most common obstacle for the introduction of a number of commercial platforms in 
real life applications, and defines a sharp line between a clinically useful tool and a 
research apparatus, to be used within academic settings.  Similarly, the platform needs to 
be user-friendly, and ideally usable by untrained phlebotomists right after blood draw: 
disposable parts are required to be easy and fast to mount onto the platform.  The whole 
protocol needs to run automatically without user interference.  Furthermore, the device 
needs to be “self-contained”, meaning that it should not rely on other external equipment.  
Finally, while the automated platform needs to be compact, light and portable, cartridges 
needs to be disposable to avoid cross-contamination.  For translation and commercial 
viability, the cartridges need to be easily mass-manufactured and free from expensive 
embedded actuators. 
  
39 
 
CHAPTER 3: DESIGN OF CNAS EXTRACTION CARTRIDGES 
In this chapter is discussed the design of disposable cartridges for the extraction of 
circulating nucleic acids from blood.  Firstly, original bench protocols are discussed 
followed by the description of the fluidic solutions that allowed the integration of these 
protocols within a portable and automated format.  The chapter ends with the description 
of two microfluidic cartridges.  
 
3.1 Bench protocol for cfNA extraction from blood 
 A conventional approach was chosen as a base for the development of an integrated 
device as well as for benchmarking this device.  Figure 6 display a workflow describing 
the transformation of blood samples into CNAs eluates, following the chemistry of solid 
phase extraction (SPE) in the presence of a chaotropic agent.  The first step is the 
extraction of plasma from blood.  Following plasma extraction, proteins, including 
enzymes that specifically digest nucleic acids, and phospholipidic membranes are 
digested by means of proteases and lysis buffer, which contains surfactants that 
destabilise the cell membrane.  After the lysis step, adsorption conditions are obtained by 
mixing the sample with a chaotropic agent, which reduces the solubility of nucleic acids 
in water.   As the mix passes through a solid membrane, CNAs are therefore adsorbed on 
its surface, while most of proteins stay in solution.  The membrane is next flushed with 
one or more washing buffer solutions to furtherly reduce the protein contents, thus 
increasing the purity of the sample.  After drying, CNAs are finally eluted in a small 
volume of elution buffer, thus leaving a highly concentrated and pure eluate of nucleic 
acids.   
In the bench protocol, liquid handling is achieved by manual pipetting. Fluids are usually 
driven through the membrane by mean of centrifugal forces (in a centrifuge) or using a 
vacuum manifold to create a pressure gradient.  Incubation steps at different temperatures 
may also be included within some protocols, so as to obtain the optimal conditions for the 
reactive steps or to ease drying.  The next two sections describe two bench protocols we 
decided to implement in microfluidic format. 
40 
 
 
Figure 6 Circulating nucleic acids extraction simplified SPE workflow 
3.1.1 Kurabo Quickgene  
The Kurabo Quickgene blood mini kit was originally developed for the isolation of 
genomic DNA from whole blood.  The method is based on a polymeric membrane, 80 
m thin, and uses ethanol as a chaotropic agent.  The lyse steps includes proteinase K and 
a lysis buffer and, after the binding step, only one wash buffer is required for the 
purification of residual contaminants on the membrane. 
The Kurabo protocol was first integrated in a microfluidic format at Fraunhofer IMM for 
the extraction of bacterial and viral DNA from nasal swabs133.  This protocol was deemed 
a good first approach for microfluidic integration due to its simplicity: (i) it does not 
include any incubation steps (ii) only one buffer per step is required and (iii) the thin 
membrane employed, entails low pressure drops in the fluidic path.  In Table 1 are shown 
the specifics of the protocol in comparison to QIAGEN circulating nucleic acid kit, which 
is described in the next section.  
 
3.1.2 QIAGEN circulat ing nucleic acid ki t  
The QIAGEN QIAamp circulating nucleic acids kit is the kit currently favoured in 
academia and industry for the extraction of CNAs155.  This kit is based on a multilayer 
silica membrane and, a mixture of ethanol or isopropanol with an ACB buffer containing 
specific salts as a chaotropic agent.  As this protocol is designed specifically for the 
extraction of  CNAs, much less abundant than genomic NAs, it is more complex than the 
Kurabo protocol, previously described, and includes a triple wash with three different 
washing buffers.  Before extraction the lysis buffer needs to be mixed with carrier RNA 
to enhance extraction efficiency156 and a three incubations steps (at 60 °C, 0 °C and 56 
°C respectively) are included in the workflow. 
3.1.3 Bench protocols  comparison  
In Table 1 the different aspects of the two chosen protocols are showed step by step.  A 
direct comparison of the two is difficult, as are different their initial purposes.  In the next 
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section, the fluidic solutions to integrate variations of these two original protocols within 
microfluidic devices are shown in detail. Buffers are indicated by their commercial name.  
EDB is code name given to proteinase K in the Kurabo protocol.  LDB, in Kurabo 
protocol, and ACL, in Qiagen protocol, are lysis buffers, containing surfactants to 
destabilise cell membrane and additional salts to help the chaotropic effect of ethanol, in 
Kurabo, or either ethanol or isopropanol added to the salts solution called ACB buffer in 
Qiagen kit.  WDB, used in two consecutive steps in the Kurabo protocol, and ACW1, 
ACW2 used in the Qiagen kit, are saline buffers containing a high percentage of ethanol, 
so as to maintain chaotropic conditions on the membrane (in order not to elute any NAs 
previously bound), and at the same time effectively wash proteins.  In the Qiagen protocol 
the salt concentrations of buffers decreases from the ACW1 to ACW2 and the final wash 
is given by pure ethanol with no salts.  Finally, elution step is given by CDB and buffer 
AVE, in Kurabo and Qiagen kit respectively.  These buffers are basically aqueous 
solutions, so as to annul chaotropic conditions and allow NAs to unbind from the 
membrane, containing stabilisers to ease the long-term storage of the eluate. 
Extraction protocol/steps 
Kurabo Quickgene spin 
column (200 l whole blood) 
QIAgen QIAamp 
circulating nucleic acids 
kit (1 ml plasma) 
Lysis step 
EDB (Proteinase K) - 30 l Proteinase K - 100 l 
LDB - 250l 
Buffer ACL+carrierRNA - 
800 l 
2 mins incubation at 56°C 30 mins incubation 60°C 
Binding step Ethanol - 250l 
80%Ethanol+20%ACB 
buffer 1 - 800l 
5 mins incubation at 0°C 
Washing step 
WDB – 750 l 
WDB – 750 l 
Buffer ACW1 - 600l 
Buffer ACW2 – 750 l 
Ethanol – 750 l 
Drying step  
3 minutes full speed 
centrifuge  
10 mins incubation at 56°C 
Elution step CDB - 200 l Buffer AVE – 20-150 l 
Table 1 Comparison of two NAs extraction protocols chosen for microfluidic implementation 
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3.2 Cartridge Design 
The role of the microfluidic cartridge is to integrate the different steps necessary for the 
extraction of CNAs from blood in one single device and without the need for operator 
handling steps.  Several generations of cartridges were developed during the first part of 
the project (eleven, plus a few variants in each generation), tackling in different ways the 
fluidic issues encountered, while two cartridge models were thoroughly characterised 
with biological samples and results are included in Chapter 5 and 6.  
In Figure 7 is shown a block diagram for the operation performed within the cartridge.  
The colour code refers to the kind of operation undertaken in the block, therefore 
operations described by the same colour can be performed in a technologically similar 
way.  Plasma extraction is coded in yellow and it is performed through the blood plasma 
separation microfluidic unit described in 3.2.1.  Mixing steps are marked in green.  
Different approaches to mixing are described in 3.2.2.  In red are marked all the steps in 
which a liquid is required to flow through the adsorption membrane.  As described in 3.3 
this was performed driving the liquid through the membrane with an airflow in all the 
cartridge versions with the exclusion of the first two.  Finally, the drying of the membrane 
is marked in blue.  Drying strategy is briefly described in 3.3 while in Chapter 6 is shown 
a more thorough study on drying, together with the effect that this has on cfDNA 
extraction yield. 
 
 
Figure 7 Cartridge workflow block diagram colour mapping refers to the kind of operation undertaken in the 
block. Yellow: plasma extraction. Green: mixing steps. Red: operations requiring liquid flow through the membrane. 
Blue: membrane drying. 
Here, we describe the different approaches undertaken during the project, to solve the 
problems rising in the design of the microfluidic cartridge.  Sections are divided according 
to the aim of the modules described and, before the detailed description of the two most 
relevant cartridge models developed, a brief overview on the chronological development 
of the various models is given. 
3.2.1 Blood plasma extrac t ion 
A blood plasma separation (BPS) chip developed in our group157 was chosen as preferred 
method for this step. Briefly, this method works through hydrodynamic focusing in 
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microfluidic channels, shaped as an alternated sequence of constrictions and openings.  
While crossing a constriction, RBCs are accelerated and packed in the central part of the 
channel by inertial and viscous lift forces, creating an enhanced cell free layer on the 
edges of the constriction channel.  A side channel is placed after each constriction, so as 
to extract clean plasma.  In Figure 7 is shown a schematic of one of the first models of 
BPS chip, featuring one inlet and three outlets.  Since then the technology was further 
developed, pressure drops in the side channels optimised, the footprint reduced and the 
design adapted for microinjection moulding, although in this study we used chips 
manufactured by Epigem (UK) in SU8 and PMMA.  
Starting from 3 ml of blood diluted in PBS (1:1), the chip performs the separation of clear 
plasma in about 20 minutes.  The actuation is provided by a syringe pump and the quality 
of the extracted plasma is comparable with the one obtained through bench double 
centrifugation when analysed with qPCR (results in Chapter 5).  Naturally, the dilution 
of blood causes a dilution in the CNAs to be extracted, but we consider the advantage of 
operating in-line in one device, without the need of a centrifuge and, most importantly, 
of the manual pipetting steps necessary for the process, far superior than this drawback.  
 
Figure 7 Schematic of a 20 m wide microchannel blood plasma separation157  Sample enters the system from 
the Blood inlet and passes through the main channel. After each constriction, a cell-free zone is created and clear 
plasma withdrawn through side channels (1-8). Cell enriched stream exits the microfluidic chip through the Cell 
outlet, while plasma is collected from the plasma outlets (collection 1 and 2). In the blow-up section, geometrical 
characteristics of the main channel unit.  
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The integration of the Blood Plasma Separation (BPS) chip within the disposable 
cartridge does not represent any technical difficulty, except the possibility to have leak-
proof channels that can resist the inlet pressure and to easily fix attachment to the platform 
structure.  As described in the next chapter, our bonding method allows for high-pressure 
resistant channels.  For the connections with the outside, used to connect both the BPS 
chips and inlet or output tubing to the cartridge, we used Epigem ltd (UK) connections, 
which include compressible ferrules that, once the parts to connect are pressed together 
by mean of simple bolts, ensure hydraulic sealing.  
After the BPS chip, an additional step can be included to enhance the purity of the 
extracted plasma.  Indeed, as the BPS module works by hydrodynamic focusing of the 
red blood cells (RBC), during priming of the chip, before stationary flow is achieved, a 
small plug of RBCs can escape towards the plasma outlet.  
This further purification can be achieved in different ways, we focused on settling and 
filtration.  Settling of RBCs was performed following different geometries, designed to 
slow the fluid down and allow the irreversible sedimentation, by gravity, of cells at the 
bottom of small chambers.  Filtration was performed using a Vivid™ Plasma Separation 
Membrane (Pall), implementing a filter chamber in one of the layer of the cartridge.  
There are different methods to fix a filter within the cartridge; they are briefly described 
in 3.3.1 and 3.3.2 relatively to the cartridge model discussed.  Adsorption membranes can 
be fixed in the same ways as filters.  In Figure 9 is shown an integrated membrane 
(Quickgene) fixed with tape to one of the layers before the final bonding process that 
enclosed it in the microfluidic network. 
 
Figure 8 detail of cartridge 8: A) static mixer, realised in three layers, with ovals in 0.2 mm thick PMMA 
connected by thin channels through a 2mm thick PMMA layer b) adsorption membrane, C) turning valve. 
In Figure 9, it is as well possible to notice a turning valve (bottom) and a static mixer (on 
top).  These features are described in 3.2.2 and 3.2.3. 
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3.2.2 Mixing 
After BPS, the extracted plasma needs to be mixed with reagents (proteinase K, Lysis 
buffer) and the chaotropic agent, before passing through the membrane.  Partial mixing 
can entail a significantly lower NA yield in the final eluate.  Indeed, incomplete reactive 
steps entail leaving the CNAs bound to proteins or within micro-vesicles, thus reducing 
the amount of CNAs physically available for adsorption.  On the other hand, uneven 
mixing of the chaotropic agent would allow through the membrane volumes of fluid in 
which adsorption conditions are not favourable.  This would not only avoid the adsorption 
of the CNAs present in these portions of fluid, but would most likely entail an untimely 
elution of the previously adsorbed CNAs, that would be lost in the waste stream.  
Within the bench extraction protocols described in the previous section, each time 
multiple fluids are put in contact, a 10-30 seconds mixing step using a vortex is 
performed, so as to insure thorough mixing of the fluids.  Mixing is a common problem 
in microfluidics, as flow is usually laminar and mixing only occurs by diffusion.  During 
the development of the different generation of cartridges, several mixing strategies were 
adopted.  
 
Figure 9 detail of cartridge1: A) multiple inlets mixing, B) an Epigem connector allows in the cartridge the blue 
liquid from a syringe pump C) yellow fluid, leaving the BPS chip. 
In Figure 9 is shown a detail of a mixing module (A) in the first cartridge developed along 
the project (Full cartridge picture and CAD drawing in Figure 10).  In this model, the 
yellow fluid coming from the BPS extraction module (C) (the screws tightening the chip 
are visible on the right of the figure) is mixed with a blue fluid, simulating a reagent, 
entering the system through an additional inlet and pushed by a second syringe pump.  
Both syringes are connected to the platform through the Epigem connection visible on 
the left of the picture (B).  The two fluids get in contact through several small channels, 
while a series of constrictions enhances the mixing; a uniform green mixture is obtained 
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at the end of the process.  This method is effective and simple, although the use of a 
different syringe pump per reagent is required.  This is a considerable drawback when 
several reagents need to be mixed together and even more so when the platform needs to 
be deployed at the point of care.  All the following cartridges were therefore designed 
with chambers, so as to contain all the necessary reagents contained within.  In this way 
it was possible to limit the use of syringe pumps to two, one used to drive through the 
inlet sample and one, filled with air, intended to supply compressed air able to move the 
reagents contained within the chambers, relying on turning valves to manipulate air flow 
direction.  To enhance mixing in these systems several strategies were adopted, mostly 
relying on static mixers such as the one already shown in Figure 8, in which the fluid is 
forced through a series of constrictions involving three layers of the device, so as to 
improve mixing due to the velocity gradients.  In the latest models of cartridge, a new 
mixing system was developed and used in combination, or not, with static mixers, as the 
main mixing strategy in the platform.  This mixing method allows at the same time for 
the removal of air gaps in between the different reagent chambers.  This means that 
chambers containing different reagents can now be put in line, one after the other, without 
the risk that the incoming fluid will push all the reagents placed in the next chambers 
outside the system, through the adsorption membrane, before having the chance to mix 
with them, and being still isolated by air-gaps.  This strategy is based on the use of air-
bubbles and their separation from the fluid and is now being patented (P33710GB1), it 
will not therefore be discussed further within this thesis.  As the mixing occurs at the 
same time as the blood plasma separation, the first volume of plasma extracted will be 
incubated with the reagents for a longer time than the last portion of it.  Although this is 
can be regarded as disadvantageous, preliminary testing performed in our lab (by Ieva 
Keraite, results not shown in here) showed that incubation during lysis step does not 
strongly affect NA extraction yield. 
3.2.3 Valving 
Valves are essential to the control of fluid-flow, particularly in highly integrated 
cartridges containing different chambers.  Several valving alternatives are possible within 
microfluidic systems.  We explored two main options: magnetic and turning valves.  
Herein, with magnetic valving we refer to the possibility to alternatively close channels 
with a moving object sensitive to a magnetic field.  More specifically, we used 600 m 
diameter magnetic spheres, placed in an 800 m thick enclosure, where the fluid is 
received.  The sphere can be attracted by a magnetic field towards the top or bottom of 
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this enclosure, differentially opening and closing two fluid outlets.  The method has some 
advantages, for example a nearly immediate actuation.  Nonetheless, it only allows the 
discrimination between two channels at a time.  To increase our control flexibility without 
complicating the design with several magnetic valves operating in concert, we opted for 
turning valves (already shown in Figure 8).  Thanks to turning valves, it is possible to 
connect selectively one central channel to many different secondary channels.  The central 
channel is opened towards the external surface of the cartridge and it is the valve itself, 
pushed against the cartridge by a spring, to ensure sealing and close the fluidic path.  The 
valve features one or more grooves which, according to the position of the valve, can 
create a communication passage between two channels with opening exposed to the valve 
surface.  In the most common application, a radial groove rotates, alternatively opening 
communication between one central channel and one of the multiple channels possessing 
one opening placed in a circle around this central channel.  
 
3.2.4 Phaseguides  
As we opted for the use of compressed air to drive the motion of all the fluids present 
inside the cartridge but the inlet blood, it was necessary to ensure that this did not 
compromise the controllability of the system.  As we already mentioned, the last 
generations of cartridges feature a novel method to handle this problem.  In the previous 
generations, we resolved for using phase-guides.  In the next section, dealing with the 
chronological development of the microfluidic platform, are shown some of the CAD 
design of these models of cartridge; in both Figure 11 and Figure 12 several generation 
of cartridges feature chambers including lines patterned along their surface.  These are 
called phase-guides and allow for the controllable filling and emptying of chambers, 
avoiding the risk of formation of bubbles or preferential air passage, which would result 
in reagents stagnating within the device, and were featured in all chambers and wide 
channels.  The idea behind phase guides lies on a step-wise advancement of the air-liquid 
meniscus, accomplished by geometrical features that change meniscus curvature158.  In 
our case, this was obtained thanks to 0.2 mm tall stripes patterned at the bottom of 1-2 
mm tall channels/chambers.  Due to the so-called meniscus pinning effect, a phase (air or 
liquid) is allowed to fill a patterned region only after the complete filling of the previous 
one, thus permitting the control of phase advancement.  Phase guides were shown to work 
also for other applications, such as pressure related passive valving159.  The position in 
which the incoming phase will overcome the phase-guide is usually related to the sharpest 
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angle in it.  Also, the higher is the pressure in the incoming phase, the taller the phase 
guides will be required to be in order to maintain control of the flow.  The aforementioned 
statements were taken into account during the design of phase-guides within the different 
generations of platforms. 
3.3 Design iterations 
 All the cartridges were designed in AutoCAD (Autodesk, CA).  For the manufacturing, 
we opted for using a laser cutter to shape layers out of poly(methyl-methacrylate) 
(PMMA) sheets, with different thickness, and then bonding them together to form 3D 
structures starting from 2D designs, as described in Chapter 4.  In microfluidic literature 
concerning nucleic acids and thermoplastic materials, PMMA is considered one of the 
less compatible with the process, because of the inhibitor effect that PMMA can have on 
PCR.  Nonetheless, it was shown that this is mostly due to polymerase inhibition by the 
PMMA and not by binding of nucleic acids on the surfaces of the material160, therefore 
we decided the advantages of working with this material were not compromised, at least 
for our current purpose.  The benefits of choosing this material and the details of our 
custom bonding method are discussed in Chapter 3.  
 
Figure 10 Cartridge, 1st generation.  Picture and CAD drawing (overlapped layers) of cartridge 1 connected to 
Eppendorf tube.  The numbers indicate 6 inputs (whole blood (1), Proteinase/lyse buffer (3), Wash Buffers (4)(5), 
Elution buffer (6) and compressed air (2)), and two outlets with eppendorf connections (RBC (7) and membrane 
outlet (8)).  Capital letters are used to indicate: connections for a BPS microfluidic chip (A), a static mixer to mix 
plasma and protease/lyse buffer (B), a chamber (D) where fluid is collected before being pushed through the 
membrane (E) by mean of compressed air and connections to a valve (C) to regulate flow within the device. 
In Figure 10 is shown a picture of the cartridge developed for the 1st generation.  As the 
cartridge has six inputs, follows that six syringe pumps were necessary for the 
manipulation of the different fluids.  This resulted in a large footprint of the device on the 
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bench, totally incompatible with point of care applications.  Chamber D was the only one 
included in the platform and served the purpose of incubating the reagents and sample 
before compressed air pushed them through the adsorption membrane (E).  
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Figure 11 Cartridge development: overview on the eleven generations.  Overlapped layer CAD drawings of ten of 
the most representative cartridges developed along the project. 
In Figure 11 are shown the overlapped CAD drawings of ten representative examples, 
which describe the cartridge evolution along this project.  All of these cartridges are sized 
56 mm x 76 mm and have thicknesses in the range of 4.8-6.4 mm. Within the eleven main 
generations, some variants were developed as well, identified by Greek letters, in which 
minor problems were fixed without changing any fundamental details, or alternative 
features (such as mixing structures, different phase-guides etc) were tested.  Cartridge 2 
differs from cartridge 1 mostly for featuring a smaller incubation chamber.  Also, a 
different positioning of one of the turning valves allows reagents to be deployed directly 
on the membrane, by-passing the incubation chamber that is used only for the lyses step.  
Indeed, for the correct filling and emptying of a chamber as large as the one featured in 
cartridge 1, it is necessary an accurate tuning of the flow-rates.  Operating with a smaller 
chamber ensure the possibility to operate at higher flow rates, therefore shorter times, 
without the risk that the fluid does not follow the phase-guides.  For the very first 
generations (cartridge 1 and 2), reagents were handled within external syringe pumps.  As 
mentioned earlier in this section, this is inconvenient, due to the pumps footprint, not to 
mention the additional cost.    Starting from cartridge 3, the number of chambers increased 
to five while the inputs decreased to two.  Indeed, only two syringe pumps are used in 
these systems.  One of them handles the blood inlet flow, while the other supplies the 
compressed air which, directed by turning valves, controls the rest of the process.  In 
addition, from the development of cartridge 3 on, all the cartridges were featured with a 
section for RBCs purification after the BPS chip, initially accomplished through gravity 
settling of cells within weirs.  Cartridge 3, due to the chambers arrangements, showed 
issues related to flow control after the BPS unit.  Indeed, the sample was received into a 
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mixing unit opened both towards an incubation chamber and a chamber which worked as 
a tank for the lyse reagents mix and the control over the flow at the fork, by mean of 
compressed air, proved harder than expected.  Cartridge 4 was therefore designed so as 
to receive the sample in the same chamber as the one containing the reaction mix.  This 
configuration did not entail the backpressure issues of the previous nonetheless, the 
removal of the air contained between the incoming sample and the reagent chamber 
became a problem.  To solve this, several attempts were made, including passive and 
active valving aiming at letting the air go out of the system through the membrane without 
pushing the reagents while doing so.  In here I do not show cartridge 4, as its design is 
substantially the same to that of cartridge 5, although the latter implemented a magnetic 
valving system, as described in 3.2.3, to guide the air towards one outlet and then the 
sample toward the reaction chamber.  The last few generations of cartridges, starting from 
cartridge 7, implemented our new mixing strategy (patent P33710GB1), and going further 
with the cartridge development we can observe smoother shapes and a simpler design.  
Also, the RBC purification after the BPS unit, accomplished by settling up to the 9th 
generation, was enhanced in cartridge 10 and 11 with the implementation of a filter.  The 
next two sections describe in more details the two cartridges that were used most 
extensively in the biological characterisation of the CNAs extraction performances, 
treated in Chapter 4 and 5. 
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3.3.1 Cartr idge 9  
 
Figure 12 exploded view of the 5 layers composing cartridge 9From the top: layer 1 - 2 mm thick, connections 
for the BPS chip. Layer 2 - 0.2 mm thick, channels. Layer 3 – 2 mm thick, reagent chambers, adsorption membrane, 
RBC settiling strucutre. Layer 4 – 0.2 mm thick, channels. Layer 5 – 2 mm thick, channel openings for turning 
valves, connections to external tubings for inlet and outlet streams. 
The disposable cartridge described in this section (Figure 12) was thoroughly 
characterised on miRNA extraction as described in Chapter 5.  Cartridges were 
manufactured by laser cutting (Mini 18, Epilog (USA)) five layers out of PMMA cast 
sheets (Weatherall ltd, UK) of different thicknesses (2mm-0.2mm) and bonding them 
together, using a 2 minute solvent assisted thermal process161, as described in the next 
chapter.  The cartridge features six preloaded reagent chambers and one embedded 
polymeric membrane obtained from a Kurabo quickgene spin column and fixed with tape 
before bonding.  Reagents amount was tuned so as to treat a 400 l plasma sample.  The 
first chamber (C1) is filled with proteinase K, C2 contains lysis buffer, C3 contains 
ethanol while C4 and C5 provide washing buffer and elution buffer respectively. Food 
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dye solutions were added to ease the visualisation of fluid paths, and ethanol was added 
to lyse buffer to decrease surface tension and avoid formation of bubbles during the filling 
step, more detailed description of chamber contents can be found in Table 2.  In order to 
fix the CNAs adsorption membrane within the cartridge it was used a biocompatible 
double-layer tape162, laser cut in toroid shape.  This allows the plasma to flow through the 
central part of the filter and avoids side-flow.   
Chamber Main reagent Supplier Additional 
C1 Proteinase K 70 l QIAgen Dye 5 l 
C2 Lysis Buffer 250l Kurabo 
Ethanol 50l, dye 
15l 
C3 99.95% Ethanol 330l Sigma Aldrich Dye 16l 
C4 Washing Buffer 100l Kurabo Dye 50 l 
C5 Elution Buffer 65l Kurabo 5 l 
 
Table 2 Composition and supplier for reagents in the different chambers of cartridge 9. 
The plasma (directly pumped in or coming out of the BPS chip) inside the device is 
pushed through C1, C2 and C3, where it gets in contact with the reagents, before passing 
through the silica membrane, where the elevated concentration of ethanol favours the 
adsorption of nucleic acids.  Later, the washing buffer stored in C5 is pushed through the 
membrane to remove proteins and impurities and finally, after drying with air at 550 ml/h 
for 5 minutes, the elution buffer is gently pushed through the membrane at 10 ml/h. Fluid 
motion within the cartridge is regulated through two syringe pumps (World Precision 
Instrument, UK).  One pushes the plasma through the device, the other is loaded with air.  
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Three turning valves are used to direct the airflow through the different chambers and 
similarly putting the membrane in contact with them alternatively.  The third valve allows 
to direct the fluid leaving the membrane to the waste or elution outlet.  Details on the 
automation support are given in section 3.4. 
 
3.3.2 Cartr idge 11 
 
Figure 13 exploded view of the 5 layers composing cartridge 11 From the top: layer 1 - 2 mm thick, connections 
for the BPS chip. Layer 2 - 0.2 mm thick, channels. Layer 3 – 2 mm thick, reagent chambers, adsorption membrane, 
RBC filter. Layer 4 – 0.2 mm thick, channels. Layer 5 – 2 mm thick, channel openings for turning valves, 
connections to external tubings for inlet and outlet streams. 
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The cartridge described in this section and shown in Figure 13, was developed for the 
purpose of the integration of the gold standard cfDNA extraction protocol developed by 
QIAGEN.  With respect to the original protocol shown in 3.1.2, several incubation steps 
were omitted and as adsorption membrane we resolved to use Econospin membranes 
(Epoch Life Science) which, in preliminary tests shown in Chapter 6, gave the same 
results as QIAGEN membranes for a fraction of the price.  The process workflow of this 
cartridge is very similar to the one described in the previous section for cartridge 9, 
although several differences exists in the execution of the steps.  First, following the 
microfluidic plasma extraction, the occasional red blood cells escaping the module are 
not removed by a series of weirs by settling, as in the previous model, but through a 
Vividtm plasma separation membrane (Pall).  This filter was fixed to the platform by mean 
of toroidal indentations engraved in one of the PMMA layers.  Before bonding, the filter 
is placed on top of these indentations so that once the layers are pressed together, the filter 
is locked in position by mechanical clamping.  Mixed within the lyse buffer, in C2, carrier 
RNA was added to the reagents, in agreement with the notion that this can markedly 
increase cfDNA yield, probably by sacrificially binding to site in the silica membrane that 
would irreversibly bind DNA strands if left active156.  The chaotropic agent chamber, C3, 
occupies a larger volume and not all of it is occupied by the reagent itself. Indeed, 
chamber C3 is empty for about one third.  This allows the incoming fluid to fill the 
chamber without pushing away any of the reagent, which would otherwise be lost before 
mixing with the entering sample.  The washing buffer chamber C4, is divided in three 
slots, to allow for the storage of the three different reagents required for the washing step 
by this more complex extraction protocol.  The content of the different chambers is 
described in Table 3Table 2.  The adsorption membrane is fixed in the platform by using 
an O-ring that once the PMMA layers are bonded together, clamps it into position.  
Finally, more relevance was given to the drying step: a separated channel was built to 
connect the membrane directly to the air source, contrary to the previously described 
cartridge, in which the air was pushed through the C4, still wet of the washing buffer.  To 
furtherly increase the drying rate a specific allocation for a small heater was designed on 
top of the membrane section.  Heater specifics are described in section 3.4, together with 
those of the automation support.  Together with cartridge 9a, this cartridge was 
characterised on miRNA extraction as shown in Chapter 5.  Additionally, Chapter 6 deals 
with the optimisation of the operative parameters of the cfDNA extraction operated 
through this cartridge model.   
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Chamber Main reagent Supplier 
C1 Proteinase K 40 l QIAgen 
C2 
Buffer ACL 400l  +  
carrier RNA elution 6l 
QIAgen 
C3 
80%Ethanol (99.95%)+20% ACB buffer 
- 800l 
Sigma 
Aldrich/QIAgen 
C4 
Slot1 Buffer ACW1 - 200l QIAgen 
Slot2 Buffer ACW2 – 200 l QIAgen 
Slot3 Ethanol – 200 l Sigma Aldrich 
C5 Buffer AVE 65l QIAgen 
 
Table 3 composition and supplier for reagents in the different chambers of cartridge 11 
3.4 Automation support design and software 
An important requirement of the platform is the ability to process samples in a robust 
fashion, free from human errors.  Hence, an automated protocol is necessary, so as to 
ensure that all the samples are treated in the same way.  Three stepper motors, a three 
modules syringe pump together with electronic control card and a software as well as a 
small heater with temperature controller, were commissioned from partners in Germany 
(Fraunhofer Institute Meinz, DE).  A PMMA case was home-built from 5 mm thick black 
PMMA (Weatherall ltd, UK) with screws and hinges (RS components, UK) for easy 
assembling.  The case encloses the electronic components and creates an allocation for 
the microfluidic cartridges, through a custom-made polyether ether ketone (PEEK) 
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connector (cf following section) which includes all the fluidic connections, the allocations 
for the turning valves and threads to allow the system to be put together.  The three stepper 
motors allow for the control of the three turning valves, in a simple and reliable way.  
Only two of the syringe pump modules are currently used, one for the sample and one for 
the air that drives the flow within the cartridge.  In a later development of the platform, a 
peristaltic pump substituted the syringe pump assigned to the control of the air.  In the 
next sections, I am going to discuss in details the different components of the automation 
platform. 
 
3.4.1 Mechanical  components  
 
Figure 14 Mechanical component of the automation platform.  A) Cartridge assembled on B) peek connector, C) 
stepper motors support and D) electronic control board. 
In Figure 14 is shown a cartridge 9 assembled to a custom-made PEEK connector (B).  
The connector carries out several tasks.  First, it ensures hydraulic connection between 
the cartridge, two syringe pumps and three collection tubes through five channels.  These 
channels are accessible to 6M screws from the sides of the connectors (three on the left, 
as visible in Figure 14, and two on the right), with these screws is possible to effectively 
push external tubes against a small channel internal to the connector.  Collapsible ferrules 
supplied by Epigem ensure fluidic sealing.  The small internal channels (0.8 mm OD) 
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feature 90° bends and lead to the front of the PEEK connector, where five cavities (1.8 
mm OD) fit five ferrules (Epigem) placed as sealing between the five cartridge inlet or 
outlets and the connector.  The cartridge is pressed against the connector by five screws 
(Four at the corners and one in the centre), ensuring the gentle squeeze on the ferrules 
that guarantees the fluidic sealing.  
 
 
Figure 15 turning valves. Close up and technical drawing by Fraunhofer IMM. 
In Figure 15 are shown details of the Fraunhofer turning valve used for the automation 
support.  A radial groove on the turning component (green in the pic) allows to put in 
fluidic contact the central channel with all the others having an opening inscribed within 
the valve circle, once the grove is turned in the suitable position.  To create the proper 
allocations, 0.635 mm (1/4”) OD cavities were dug in the PEEK connector to a depth of 
8mm.  A spring is placed in each cavity before the valve, ensuring that the latter is forced 
against the cartridge once this is screwed to the connector, giving fluidic sealing.  At the 
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bottom of each cavity a 3.7 mm OD opening allows the head of a stepper motor to fit in 
a half-circle indentation at the bottom of the turning valve shaft.  In this way it is possible 
to control the turning of valves without human intervention, through precise and 
automated rotations of the stepper motors. 
 
 
Figure 16 heater support A) machined part B) assembled heater support. 
In Figure 17 is shown the custom support designed for the heater module.  The heater is 
a 50 W thick film resistor from Reichelt Elektronik (AT).  Having a very low heat 
capacity, operating simply by putting the heater in contact with the cartridge, would result 
in very sharp heat oscillations, with hot peaks incompatible with the stability of both the 
biological sample and the PMMA cartridge.  To increase the thermic inertia of the system 
I decided to add a small aluminium support that I machined for the purpose (A) and 
connected to the heater (B). The four corner screws fit in lodgings on the cartridge, around 
the membrane, so as to ensure 1) a stable position for the heater and 2) a more even heat 
distribution around the membrane, thus easing thermal transport.  A comprehensive study 
of the process, was not performed yet. The effect of the heater on the drying of the 
membrane, and its effect on CNAs extraction yield, was tested and results are shown in 
Chapter 5.  
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3.4.2 Software  
 
 
 
Figure 17 Automation software interface supplied by Fraunhofer Mainz 
 
In Figure 17 is shown the interface of the custom software realised by Fraunhofer Mainz 
for the control of the automation module.  In the top part is possible to select the valve 
which needs to be turned and the number of steps. As 360° correspond to 6000 steps, a 
very fine control of the valves position is easily possible.  The three syringes can be 
controlled separately and the same goes for the heater, which can be set to reading the 
temperature only or to actively heat up the system.  A custom “assay programmer” allows 
to write in advance the actions that needs to be performed during an automated extraction, 
dividing the protocol into “chapters” and selecting the conditions to pass from one chapter 
to the other.  For example, the turning of valves from one configuration to another can be 
actuated after a determined volume has been pumped out of a syringe and the heater can 
be turned on and off for specific steps.  For time constraints reason, this modality has not 
been thoroughly explored and used in the biological characterisation of the samples, 
although we reckon that it is a straightforward step and will substantially ease the process.  
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3.5 Final Remarks 
 
This chapter described the design process which led to the realisation of the two cartridge 
models and the automation support that controls them.  As from the premises of this 
thesis, in 2.6, these cartridge models and automation support represent the core of our 
solution for the fast and robust sample preparation, close to patient, starting from whole 
blood and delivering a stable CAN eluate.  The next chapter describes the fast prototyping 
method that eased the cartridge design process, allowing to operate in an iterative way 
without lead time between design and prototype testing. The two cartridges were 
extensively characterised on miRNA, as shown in Chapter 5, and single microfluidic steps 
were optimised as shown in Chapter 6. 
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CHAPTER 4: ULTRAFAST METHOD FOR PMMA BONDING AND 
MICROFLUIDIC PROTOTYPING 
 
4.1 Introduction 
This chapter describes a method developed during this PhD to accelerate the development 
of microfluidic polymeric cartridges for translation into commercial products.   
As discussed in the state of the art, among the requirements for the effective translation 
of microfluidic device into commercialisation, is the possibility to move from the lab 
production to large scale manufacturing.  In order to reduce development time, fast 
prototyping is desirable.  Prototypes must respond to a series of criteria including having 
similar functional, chemical and mechanical properties to a final product.  This chapter 
describes a fundamental step this approach allowing the iterative design and prototyping 
of the cartridges composed of multiple layers of polymethylmethacrylate (PMMA).  This 
method was developed with the goal of ensuring the fast, safe, cost-effective and reliable 
manufacturing of microfluidics prototypes, starting from laser cut sheets of PMMA of 
different thicknesses.  PMMA is a common material in injection moulding. Therefore, 
the prototypes developed with the rapid-prototyping technique can be rapidly translated 
in an injection moulding workflow, thereby accelerating the development time.  
The sections provide a more in-depth overview of current microfluidic prototyping 
techniques while the main part of the chapter is based on a paper published in 2016 
describing the process developed in this thesis and the characterisation steps that led to 
the choice of the optimal parameters. 
 
4.1.1 Soft  l i thography 
Different material and manufacturing methodologies have been developed for the purpose 
of microfluidic research, depending on the features to obtain and the accuracy required, 
as well as the infrastructure available.  
Poly-dimethyl-siloxane (PDMS), is one of the most common material for microfluidic 
microfabrication163 in research environment.  PDMS is usually shaped through a 
technique called soft lithography.  Briefly, a UV light filtered through a mask is used to 
draw a pattern on a photosensitive material.  This leads to the formation of a master 
mould.  Liquid PDMS is cast and cross-linked over the master mould, which results in 
the imprinting of the microfluidic features on the material.  The PDMS layer can then be 
peeled off and sealed to a substrate to close the channels.  This is often performed using 
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a glass lid and a plasma treatment to activate the surfaces164.  Through this process, it is 
possible to obtain very accurate features with dimensions down to the nanometre scale 
(depending on the mask), on the other hand it is a slow procedure.  Usually, a photoresist 
material is spin coated on a silicon wafer, which is previously thoroughly washed to avoid 
any defect on the surface.  After a soft baking step, the wafer is exposed to UV light, 
through a photomask that defines the features to impress on the material.  After UV 
exposure, the wafer is baked again and finally, during development, the non-cross-linked 
regions are dissolved in a buffer.  Other optional steps, such as a final hard baking or a 
vapour deposition of chemicals, to change surface properties, can be performed to 
furtherly improve the final mould.  PDMS is cast on the mould, degassed under vacuum 
to remove bubbles and peeled off once cross-linked (cross-linking time mostly depending 
on the temperature).  Often, holes for connections are punched in the PDMS layer before 
bonding it to a glass slab, to enclose the microfluidic features, and the same mould can 
be used again several times.  Alternatively, the photoresist layer, usually made of SU8, 
can be used directly to shape the channels of the device; this results in a more expensive 
and time consuming procedure, but the final device is much less sensitive to shape 
variations or delamination due to hydraulic pressure165.  Soft-lithography is not 
particularly suitable for multilayer fabrication, due to alignment and other technical 
difficulties, although some solutions were developed to ease these problems166.  Casting 
PDMS on metallic moulds, before bonding to glass, has been used as a simpler alternative 
to common photolithography based methods167.  
Although PDMS is an accessible, relatively inexpensive material, and allows the shaping 
of small features, it requires batch manufacturing, degassing and curing step, and its 
production is suitable only for small volumes168.  Also, each iteration, requires the 
production of a new photomask, which is time consuming and, according to the quality 
required, expensive (base price around £80), so the procedure is not the most suitable for 
iterative prototyping. Companies such as Kloè (France) developed instruments capable 
of performing laser soft-lithography which does not require masks.  Nonetheless, the 
instrument cost range is above £100 k.  
 
4.1.2 3D print ing 
Addictive manufacturing of microfluidics is a feasible alternative and, as 3D printing 
technologies are becoming cheaper and more easily accessible every year, it is getting 
more attention.  Several technologies were developed for 3D printing, including selective 
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laser sintering (SLS), fused deposition modelling (FDM) and stereolithographic apparatus 
(SLA).  Each process has advantages and disadvantages but they are all generally time 
consuming even when relatively low resolutions are required.  Also, procedures to 
remove residual material from fluidic channels are required in some of the processes.  
Generally, although 3D printing overcomes some limitations of other technologies, such 
as working with planar geometries, or assembly issues169, allowing assembled parts to be 
printed together, due to its slowness, it is only suitable for very small volumes of 
production and proof of concept prototyping. 
 
4.1.3 High volume manufacturing  
Injection moulding of plastics allows for very fast manufacture of scale.  The procedure 
consists of injecting molten material at high pressures into a mould with the desired shape.  
Usually the material is loaded into a hopper, from there it enters an extruder, where it is 
molten and compressed, and finally enters the mould.  Cooling coils within the mould 
may help solidification of the material.  A particular moving screw of the extruder exerts 
the pressure required to minimize shrinkage after cooling down.  The mould, which can 
have more than one cavity, allowing for the manufacture of several pieces at the same 
time, is quickly emptied and filled again, performing several cycles per minutes.  Most 
common materials used in the process are thermoplastics, such as acrylonitrile-butadiene-
styrene (ABS), nylon (PA), polycarbonate (PC), polypropylene (PP), polystyrene 
(GPPS). 
Hot embossing, in which a sheet of pre-heated material is compressed between two sides 
of a mould, is another technique with very rapid turnaround that has been successfully 
applied to microfluidics.  Nanoimprint lithography, substantially a variant of hot 
embossing dealing with smaller features, has similarly been applied to nanofluidics170.  
Lab on Printed Circuit Board, suggested many years ago and which recently raised new 
interest171, is more easily translated to high manufacture volumes than soft lithography, 
thanks to being based on a very mature branch of manufacture industry, but presents the 
same, or worse, difficulties in regard to iterative prototyping, involving photolithography 
and several other steps. 
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4.1.3 Thermoplast ics  for  Translat ional  rese arch  
Protocols such as injection moulding and hot embossing, for industrial volume 
productions, similarly to photolithography, commonly used in research labs, require an 
initial step to shape the mould before the actual chip manufacturing, which makes them 
somewhat less suitable for prototyping purposes172, where it is often needed to rapidly 
change the design173. 
Due to their compatibility with large scale production methods, thermoplastic materials, 
such as poly methyl methacrylate (PMMA), cyclic olefin copolymer (COC), poly 
carbonate (PC) and others, are the most used in microfluidic translation174 and they are 
acquiring growing popularity even for nanofluidic applications170.  Within research labs, 
the production of microfluidic devices in these materials, usually requires a step in which 
layers are shaped, by mean of different techniques including laser cutting and 
micromachining, followed by a bonding process of these layers.  The bonding process 
can be performed in several different ways, each one with its pros and cons, and new 
methodologies to improve the protocols are published every year175. 
The most commonly used strategies include solvent bonding, usually with toxic organic 
chemicals which require handling within a fume hood, the use of adhesive layers176, 
which adds layers with different superficial properties within the device, and thermal 
bonding, which entails deformations of the artefact and slow heating or cooling protocols. 
Several alternative fabrication methods were developed for different applications.  Joint 
assisted bonding, in which a hollow metal frame is used to compress together layers 
including softer and harder ones, so as to give hydraulic seal once they are tightened 
together, was tested with multilayer devices177.  Hot roll lamination, usually with a hot 
melting material in combination with adhesive intermediate layers not to limit the speed 
of the process (in the order of several meters per minute), and laser welding, where a 
focused laser welds polymer leaving free of stress the bulk of the material, are both 
commonly used methods178.  Simple magnets were used to press together PDMS 
structures within two PMMA housings, to give a reversible bonding withstanding 
pressures up to 35 kPa179. 
Therefore, when the bonding procedures do not entail toxic solvents or extremely lengthy 
protocols, they still require additional frames or housings to hold the layers together or 
entail the use of a different material between the thermoplastic layers, creating a prototype 
with characteristics dissimilar from the one that the final, commercially available product 
would have.  
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Within the paper we present herein, a more thorough state of the art on bonding strategy 
for thermoplastics microfluidics purposes is presented, together with a comparison of our 
results with the performances of the most relevant similar technologies in the literature. 
Our method consists in a solvent-assisted thermal bonding which can be performed in 2 
minutes (time at the press) plus minimum preparation time.  We showed the 
manufacturing of a 5-layer microfluidic mixer, from CAD design to bench testing with 
food dyes, in less than 15 minutes.  Laser cutting is a well-known process and, in spite of 
not being suitable to obtain channels with features lower than 100-150 m, it guarantees 
a fast and reproducible shaping of the acrylate sheets.  The choice of working with devices 
manufactured by stacking and bonding several PMMA layers is particularly handy, since 
it allows the formation of complexes 3D structures starting from simple 2D 
manufacturing techniques180.  The solvent used in our protocol is ethanol, which is 
economically convenient, easily accessible in most lab facilities and, in the amounts used 
for the process (~10 l/cm2) does not require a fume hood.  As shown in the paper here 
reported, our optimised temperature is 70°C, which is easily achieved through small 
heater cartridges and allows the handling of the heated plates just wearing light protection 
gloves.  Most importantly, being the temperature decisively colder than PMMA glass 
transition (depending on the material specific, but usually around 110°C), our method 
minimises the deformations in the bulk of the material and only the ethanol wetted 
surfaces are substantially modified.  This allows to skip time consuming steps for slow 
heating/cooling that in normal thermal bonding are necessary so as to minimise 
deformations in the final product.  Optimal bonding pressure is ~ 1.6 MPa, which is in 
the lower range of most hydraulic presses commercially available, when the area to bind 
is comparable to one or two microscope slabs.  These optimised parameters were chosen 
after testing bonding strength, with shear stress analysis and burst tests, and channel 
deformations, through cross-section analysis.  Several exemplary demonstrators were 
designed and manufactured with these method, including common microfluidic 
applications such as a H filter device and a droplet generator.  
The possibility to safely and quickly prototype thermoplastic microfluidic devices, 
enables the microfluidic community to overcome the bottleneck of thermoplastics over 
PDMS.  Easing the research on thermoplastic microfluidics also ease the following 
translation to mass production, which is not compatible with PDMS devices, usually 
employed in academic settings. 
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4.2 Safe and cost-effective rapid-prototyping of multilayer PMMA microfluidic 
devices 
This paper, published in Microfluidics and Nanofluidics in December 2016, is co-
authored by myself (AL), Jonathan A.S. Morton (JM) and Maïwenn Kersaudy-Kerhoas 
(MKK).  AL and MKK gave substantial contribution to experimental conception and 
design, and drafting and revising the article.  AL manufactured all the specimens used in 
the study and performed tensile tests, burst tests and aging tests.  JM performed the 
deformation analysis on the specimens.  AL and MKK worked on data analysis and 
presentation and prepared all the demonstrator chips and tests.  AL, JM and MKK gave 
substantial contribution to the final writing of the submitted manuscript. 
  
1 3
Microfluid Nanofluid  (2016) 20:164 
DOI 10.1007/s10404-016-1823-1
RESEARCH PAPER
Safe and cost‑effective rapid‑prototyping of multilayer PMMA 
microfluidic devices
Antonio Liga1,2 · Jonathan A. S. Morton3 · Maïwenn Kersaudy‑Kerhoas1,2  
Received: 10 August 2016 / Accepted: 3 November 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
literature), with minimal channel deformation (<5%). This 
technique, which we demonstrate on assembly comprising 
up to 19 layers, presents an exciting improvement in the 
field of rapid prototyping of microfluidic devices, enabling 
extremely fast design cycles in microfluidic research with a 
material compatible with mass manufacturing, thus allow-
ing a smoother transition from the laboratory to the market. 
Beyond the research community, this robust prototyping 
technique has the potential to impact on the deliverability 
of other scientific endeavours including educational pro-
jects and will directly fuel the fluidic maker movement.
1 Introduction
Due to its low cost, optical transparency and the availabil-
ity of a range of processing methods, poly(methyl meth-
acrylate) (PMMA) has been adopted for many microflu-
idic applications (Das et al. 2015; Pagaduan et al. 2015). 
Compared to silicon-based materials used for microfluidic 
applications, PMMA is less fragile and does not require 
expensive manufacturing techniques. PMMA is therefore 
preferred, together with plastics like polystyrene, polycar-
bonate and cyclic olefin copolymer, for the manufacturing 
of disposable devices required for commercially orien-
tated applications (Romoli et al. 2011). PMMA structures 
can be created by a wide range of techniques including hot 
embossing, injection moulding, laser ablation, reactive ion 
etching or deep UV lithography and have mechanical prop-
erties superior to those of poly(dimethylsiloxane) (PDMS, 
another material of choice for microfluidic applications), 
guaranteeing a better fidelity to the initial shape under 
mechanical stress conditions (Madadi et al. 2013). How-
ever, sealing of PMMA devices is not as straightforward 
as that of more conventional materials used traditionally in 
Abstract The rapid translation of research from bench to 
bedside, as well as the generation of commercial impact, 
has never been more important for both academic and 
industrial researchers. It is therefore unsurprising that more 
and more microfluidic groups are investigating research 
using a wide range of thermoplastics which can be read-
ily translated to large-scale manufacturing, if the technol-
ogy is taken to commercialisation. While structuring, via 
additive or subtractive manufacturing, is becoming rela-
tively easy through the use of commercial-grade devices, 
reliable and fast assembly remains a challenge. In this 
article, we propose an innocuous and cost-effective, under 
2-min technique which enables the bonding of multiple 
poly(methyl methacrylate) layers. This bonding technique 
relies on the application of small amounts (10 µl/cm2) of 
ethanol, low temperatures (70 °C) and relatively low pres-
sures (~1.6 MPa). Our characterisation analysis shows 
that using a bonding time of 2 min is enough to produce 
a strong bond able to withstand pressures always above 
6.2 MPa (with mean of 8 MPa, highest reported in the 
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microfluidic research, such as PDMS, and mostly relies on 
methodologies that can lead to severe changes in the mor-
phology of the final product (Tran et al. 2013). The need 
of a reliable and high-throughput bonding method becomes 
critical as applications are rapidly translated into commer-
cialised products, in particular for clinical products (Tsao 
and DeVoe 2009; Becker 2010). Additionally, over the last 
5 years small milling machines and table-top laser sys-
tems have become available and form, besides 3D print-
ing, the bases for the maker movement. These structuring 
techniques can also be used for generating microfluidic 
structures well suited for the education of students and for 
prototyping at many places around the world backed by 
networks such as the Fab Lab network (Nascimento and 
Pólvora 2016). However, up to now, no satisfying bonding 
technique has been developed. Double-sided adhesive tape 
is often used for convenience and price, but has a number 
of drawbacks including poor optical qualities and chemical 
incompatibilities. In this work, we show a bonding method 
that allows for the fast, cost-effective and safe bonding of 
multilayer stacks of PMMA, thus overtaking part of the 
barrier that prevents the translation of microfluidics from 
the laboratory to the real world. The most common PMMA 
bonding technique is thermal bonding, in which PMMA 
elements are heated above the glass transition temperature 
[Tg ranging from 85 °C to 165 °C depending on the com-
mercial composition (Duan et al. 2010) but usually around 
110 °C (Li et al. 2015)] and pressed together. During ther-
mal bonding, the diffusion of polymer chains between the 
two interfaces leads to the formation of entanglements 
among the macromolecules (Baldan 2012) and permanent 
bonding. The influence of PMMA molecular weight on 
thermal bonding was studied, showing that longer macro-
molecules can form stronger bonds (Nayak et al. 2009). 
Thermal bonding protocols often include temperatures up 
to 140 °C at the pressing plates, to ensure that the whole 
PMMA artefact is above the PMMA glass transition tem-
perature (Tg). To avoid thermally induced stress that would 
result in layers bending, the material needs to reach the 
final temperature slowly and similarly requires a slow cool-
ing. Therefore, the entire process can last for several hours 
(Zhu et al. 2006; Mohammed et al. 2013). Widely used due 
to its simplicity, this technique does, however, result in the 
distortion of the PMMA elements. More elaborate solu-
tions to alleviate this distortion issue have been devised, but 
are not free from drawbacks. Intermediate adhesive layers 
have been proposed, but can interact with the fluid passing 
through the microfluidic channels. Surface modification 
and solvent-assisted bonding (Brown et al. 2006) which 
can change surface shape but usually involve highly toxic 
chemicals (chloromethane, dichloromethane, chloroform) 
(Jiang et al. 2015) are other proposed methods. Further-
more, both methods can lead to clogging of the channels 
(Lin et al. 2007). Variants of the aforementioned solutions 
include the use of UV light to activate surfaces (Tran et al. 
2013), microwave heating combined with a conductive 
layer [patterned gold (Toossi et al. 2015), conductive pol-
ymer (Holmes et al. 2011) or metal clips acting on a sol-
vent layer (Mona et al. 2010)], or plasma treatment (Cheng 
et al. 2015), which can be optimised to reach a bonding 
strength of 0.57 MPa in 20 min (Zhifu et al. 2015). Gener-
ally these procedures are time-consuming and require spe-
cialist equipment (Lin et al. 2007). It was shown that con-
tainment grooves between the layers to bond can improve 
the efficiency of solvent-assisted bonding methods (Wan 
et al. 2015). Interfacial heating caused by low amplitude 
ultrasonic was used to bind preheated PMMA layers with 
imprinted nanochannels (Zhang et al. 2010). With the use 
of plasticisers, bonding can be performed at lower tem-
peratures by lowering the glass transition of the material. 
Low deformation (<10%) low temperature (90 °C) PMMA 
bonding was achieved using dibutyl phthalate (DBP) as a 
plasticiser (Duan et al. 2010). Nonetheless, DBP is a sus-
pected teratogen banned in many countries, and its pres-
ence within the bulk of the final artefact could make the 
bonding step unsafe and prevent its use in medical applica-
tions. A fast PMMA prototyping methodology, developed 
by Sun et al. (2007), consists of a solvent-based imprint-
ing and bonding strategy. This method allows for the reali-
sation of PMMA chips in 15 min; nonetheless, it requires 
the use of photolithography techniques for the realisation 
of a template for the imprinting in a photoresist material, 
commonly SU8. Custom devices were built so as to per-
form thermal bonding in line with injection moulding, so 
as to save processing time and thermal energy. This method 
is fast and reliable, but requires a custom device and only 
allows the bonding of two layers, thus significantly limiting 
chip design (Chu et al. 2015). Using layers of a lower Tg 
polymer, such as TMMF (photosensitive epoxy laminate) 
for the thermal welding of PMMA, reduces deformation on 
the PMMA bulk, although the procedure is time-consum-
ing and requires photolithography equipment for the shap-
ing of TMMF (Kalkandjiev et al. 2010).
We propose an optimised solvent-assisted thermal bond-
ing method, allowing for cost-effective, innocuous and 
ultrafast bonding. The solvent used is absolute ethanol, 
which is nontoxic, does not require to be handled under a 
fume hood in the small amounts required for the process 
and is extremely cheap (~$5/L). This method is therefore 
ideal for fast prototyping and manufacturing, and its use 
might encourage the use of PMMA, a material more easily 
adapted to industrial translation than PDMS, in microflu-
idic research settings. This technique might also be of inter-
est to the so-called Maker movement and the burgeoning 
microfluidic “spin-off” of this movement (Frot et al. 2016; 
Silva et al. 2015). The concept of ethanol-assisted thermal 
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bonding has been described before (Klank et al. 2002) and 
is driven by the need for maintaining the initial shape of 
every layer involved in the bonding process. Indeed, by 
acting at a temperature at which only the ethanol-wet sur-
faces are modified, it is possible to minimise the effect on 
the bulk of the material. Ethanol acts both as a solvent (we 
noticed deposits of PMMA in the channels when prelimi-
narily testing with large amounts of ethanol) and as a plas-
ticiser, as it was shown (Wang et al. 1994) that it lowers the 
Tg of PMMA to 11 °C, thus allowing the movement of pol-
ymer chains at the interfaces. Yang described the character-
isation of postembossing ethanol bonding technique lasting 
a total of more than 6 h (Yang 2014). In another example, 
Hsu and Chen explored bonding with ethanol, methanol 
and isopropanol using a Taguchi approach for experiments 
planning (Hsu and Chen 2007). However, as the Taguchi 
method aims to reduce the amount of total experiments 
required by adding together the main effects of independ-
ent variables, it was not applicable to this study and led to 
misleading results in optimisation terms. Indeed, solvent 
type, temperature and bonding time cannot be considered 
as independent variables and their effects are not separable, 
as the physics ruling the bonding process (solubilisation of 
the polymer chains, diffusion of solvent within the polymer 
matrix) follows kinetics in which the solvent molecules/
polymer interactions are strictly connected to tempera-
ture (Santos et al. 2016; Bird et al. 2002; Green and Perry 
2008). Also, bonding strength is not a monotonic function 
of bonding pressure (as we demonstrate), another assump-
tion that needs to be respected in order to use the Taguchi 
method. To the best of our knowledge, we demonstrate for 
the first time that a bonding time of only 2 min is needed 
to achieve crack-free structures with a reliable bonding 
strength, furthermore using a cost-effective and safe solvent 
and a readily available experimental set-up costing under 
$1200. As our example of prototyping method, we chose 
laser cutting (Fig. 1) as a first step, in order to produce the 
different layers out of PMMA sheets with different thick-
nesses; nonetheless, other layer shaping techniques can be 
coupled with the bonding method described herein. Bond-
ing stability was tested by means of quickened ageing in 
an oven at 90 °C and in water incubation at 37.5 °C. The 
application of rapid prototyping methods from structuring 
to sealing is well justified and may alleviate issues encoun-
tered in the translation to production (Hardt et al. 2005). 
Together with its rapidity, another great advantage of this 
method lies in the possibility to assemble several layers, 
thus allowing the formation of complex 3D microfluidic 
structures.
2  Materials and methods
2.1  PMMA bonding
PMMA sheets of 0.2, 0.8 and 2.0 mm thicknesses acquired 
from various suppliers were used in this study. Bonding 
optimisation studies, as well as exemplary chips (Sect. 3.6), 
were realised with Clarex® (Nitto Jushi Kogyo Co. Ltd, JP) 
cast PMMA sheets supplied by Weatherall Ltd, UK. For 
Fig. 1  Ultrafast prototyping scheme, cost factors and process times. 
The *step timing is directly depending on the complexity of the 
device design. We demonstrate a laser cutting time of 4′09″ for a 
five-layer microfluidic mixer unit with the size of typical microscope 
slide (Suppl Info video). **Yearly maintenance cost per device is 
estimated at $500 per year divided by the production of 5000 units a 
year. ***This is based on a $800 manual hydraulic press and a $400 
custom-made thermal controller (Suppl. Inf Table 1)
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material comparison, Oroglas® (Oroglas Ltd, FR) and Per-
spex® (Lucite International Ltd) cast sheets were obtained, 
respectively, from Easter Road Plastics Ltd, UK, and Engi-
neering and Design Plastics Ltd, UK. Extruded Perspex®, 
supplied by Engineering and Design Plastics Ltd, UK, was 
also included in the material comparison study (for mate-
rial details, c.f. Table S1 Suppl. Inf). Absolute Ethanol 
(%w > 99.95 %w) was used as a solvent (Sigma-Aldrich, 
UK). A custom-made heating plate and control unit were 
developed to heat up and maintain the layers at the correct 
temperature during bonding (c.f. Suppl. Inf. Table S.2). 
As a source of pressure, we used a Bonny Doon Classic 
20-Ton Manual Press (Rio Grande, USA) or a manual 30 
tons hydraulic pellet press (Research & Industrial Instru-
ment Company, UK). Results obtained from both presses 
are compared in the results and discussion section.
After laser cutting the desired shapes using a CO2 laser 
cutter (Epilog Mini 18, Epilog, USA), PMMA layers were 
cleaned with clean-room tissue and ethanol to remove 
dust. In this step, the minute amount of ethanol applied to 
the layers via the tissue evaporates in a few seconds after 
application and does not affect the bonding subsequently. 
Ethanol was spread between the layers with a pipette just 
before bonding (20 µl for shear stress test specimens, 80 µl 
for deformation specimens, burst test specimens and our 
application examples). This allows for the partial melting 
of a superficial layer and the formation of a strong bond 
between the PMMA elements even if operating below 
PMMA Tg.
In Fig. 1, the workflow of the process is shown together 
with economic considerations on equipment and mainte-
nance. Layers were aligned in holders specific for each of 
the sample types. When several layers needed to be aligned 
with precision, such as in the realisation of complex micro-
fluidic platforms, custom-made plates with pins for align-
ment of the layers are preferred; therefore, individual lay-
ers were featured with corresponding alignment holes. For 
more simple geometries, custom frames were laser cut in 
PMMA. As the thermal profile within the PMMA layer 
stack to bind is dependent on its thickness, all the speci-
mens for shear stress, burst and deformation analysis were 
realised in stacks 4–4.2 mm tall. The microfluidic device 
examples shown in Sect. 3.6 have thickness ranging from 
2.4 to 5.2 mm and showed high performances without 
the need of further tuning of the bonding parameters. For 
PMMA stacks taller than 6 mm, a longer bonding time than 
the one suggested in this paper will be required.
2.2  Shear stress analysis
Shear stress testing was performed by means of a tensile 
test equipment (Instron 3367, Instron, UK) with an elon-
gation speed of 0.05 mm/s and recording the highest load 
before sample break. The two sides of T-bones specimens 
with no microfluidic features were laser cut from 2.0-mm-
thick sheets, and an additional layer was added with dou-
ble-sided tape on the gripping side, to ensure alignment 
during bonding and shear stress test (c.f. Suppl Info Figure 
S.1). They were fixed in a custom holding frame, placed on 
the bottom heater plate, and 20 µl of ethanol was pipetted 
within the overlapped area (2 cm2). The top heater plate 
was placed above the specimens before applying pressure 
using the hydraulic press. The influence of temperature was 
studied by keeping bonding pressure and time constant at 
5 tons at the ram (2800 psi inside the cylinder/1.57 MPa 
on the specimen surface) for 120 s. Tests were run for a 
range of temperatures between 50 and 110 °C. The effect of 
pressure was studied at a bonding temperature and time of 
70 °C and 120 s, respectively; 2, 3, 5, 8 and 12 tons at the 
ram were used during specimen preparation, corresponding 
to 0.63, 0.94, 1.57, 2.51 and 3.76 MPa applied on the sur-
face of the specimens. Finally, in order to analyse the influ-
ence of time on bonding strength, tests were performed at 
70 °C and 5 tons at the ram for 10, 30, 60, 120, 300 and 
480 s. Between 6 and 12 specimens were used for each set 
of parameters.
Statistical relevance was calculated with ANOVA tests 
and, when necessary, with an unpaired, two-tailed student’s 
t test (VassarStats/GraphPad software).
2.3  Burst test analysis
One of the most important requirements for a microfluidic 
bonding method is its ability to efficiently seal channels, in 
such a way that they can stand pressure without suffering 
from leaks. Therefore, burst test analysis was performed 
within the same range of bonding pressure, time and tem-
perature used for shear stress testing. Considering the 
larger area to bind, 80 μl of ethanol was spread between 
each of the layers. Chips featuring a 0.5-mm-wide channel 
leading to a dead-end 4-mm-diameter round chamber were 
realised sandwiching a 0.2-mm-thick layer, between two 
2.0-mm-thick PMMA layers, one of which served also for 
the fluidic connection (realised through ferrules and con-
nectors, supplied by Epigem Ltd, UK, tightened to the chip 
by a screw/nut system). A Nemesys mid-pressure (up to 
20 MPa) syringe pump (Cetoni Gmbh, DE), with a medium 
pressure stainless steel 5-ml syringe was used to push 
deionised water within the specimens at 0.5 ml/min. As 
there is no way out, the air enclosed within the channel and 
chambers is gradually forced in a smaller volume and its 
pressure increases. Pressure changes were monitored with 
a Nemesys pressure sensor for measurement up to 20 MPa 
(Cetoni) through a Nemesys user interface PC Software 
v20151214. The highest pressure reached before chip fail-
ure was considered the burst limit of the specimens. As 
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just above 10 MPa of pressure, leaks were noticed at the 
syringe pump and tubing connection, testing was stopped 
every time 10 MPa was exceeded; thus, the pressure limit 
reported for some specimens is safely underestimated with 
respect to the actual resistance of the chip. At least three 
specimens were used for each bonding condition.
2.4  Deformation analysis
Tests were performed to study how bonding parameters 
(pressure, temperature and time) affect the shape of the 
channel. Rectangular (81 × 40 mm) specimens were fab-
ricated by laser cutting sheets of PMMA and sandwiching 
a 0.2-mm-thick layer between two 2.0-mm-thick layers. 
To allow a direct comparison, the area of these rectangles 
was chosen in order to have the same pressure distribu-
tion sustained by the shear stress and burst test specimens 
when the same force is applied at the ram. In the central 
layer, three 0.5 × 10 mm channels were laser cut. Before 
hot pressing the three layers together, 80 µl of ethanol was 
pipetted between each of the layers and spread along the 
whole surfaces by gently rubbing them together. Tests were 
performed in the same range of bonding temperature, pres-
sure and time as shear stress analysis. To check the differ-
ent impact that bonding time may have below and above 
glass transition temperature, tests at 70 and 110 °C were 
also performed for 480 s. Finally, an extreme case study 
was realised by bonding a specimen at 110 °C and 12 tons 
at the ram (3.76 MPa) for 480 s.
Samples were prepared for cross-sectional analysis by 
cutting through the imbedded channels using a diamond 
saw. Imaging of the channel cross sections was carried out 
with a Leica DM6000 microscope with bright-field illumi-
nation in transmission mode. An overall magnification of 
50Χ was used to record the images. For some specimens, 
a deformed area was noticed around the channels, prob-
ably due to solvent swelling. Both a channel height and a 
deformed area height were recorded. In order to compen-
sate for the variations in the thickness of the central layer 
(200 µm ± 10% according to manufacturer), the recorded 
heights were divided by the initial measured thickness for 
each chip and data are reported as dimensionless normal-
ised deformation.
2.5  Ageing testing
In order to test the stability of the bonding under long-term 
storage, 18 shear stress specimens were manufactured, 
starting with elements cut from the same 2.0-mm-thick 
PMMA sheet, bonding at 70 °C and 5 tons at the ram for 
2 min (optimal conditions). Six specimens underwent shear 
stress testing within the next 24 h from the bonding step, 
being stored at room conditions. For accelerated ageing, six 
were incubated within a closed bottle filled with deionised 
water at 37 °C for 216 h, before testing. Similarly, the last 
six were kept at 90 °C for 216 h before testing. Incubation 
steps were performed in a MK 53 Dynamic climate cham-
ber (Binder GmbH, DE).
3  Results and discussion
In this part, results and discussions are separated in sec-
tions aimed to explain how pressure, time and temperature 
affect the bonding strength.
3.1  Influence of pressure
The bonding strength was shown to follow a nonmonotone 
trend by both shear and burst analysis (Fig. 2a). The plots 
report the load at break (N). The shear stress at break (N/
m2) was not reported because in most cases concentrated 
shear stresses at the bent interfaces cause normal stress fail-
ure. The plots show a clear trend, and in particular, a peak 
in bonding strength is present for specimens bonded press-
ing with 5 tons at the ram. In order to explain the inefficient 
bonding at low pressure, it is easy to invoke an incomplete 
adhesion between the layers to bind and, often, bubble-
shaped unbonded areas were noticed for low pressure bond-
ing. Regarding the behaviour shown at higher pressures, 
two possible scenarios can be considered. During prelimi-
nary testing, it was noticed that excessively high-pressure 
results in wrinkles in the PMMA layers. This could result 
in incomplete matching of the surfaces. Another way of 
interpreting the phenomenon is considering that, when 
pushing the two surfaces together, a higher pressure will 
result in a thinner film of ethanol spread in between the 
PMMA layers, thus reducing the effect of the solvent. It is 
worth noticing that all the results obtained with the 20 tons 
press, although showing exactly the same trend as those of 
the 30 tons press, always showed higher bonding strength. 
The ram of this press terminates in a square plate that fits 
perfectly the custom-made heater plates. On the contrary, 
the ram of the 30 tons press was round and, due to the 
shape of the piece of equipment, it was hard to place the 
heating system exactly at the centre of the pressure point. 
We decided to show both results, as they show the same 
trend as well as give an indication that a good alignment 
can guarantee a more even pressure distribution, resulting 
in stronger bonding. 
Deformation does not seem to strictly depend on pres-
sure, although at higher pressures (8–12 tons at the ram) 
cracks were often noticed around channels (Fig. 3a). The 
internal heights of the channels were shown to reduce 
between 1 and 3% (sagging) while the deformed layer was 
7–8% higher than channels. An increase in channel height 
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was shown for 0.3 MPa bonding, probably due to a slight 
solvent erosion effect (~10 μm) occurring at lower pres-
sure, when the amount of ethanol constrained within the 
layers is reasonably higher.
3.2  Influence of time
Shear stress testing at 70 °C and 5 tons at the ram 
(1.57 MPa on specimens) showed that bonding strength 
is strongly dependent on bonding time for the first 120 s. 
After this, a plateau is reached and pressing the specimens 
for longer did not result in any advantage in terms of bond-
ing strength. On the other hand, not all of the specimens 
processed for times shorter than 60 s were completely 
bonded (Fig. 2b.i), and sometimes bonding failure occurred 
while clamping the specimens to the tensile stress equip-
ment or removing them from the hot plates. Burst test con-
firmed the existence of a plateau at about 8.3 ± 1.6 MPa, 
a pressure much higher than those required for the great 
majority of microfluidics applications. The burst pressure 
Fig. 2  Results for shear stress test (row 1) (N = 6–12), burst test (row 
2) (N = 3) and deformation analysis (row 3) (N = 3–6) as a function 
of bonding pressure (column 1), time (column 2) and temperature (col‑
umn 3). On all graphs, the vertical dash lines and white background 
zone highlight the optimal parameters. The SDs on all graphs are rep-
resented using coloured regions. The width of the region at a given 
data point of the graph gives the exact SD at this point. Between data 
points, the upper and lower SD is connected by a straight line to facili-
tate the reading of trends. Shear stress results (row 1) are shown for 
specimens bonded with both a 20 tons BD press (black squares) and 
a 30 tons RIIC press (grey circles). The 20 tons BD press was pre-
ferred for all subsequent experiments (including  rows 2 and 3 and 
subsequent result sections). Hydraulic equivalents are given in the text. 
On the burst test (row 2) results, the dash horizontal line corresponds 
to the maximum value achieved by the Nemesys high-pressure equip-
ment. For the deformation analysis (row 3), the plot reports the height 
of both the channels (which sag during harsher bonding conditions, 
black squares) and the deformed areas around channels (which on the 
contrary grow with harsher bonding conditions, grey triangles). For 
readability, the horizontal dash line indicates the absence of deforma-
tion. The collective reading of the three tests (shear stress, burst, defor-
mation) against each of the parameters (pressure, time, temperature) 
gives a clear reading of the optimal parameters, highlighted by the 
white zones for each parameter
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detailed in this study is higher than any previously reported 
for PMMA in the microfluidic literature, where the usual 
range is 0.5–0.6 MPa (Hsu and Chen 2007; Romoli et al. 
2011; Tran et al. 2013) with a highest previously reported 
operating pressure of 2.6 MPa (Lin et al. 2007) (calcu-
lated). It should be noted that the failure point for most 
previous burst test studies occurred at the connections. 
Above 120 s of bonding time, on average one specimen out 
of three withstood over 10 MPa, and it was not possible to 
go above this, due to failure of the high-pressure syringe 
pump. Hence, the reported maximum values are probably 
lower than the actual ones. All the specimens bonded for 
120 s or longer stood at least 6.2 MPa before bursting.
Although after 120-s bonding time does not seem to 
affect bonding strength, cross-sectional imaging showed 
that a longer time resulted in higher deformations (Fig. 2b.
iii), both in terms of channel sagging and growth of 
deformed area around channels (6 ± 6 and 36 ± 4%, 
respectively, for 8-min bonding, compared to 1 ± 1 and 
0 ± 0%, respectively, for 1-min bonding).
3.3  Influence of temperature
Contrary to what was shown in the previous two sec-
tions, shear stress and burst analysis gave different results 
when testing specimens bonded at different temperatures 
(Fig. 2c.i, c.ii). Burst tests show that bonding becomes reli-
able after 70 °C and bonding strength remains nearly con-
stant from this temperature on. In shear stress analysis, on 
the contrary, after a peak at 70 °C, bonding strength con-
siderably drops at 85 °C and then shows a mild increase at 
100 and 110 °C. To explain this discrepancy between the 
two modes of analysis, we need to consider that, at atmos-
pheric pressure, ethanol boils at 78 °C. Hence, even if the 
same amount of ethanol was deposited through a pipette 
on the surface of each specimen, the ones treated at higher 
temperature must have lost, by evaporation, a considerable 
part of it before pressure was applied to the system. The 
evaporation of the solvent affects the burst test specimens 
to a lesser extent, as they are bonded on a much larger area, 
thus trapping ethanol within the layers to be bound and 
offering less air–ethanol contact surface available for evap-
oration to occur. Deformation analysis at 110 °C showed 
a 90% reduction in the cross-sectional area of the chan-
nels (Fig. 3b). In contrast, a deformed ellipsoidal zone is 
clearly visible, with area 2.5 times larger than initial chan-
nel. Complete channel disappearance and maximum defor-
mation (nearly 400% in height) were obtained for samples 
bound at 110 °C for 8 min, irrespective of whether the pres-
sure was 5 or 12 tons at the ram (1.57 or 3.67 MPa on spec-
imen) (Fig. 3a).
3.4  Comparison of different brands of PMMA
PMMA sheets are mainly produced using two methods, 
casting or extrusion. While extrusion produces PMMA 
sheets with better thickness tolerances, cast PMMA has 
higher thermal stability and optical properties. Depending 
on the manufacturers, PMMA mechanical and chemical 
properties such as molecular weight and degree of poly-
merisation can vary within a certain range and may affect 
the bonding optimisation. Here we show how our opti-
mal parameters [70 °C, 5 tons (1.57 MPa on specimen), 
2 min] perform with PMMA supplied by different manu-
facturers, without further optimisation. Interestingly, Per-
spex® PMMA, no matter if cast or extruded, performed in 
the same way as Clarex® PMMA and shear stress results 
gave nearly overlapping bonding strengths. On the other 
hand, several cracks were noticed on the specimens cut-off 
extruded sheets. Also, this material showed the tendency to 
arch and deform during laser cutting, probably due to the 
relaxation of stress induced during manufacturing. Oro-
glass® PMMA showed lower bonding strength compared to 
the others. These results suggest that the applicability of our 
Fig. 3  a Microscope photographs of the channel cross sections 
showing the deformation in and around the channels at different 
bonding conditions. b Cross section of a channel bonded at 110 °C, 
2 min, 5 tons: as the real channel sags to a tenth of the initial area, the 
solvent changes the morphology of a large surrounding area
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method does not depend on the manufacturing process (cast 
or extruded) used, but rather on the grade of the polymer. 
Long polymer chains require greater energy to move than 
shorter ones; thus, the bonding of higher molecular weight 
(Mw) PMMA will require longer time and higher amount 
of solvent to be as efficient as the bonding of lower Mw 
PMMA. Since Oroglass® material reports higher mechani-
cal and thermal properties (see Table.S1 Suppl. Inf.) than 
the others, it is legitimate to assume that it is composed of 
a heavier polymer (Nguyen and Kausch 1999) which would 
explain why it is harder to create a bound using the same 
bonding conditions. Unfortunately, the different suppliers 
have not yet replied to our questions regarding their poly-
mer composition, and our hypothesis remains unconfirmed. 
Nonetheless, it must be noticed that complete bonding was 
achieved for the whole surfaces treated regardless of the 
brand, thus showing the general applicability of the method 
(Fig. 4).
3.5  Bonding stability and quickened ageing
Quickened ageing tests were performed to verify bond-
ing stability under extreme conditions. Statistical analy-
sis shows that there is no significant difference between 
untreated specimens and those aged at 90 °C in dry condi-
tions or in water at 37.5 °C for 216 h, and differences in the 
mean can be related to statistical variability alone (p = 0.87 
and 0.19, respectively). These results, shown in Fig. 5, 
beside holding good promises for long-lasting shelf life 
(even if a thorough characterisation for longer times would 
be necessary), show that microfluidic chips bonded using 
this method can be applied to several different biological 
studies, including cell-related investigations, where 37.5 °C 
water incubation is frequent, and even on-chip PCR which 
involves temperature cycling up to about 95 °C.
3.6  Microfluidic device examples
To prove the reliability of the bonding protocol to common 
microfluidic tasks, several typical microfluidic applications 
are demonstrated. All the devices were produced by designing 
their layers on AutoCad (Autodesk, UK) and laser cutting them 
from sheets of PMMA with thicknesses 0.2, 0.8 or 2 mm.
3.6.1  Five‑layer split‑and‑recombine mixer
A five-layer split-and-recombine mixer was realised and 
tested under a range of flow rates. The bottom layer (#1) 
was realised in 2.0-mm-thick PMMA, to allow for micro-
fluidic connections. The other four layers (#2, 3, 4 and 
5) were realised in 0.2-mm-thick PMMA (Fig. 6a.i). The 
average channel cross section was 200 µm × 500 µm. The 
bonding step was realised with the optimal parameters 
70 °C, 1.57 MPa, 120 s (respectively bonding temperature, 
pressure and time). Two syringe pumps (World Precision 
Instruments, UK) were used to drive blue and yellow food 
dyes mixed with deionised water through the device. Flow 
rates (always equal for both syringe pumps) ranged from 
10 up to 170 ml/h (upper limit for the pumps used) (Fig. 6a.
ii). Although the chip shown here simply mixes two liquid 
streams, it proves that leak-proof 3D microfluidic structures 
Fig. 4  Comparing PMMA from various manufacturers. To test the 
applicability of the technique to multiple brands of PMMA, Instron 
shear stress testing was performed on specimens machined from 
PMMA sheets [N = 9 for all samples, but Perspex® cast (N = 7) and 
Clarex® (N = 12)]. Error bars show the SD
Fig. 5  Bonding stability at different environmental conditions. 
Instron shear stress testing was performed on specimens bonded 
at optimal conditions and then aged at 90 °C in dry conditions or 
37.5 °C in water, for 216 h. Error bars show the standard deviation. 
There are no statistical differences between the treated and untreated 
specimens (respectively, p = 0.87 and 0.19). N = 9 for all samples 
but ambient conditions N = 12
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can be realised in a single bonding step. The five-layer 
mixer showed no sign of clogging nor leaking for any of 
the flow rate used (10 ml/h up to the maximum pump rate 
of 170 ml/h), and bonding of the layers is consistent along 
the entire surface. Mixing of the two streams was observed 
under microscope at three locations on the device (Fig. 6b). 
As expected, mixing was more efficient at higher flow rates 
(Fig. 6a.iii and iv, respectively, 10 ml and 100 ml/h). Sup-
plementary Information video shows the complete manu-
facturing and testing of this device.
3.6.2  Three‑layer H filter
A three-layer H filter (Fig. 6b-i) was realised and used to 
demonstrate the separation of fluorescein from blue food 
dye. The design features inlet and outlets channels placed 
3 mm from the edges of the chip (Fig. 6b-ii), and with 
this feature we intended to demonstrate that the bonding 
obtained with this method is reliable along the entire sur-
face of the chip, even close to the edges of the chip. The 
length of the main channel was 30 mm, and the width on 
Fig. 6  Practical examples of microstructures manufactured using the 
proposed ultrafast method. a Five-layer split-and-recombine mixer 
test chip. a‑i Blow-up view of the chip design. The chip has the foot-
print of a microscope slide (75 × 25 mm) and is composed of four 
0.2-mm PMMA layers and one 2.0-mm PMMA layer (bottom layer). 
a‑ii Top view of the assembly. The grey zones correspond to the visu-
alisation windows: a‑iii Mixing patterns obtained at 10 and 100 ml/h 
at three locations on the chip. b H filter chip. b‑i Blow-up view of the 
chip design. B‑ii Top view of the H filter chip. The grey zones cor-
respond to the visualisation windows: b‑iii–b‑vi shows the result of 
the separation in two Eppendorf tubes. c Droplet generation and celtic 
design pattern. c‑i Blow-up view of the five-layer chip. c‑ii Top view 
of the assembly with inlets and outlets. The inset shows a tilted view 
of the droplet channel passing underneath one of the branches of the 
triquetra as well as a 300-µm interchannel gap. c‑iii Photographs of 
the device with four flow rate ratios producing four different droplet 
sizes
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drawing was 1 mm. A 3-ml syringe filled with deionised 
water was loaded on the first inlet, while a 3-ml syringe 
was filled with a mixture of fluorescein sodium salt 
(Sigma-Aldrich, 26 mg/ml), blue food dye (Classikool, 
5% v/v) and deionised water. The syringe was fitted on 
syringe pumps and actuated at 1.5 ml/h. Images were taken 
using a Dino-Lite (AM4113T-YFGW, Dino-Lite Europe, 
Naarden, Netherlands) under UV excitation (Fig. 6b-iii, 
iv and v). Fluorescein having a higher diffusion coeffi-
cient (5.4 × 10−4 cm2/min) than typical natural blue dyes 
(4.942 × 10−6 cm2/min (Kawahito and Yasukawa 2009)) 
can be separated across the length of the channel to out-
let #O1 while the food dye does not diffuse into the water 
stream and exits exclusively in outlet #O2. Figure 6c-vi 
shows the result of the extraction.
3.6.3  Droplet chip
Another five-layer device was created to demonstrate the 
intricacy of designs permitted by this technique as well 
as the reliability of the bonding for droplet applications 
(Fig. 6c-i). A microfluidic double triquetra (classic symbol 
in several European cultural groups) was created. Droplets 
are produced at the intersection of two channels merging 
in a circular channel surrounding the triquetra symbol and 
passing above and underneath the successive branches of 
the triquetra (inset, Fig. 6c-ii). Two inlet channels branch-
ing in the channel at a 90° angle allow the creation of 
droplets by flowing mineral oil at flow rate Qo and aque-
ous coloured solution at flow rate Qrd. We demonstrate the 
production of various droplet sizes using different flow 
rate ratio Q = Q0/Qrd (Fig. 6c iii, iv, v and vi, respectively, 
Q = 50, 25, 1.7 and 1).
3.6.4  Nineteen‑layer assembly
For proof of concept, we designed a nineteen-layer Lon-
don tube map, featuring 9 of the tube lines adapted to 
fit the present layout (Jubilee, Bakerloo, Metropolitan, 
Hammersmith, Northern, Picadilly, Central, Circle and 
District). The chip measures 50 × 50 mm, with channel 
widths on drawing, 200 µm. Each layer is 200 µm (total 
stack thickness is 3.8 mm). Each London tube line is filled 
with a different coloured dye corresponding to its official 
colour as illustrated in Fig. 7. This proof-of-concept chip 
was cut and assembled in minutes and thus demonstrates 
the ease and flexibility of the technique with regard to the 
number of layers that can be assembled in one single step. 
Finally we also demonstrated the use of this technique in 
the context of public engagement, school kid activities and 
undergraduate teaching (Bridle et al. 2016; Morton and 
Bridle 2016).
3.7  Comparison with existing techniques
In Table 1, our method is compared with the most recent 
advancements in PMMA bonding. The only method which 
can be performed more quickly (Toossi et al. 2015) requires 
the deposition of a gold layer to allow microwave heating 
at the surfaces. The present technique is the fastest and pre-
sents deformation in the lowest range and is the only tech-
nique that has been demonstrated with up to 19 PMMA 
layers. Additionally our method only requires a hot press 
and an inexpensive as well as innocuous solvent. Nonethe-
less, this method was always employed for channels with 
dimensions of 100 µm or more and may not be as suitable 
for nanochannels as some of the other techniques listed. No 
channel clogging was ever encountered for channel cross 
sections higher or equal to 200 µm × 200 µm; nonetheless, 
clogging might occur for smaller channel width due to the 
small solvent erosion effect discussed previously. There-
fore, the bonding technique is not suggested when features 
smaller than 100 µm are required. In comparison with 3D 
printing, another rapid prototyping method which poten-
tially alleviates the need for bonding and produces simi-
lar results for channel above 100 µm (Comina et al. 2015; 
Fig. 7  Microfluidic London tube map. Proof-of-concept, nineteen-
layer assembly representing nine of the London tube lines. The 
assembly of this chip was performed in a single step at the opti-
mum time, pressure and temperature. 250 µl of ethanol correspond-
ing to our recommend volume of 10 µl/cm2 was applied directly on 
the side of the stack prior to mounting the stack on the press. Each 
tube line is filled with diluted food dye corresponding to its official 
colour [respectively, Jubilee (grey), Bakerloo (brown), Metropolitan 
(purple), Hammersmith (light pink), Northern (black), Victoria (light 
blue), Piccadilly (blue), Central (red), Circle (yellow) and District 
(green)] (colour figure online)
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Morgan et al. 2016), our combined laser cutting and eth-
anol-assisted bonding method is faster and more flexible. 
To produce the mixer example chip (Fig. 6a) on a typical 
high-resolution 3D printer such as the multimaterial polyjet 
CONNEX 500 would take approximately 45 min, printing 
only. The resulting product would then need to be soaked 
overnight to remove the support material in the intricate 
feature of the chip. Alternatively, the chip would be printed 
in several parts and then bonded, creating the same situa-
tion as the current method.
4  Conclusions
Ethanol-assisted thermal bonding of PMMA was opti-
mised and characterised for the purpose of microfluidic 
prototyping. This method was demonstrated in conjunc-
tion with laser cutting, but is adaptable to other structur-
ing methods such as moulding, hot embossing, stamping 
and milling, and is therefore also relevant to mass pro-
duction. We showed that it is possible to reach a shear 
bonding strength of at least 1.5 MPa (dividing the load 
at break for the whole bonded area), and channels able 
to withstand pressures over 6.2 MPa (minimum burst 
pressure recorded), by pressing PMMA layers for just 
2 min at 70 °C and 1.57 MPa. These conditions are very 
mild on the material, the temperature being 40 °C lower 
than PMMA glass transition, and easy to reach, since the 
pressure required is in the lowest range of any hydraulic 
press. Bonding stability was demonstrated with quick-
ened ageing at 90 °C (dry conditions) and 37.5 °C in water 
for 216 h. Several layers can be stacked together in one 
bonding step (up to 19 have been demonstrated), creating 
three-dimensional structures. The channel height deforma-
tion observed is always lower than 5%. We demonstrated 
the manufacture of several structures including mixers, 
H filter, droplet generators capable of sustaining flow 
rates of at least 170 ml/min, which is sufficient for most 
microfluidic applications, including high flow rate applica-
tions. This ultrafast technique is applicable to microfluidic 
devices with minimum feature size of 150 µm and requires 
a low capital investment of around $16,000 (including 
laser cutter and bonding equipment). It will be particu-
larly attractive within microfluidic laboratories which are 
looking for rapid translation of devices into products, as 
well as for rapid prototyping, and the educational aspects 
of this technique will be of interest to a broader public, 
such as secondary, undergraduate and postgraduate teach-
ing professionals and more generally to developers and 
researchers requiring multilayer, polymeric and cost-effec-
tive solutions.
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Table 1  Comparisons of thermal techniques for bonding PMMA
a Involves the use of DBP, a suspected teratogen, banned for some applications in the USA and Europe
b Allows to bind only two layer and requires a sophisticated equipment
c Requires the deposition of a thin gold layer before bonding. N.C. noncommunicated
Method Bonding time T° (°C) Bonding strength 
(method)
Deformation Maximum number of 
layers demonstrated
Refs.
Oxygen plasma treat-
ment
>25 min 85 0.57 MPa (tensile test) <1% for microchan-
nels, 10% on nano-
channels
2 Zhifu et al. (2015)
Plasticiser-assisteda >20 min 90 N.C. <10% 4 Duan et al. (2010)
Acetonitrile-assisted <15 min 25 N.C. N.C. 2 Sun et al. (2007)
Ultrasound treatment 5 min 70 0.7 J/cm2 (crack open-
ing)
5% on nanochannels 2 Zhang et al. (2010)
In-moldb 4 min 100 0.35 MPa <10% 2 Chu et al. (2015)
Microwavec 35 s 50–160 1.4 MPa (tensile test) <5% 2 Toossi et al. (2015)
Ultrafast C2H6O-
assisted
2 min 70 1.23 MPa (shear test) <5% 19
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4.3 Conclusions 
 
As the goal of the project described in this thesis is the realisation of a device actually 
deliverable in clinical settings, the extraction cartridges need to be disposable.  This 
requires them to be easily manufactured, so as to keep down production related costs and 
allow the quick scale-up as the product is launching.  This confirms why PMMA, and 
thermoplastics in general, are a far better option than PDMS and silicon based materials 
for our prototypes.  In the light of what was described in the previous sections, it is easy 
to see that the developing of a fast prototyping method, compatible with materials 
employable in mass production, is a great advantage for this project.  It allowed the 
realisation of several generation of CNAs extraction cartridges, without having to wait 
for a photolithography mask, the production of a mould or even the long printing and 
cleaning times required by 3D printed structures.  The method, which allows extremely 
fast iterations, has been used since Spring 2015 by all members of our research group and 
collaborators181,182,183,184,185.  
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CHAPTER 5: miRNA BIOLOGICAL VALIDATION 
 
In Chapter 2, we discussed the relevance of miRNA circulating in plasma for diagnostics 
and prognostics purposes.  In the following chapter, we describe the results of a study on 
miRNA conducted with two different collaborations, one with Wilna Oosthuyzen and 
James Dear, CMVM, University of Edinburgh, within a Carnegie Trust grant, another 
with Juan Quintana Alcala, Paul Dickinson and Amy Buck, CIIE, University of 
Edinburgh.   
During the Carnegie Trust funded collaboration, we studied a miRNAs panel including 
miR-122, miR-126, miR-1913 and Let7d.  These miRNAs were chosen because of their 
potential as biomarkers but also for their different packaging and inherent stability in 
circulation.  Increased miR-122 levels have shown potential as a biomarker of drug-
induced liver injury and the marker showed preferential protein related (Ago2) 
packaging186,187; loss of miR-126 related to endothelial dysfunction, vascular diseases and 
type 2 diabetes188 and the marker is preferentially packaged within circulating micro-
particles189; miR-1913 and Let7d were chosen because of their common use as reference 
miRNAs190,191, due to their seeming higher stability. 
For the second study, we used an expanded panel, including the four miRNAs of panel 1, 
to allow for direct comparison of the results, plus miR-16-5p, miR-21-3p and miR-451a 
to widen the validity of our findings.  miR-16 and miR-451a are likely to derive from red 
blood cells (RBCs) and are thought to correlate with the degree of haemolysis63,192.  miR-
21, likewise other miRNAs, exists within extracellular protein complexes, mostly 
associated with Ago2 in human plasma43. 
In the next sections, we first show the effect of aging in blood samples, when left on a 
bench for 48 hours.  Following, we demonstrate that our microfluidic blood plasma 
separation module (BPS) does not affect miRNA amounts if compared to standard double 
centrifugation.  Finally, we demonstrate a microfluidic protocol on disposable cartridge 
for the extraction of of miRNA and characterise the extraction performance against the 
gold standard QIAGEN miRNEASY kit. 
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5.1 Materials & Methods 
5.1.1 Sample col lect ion  
Samples were obtained from healthy volunteers under a local ethical approval and 
conformably to the Declaration of Helsinki.  Fresh blood samples were processed within 
6 hours after blood collection unless otherwise stated for experimental purposes (such as 
in sample aging tests). 
To extract plasma, blood was spun down at 1600 g for 10 min, the supernatant fluid was 
collected in fresh tubes without disturbing the white blood cell layer (buffy coat), and a 
second 10 min spin at 12000 g was used to remove any cell debris.  Plasma was either 
processed or frozen (-80 °C) within 6 hours after blood collection unless otherwise stated 
for experimental purposes.  Once thawed, plasma was processed directly for miRNA 
extraction and never frozen again 
5.1.2 miRNA bench extract ion  
miRNA was extracted and purified using the miRNeasy Serum/Plasma kit (Qiagen) with 
an initial starting volume of 200 µl of plasma.  miRNAs were eluted in the final volume 
of 30 μL RNase-free water.  
Alternatively, when specified, total RNA from a total of 200 µl of cleared plasma was 
purified using the miRCURY RNA isolation kit - Biofluids (Exiqon).  In brief, 200 µl of 
plasma were incubated with 60 µl of Lysis solution, vortexed and incubated 3 min at room 
temperature.  After incubation, 20 µl of Protein Precipitation Solution was added to the 
mix, vortexed for 5s and spun down at 11,000g for 3 min at 4°C.  The supernatant was 
then mix with 270 µl of Isopropanol, passed through the microRNA Mini Spin Column 
BF (provided with the kit), and washed twice the washing buffers included in the kit.  The 
final elution was in 30 µl of nuclease-free distilled water, so that 1 µl of purified RNA 
correspond to 6 µl of input serum.  It is important to note that the concentration of the 
total RNA purified from human plasma was below the detection limit for standard 
spectrophotometry techniques (Nanodrop; Thermofisher).  Therefore, for subsequent 
studies by quantitative RT-PCR (qRT-PCR), we used a fixed volume of 2.5 µl of total 
RNA.  
5.1.3 miRNA microfluidic extract ion  
Microfluidic extraction were performed both from whole blood diluted in PBS (1:1 in 
volume) and including a BPS module within the platform, or from centrifuged plasma, 
within simplified cartridges not including a BPS module.  Microfluidic extraction 
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protocols were performed as described in section 3.2.  When using blood, a flowrate of 8 
ml/hr was used, and the cartridge included an additional outlet channel for the red blood 
cells enriched waste exiting the BPS chip.  When using plasma, it was pumped at 0.8 
ml/h, so as to simulate the flowrate of the stream coming from BPS chip. 
5.1.4 miRNA amplificat ion 
Reverse transcription reactions were performed using miScript II RT kit (Qiagen) in a 
510 μL RT reaction: 12μl 5x MiScript miScript HiSpec Buffer, 0.51µl 10x MiScript 
miScript Nucleic Mix, 0.51µl miScript Reverse Transcriptase Mix and 0.5µl of 0.1 pM 
synthetic cel-miR-39 (QIAGEN) to control for efficiency of RT and PCR reactions, as 
well as to monitor the presence of potential endogenous inhibitors derived from plasma 
samples.  These components were combined in what will be called master mix.  After 
mixing by inversion and centrifugation, the master mix was aliquoted into 0.2 mL RNase-
free strip-tubes, followed by the addition of 2.5 μL input miRNAs.  RT reactions were 
carried out on the Biometra thermal cycler (M-Medical) using the following conditions: 
37°C for 60 min, 95°C for 5min, and then hold at 4°C.  cDNAs were then diluted 1:10 
using nuclease-free water.  Diluted RT products were stored at- 20 °C prior to real-time 
PCR. 
Quantitative PCR reactions were performed in duplicate using the miScript SYBR 
Green PCR Kit (Qiagen).  Briefly, 10 μL reaction volumes were prepared in a 384-well 
plate using 5 µl SYBR Green MasterMix, 1µl of miScript universal primer (Qiagen), 1µl 
miRNA specific primer/probe mix, and 24 μL RT product per well.  The mix was 
aliqouted in duplicate into RNase-free strip-tubes and sealed with an optical plug.  The 
qRT-PCR reactions were carried out using the Lightcycler 480 (Roche, Basel, 
Switzerland) using the recommended following conditions: 95°C for 15 min followed by 
54 cycles of 95 °C for 15 s, 55°C for 30 s and 70°C for 30 s.  All reactions were run in 
duplicates.  The quantification cycle (Cq) is defined as the fractional cycle number at 
which the fluorescence passes the fixed threshold.  The raw data were analysed using the 
automatic cycle threshold setting for assigning the baseline and the threshold for Cq 
determination.  
For all RT-PCR and subsequent qPCR reactions, no reverse transcription enzyme controls 
(NEC) and no template controls (NTC) were included for all miRNA targets to determine 
the level of genomic-DNA contamination and tolerable threshold cut-off criteria.  
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Detectable signals < 40 Cqs were reported for the controls, Cqs > 40 were ignored if the 
lowest unknown Cq were 35193  
 
5.2 Results & Discussion 
5.2.1 Effect  of  delayed blood processing on miRNA  
As thoroughly discussed in 2.2.2, delays in sample preparation after blood draw, resulting 
in platelet activation and haemolysis, can affect the quality of miRNA extracted, thus 
leading to biased and inconclusive analysis.  We investigated the effect of a 48 h delay in 
sample processing as a pre-analytical variable on two panels of miRNAs.  Two blood 
samples per healthy volunteer (N=6) were obtained.  One sample was processed within 4 
hours after blood collection while the second sample was stored at room temperature and 
processed 48 hours after blood collection.  In both cases, following blood plasma 
separation by double centrifugation, plasma was frozen at -80 °C.  Before amplification, 
plasma was thawed and miRNA isolated using Qiagen miRNeasy extraction.  Marker fold 
change, with respect to the freshly processed samples, was calculated in absolute values 
as 𝐹𝐶 = 2|𝐶𝑞0−𝐶𝑞48| (where FC is the fold change, Cq0 the qPCR quantification cycle for 
sample processed at time 0 and Cq48 the quantification cycle for the sample processed 
after 48 h blood incubation) and plotted in the positive axis if the marker increased and 
in the negative axis if marker decreased after aging.  As shown in Figure 18, after 48 hour 
delay, average concentration of miR-1913, miR-126, miR-16-5p and miR-451 did not 
change significantly, although intra sample variance increased across subjects with 
occasional increases and decreases of the biomarker.  miR-21-3p and Let7d showed a 
general increase with processing delay.  miR-122 was the one which showed highest 
variability, with levels decreasing to the point that in some samples this biomarker was 
no longer detectable.  We show here that samples, with comparable initial marker levels, 
showed results differing up to more than two orders of magnitude after being subjected 
to the same 48h delay before processing.  This highlights the need for rapid sample 
processing to obtain accurate miRNA levels comparison. 
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Figure 18 Effect of time delay in sample processing on panel of miRNAs using standard plasma fractioning 
(double centrifugation) and miRNA extraction using the Qiagen RNeasy extraction protocol.  Data expressed 
as 𝟐
|∆𝐂𝐭|
 and reported on the positive axis when miRNA levels increased after 48 h aging and on the negative axis 
when miRNA levels decreased. Although the abnormal behaviour of miR-122 seems shown in only one data point, 
two other data points with similar results had to be discharged for inconsistency in the qPCR (Duplicates with Cqs 
differing more than 5, but both values showing 2-3 order of magnitude decrease with respect to the fresh sample). 
 
5.2.2 Blood processing and miRNA recovery :  microfluidic BPS vs 
double centr i fugat ion .  
In this module, we compared the amount miRNAs of panel 1 in plasma obtained by 
double centrifugation (DC) or microfluidic blood plasma separation (BPS).  As the 
microfluidic module works with blood diluted in phosphate buffer solution (PBS), 1:1 in 
volume, to allow for direct comparison all the blood samples (N=4) were diluted in PBS 
and then split in two aliquots, one for DC and one for BPS.  Fluidic isolation of cells may 
affect gene expression levels, as was shown that different levels are measured for some 
miRNAs, when the same sample is processed by standard or microfluidic methods194.  
However, Figure 19 illustrates comparable concentrations (p > 0.05 seen as not 
significant) obtained for miRNA panel 1, after standardised double centrifugation (DC) 
or microfluidic blood plasma separation (BPS) indicating that miRNAs are not trapped in 
this preliminary module nor that the chip walls release any PCR inhibitors inside the 
sample.  
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Figure 19 Comparisons of miRNA levels between two plasma extractions methods.  Comparison of miRNA 
expression levels after standard double centrifugation protocol (DC) and blood plasma separation platform (BPS). 
Duplicate RT-qPCR reactions for the panel of miRNAs (miR-122, miR-126, miR-1913 and let7d) extracted by 
Qiagen extraction protocol from plasma either fractioned by standard double centrifugation (DC) or through the 
blood plasma separation platform (BPS).  (Data is expressed as the raw Cq values ± SD, n=4) 
5.2.3 Evaluat ion of  an adapted protocol  for  microfluidic processing  
As shown in chapter 3, the microfluidic extraction module is engineered on the principles 
of standard Solid Phase Extraction (SPE) and two protocols were adapted for microfluidic 
extraction combining together steps from different commercially available kits. For the 
study on panel 1 we used a cartridge 9 described in section 3.3.1, with a protocol which 
integrates the Kurabo Quickgene membrane and reagents (specifics in Table 2). As this 
is not a protocol designed for miRNA nor circulating biomarkers extraction, and mostly 
derived from a genomic DNA extraction kit, its efficiency in the extraction of non-
abundant markers could not be taken for granted. To ensure the protocol chosen for the 
microfluidic extraction was suitable for the extraction of our miRNA panel, we chose to 
compare the adapted protocol (AP) on the bench, to the gold-standard Qiagen miRNeasy 
extraction protocol (GS). In spite the fact that the AP was not specifically adapted for 
microRNA extraction, results in Figure 21 show that the eluted product does contain 
detectable levels of our identified microRNAs with all Cqs within less than 2 Cqs 
difference from the gold standard reference and no significant differences found between 
the two extraction methods (Figure 20A). Using Bland-Altman analysis plots (Figure 
20B), we found the AP more successfully isolating miR-1913 (bias = 1.85) compared to 
miR-122 (-1.14) as a bias value of 1 equates to a difference of 1 qPCR cycle per method.  
However, the bias for two methods AP and GS - were only -0.47 (SD = 0.78) and -0.21 
(SD = 1.84) for miR-126 and let7d respectively showing the adapted protocol agrees with 
the gold standard extraction protocol for the isolation of these two miRNAs.  
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Figure 20 Comparison of miRNA expression levels from gold standard extraction protocol to adapted protocol 
for microfluidic operation.  A) Ten independent plasma RNA isolations with Qiagen miRNeasy Serum/Plasma (GS) 
were compared to the adapted protocol (AP) isolations in duplicate RT-qPCR reactions for the panel of miRNAs 
(miR-122, miR-126, miR-1913 and let7d).  (Data is expressed as the raw Cq values ± SEM, n=10, no significant 
differences).  B) Bland-Altman analysis plots were used for agreement between the two methods (GS and AP) 
showing the difference vs the mean at various Cq. Duplicate Cq values were used for this analysis.  Dashed lines 
indicate the 95% lower and upper limits of agreement. 
 
5.2.4 Microfluidics  vs  Benchtop adapted protocol ,  plasma extract ion   
After validating the extraction capability of the custom extraction protocol, we moved to 
the characterisation of the miRNA extraction with our microfluidic system, comprising 
the disposable cartridge and automation platform described along Chapter 2.  First, we 
characterised the performances of cartridge 9.  microRNA extractions from pure water 
were processed through the platform to check if some contaminants were present within 
the disposable cartridges or the reagents.  Following qPCR for the panel of miRNAs, no 
significant signal was detected for any of the respective miRNAs, confirming that there 
is no detectable contamination within the cartridge, meaning that the manufacturing 
process is clean enough as not to interfere with the results of plasma and blood 
extractions.  We next compared miRNA expression levels from bench adapted protocol 
(AP) eluate to the eluate resulting from the microfluidic device (MD) for plasma samples 
coming from the same patients.  Figure 21A shows a significant overall correlation 
(including the four miRNAs on the panel 1) between the adapted benchtop protocol 
compared to the miRNA platform (R=0.86) for cartridge 9.  
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During our second collaboration, the same procedure was repeated on miRNA panel 2, 
performing the extractions with cartridge 11 and its relative bench adapted protocol.  As 
can be seen in Figure 21B, cartridge 11 did not perform quite as well as cartridge 
9R, in spite of using a more complex extraction protocol which gave better 
results, during bench preliminary testing on cfDNA, then the one implemented in 
cartridge 9.  Indeed, as in Figure 21 the comparison is done between the microfluidic 
extraction and its bench counterpart, there is no difference in the chemistry involved in 
MD and AP, and data need to be interpreted only on how effectively the microfluidic 
system mirrors the bench protocol.  In cartridge 11 an Econospin membrane is 
implemented for the adsorption of nucleic acids.  This is a multilayer silica membrane 
with a high surface area, obtained through a woven structure, which gives the membrane 
a soft, fabric-like texture.  It was supposed that, in spite of the efforts to guarantee the 
proper drying of this membrane, some ethanol kept soaking it, resulting in PCR inhibition 
and incomplete elution of the membrane (as the chaotropic conditions, which favours 
NAs bonding, still applied).  This inhibitory effect on PCR was revealed spiking miR-39 
as endogenous control (miR-39 is a miRNA not found in humans) and comparing the 
amplification along sample and controls.  Indeed, contamination was found in several 
samples, spotted by delayed amplification of miR-39 in the sample with respect to the 
one in spiked water, bench extractions and non-contaminated samples (Results not 
shown).  When this delay was higher than 5 Cqs, data were discarded and are not shown 
in here.  Therefore, some of the samples shown had 2-3 Cqs amplification delay which 
explains why some of the samples are further than others from a linear behaviour in 22B.  
As cartridge 9 implements a Kurabo membrane, which is a single layer, porous 
membrane, 80 m thick, drying was straightforward even in microfluidic devices and 
ethanol contamination was not detected by miR-39 quantification. 
Before proceeding on further testing with cartridge 11, a thorough optimisation process 
was performed, as described in Chapter 6. 
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Figure 21 Comparison between adapted benchtop protocol and microfluidic protocol in terms of overall levels 
and reproducibility. All tests showed here used 400 l of plasma as inlet sample (A) Correlation plot for all 
miRNAs in panel 1 measured by qPCR in duplicate, expressed as raw Cq values for the adapted protocol compared to 
the miRNA platform using cartridge 9.  (B) Correlation plot for all miRNAs in panel 2 measured by qPCR, 
expressed as raw Cq values for the adapted protocol compared to the miRNA platform using cartridge 11. 
5.2.5 Microfluidic extract ion reproducibi l i ty  
A robust protocol for miRNA extraction needs to give the same results for multiple tests 
on the same sample.  Therefore, it was of interest to determine the repeated reproducibility 
between processing of similar samples on individual identical cartridges on the platform.  
Figure 22 shows the amplification of miR-126 through the raw Cq values for 3 individual 
runs for two plasma samples.  Each plasma sample was processed on three cartridges 9 
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and adapted bench protocol.  The coefficient of variation (CV, % expressed as the 
SD/mean*100) between the runs of the same samples on three identical microfluidic 
cartridges was small, respectively 0.88% and 1.28%.  These results show great potential 
for the future as were obtained through a semi-automated protocol and using cartridges 
made in-house.  Therefore, reproducibility is deemed to increase further once the process 
will be fully automated and the cartridges mass manufactured with quality control checks.  
Tests were performed only on miR-126 as these results were obtained during the 
preliminary phase of the Carnegie grant and it was preferred to focus on a marker 
consistently present in relatively high abundance in plasma from healthy volunteers.   
 
Figure 22 miRNA extraction reproducibility Comparison of the miRNA expression of miR-126 as representative 
miRNA between the adapted protocol and two samples (sample 1 and sample 2) processed through the platform on 3 
consecutive runs with cartridge 9. (Data from qPCR in triplicate expressed as mean ± SD. 
 
5.2.6 Microfluidics  vs  Gold s tandards ,  whole blood extract ion   
In order for sample preparation to be useful near patient, the tool has to be able to process 
whole blood and transform it into extracted miRNA.  The extraction capability of the 
integrated system, including BPS module and cartridge 9, was evaluated using fresh 
blood drawn from 6 healthy individuals processed within 6 hours after blood collection.  
The microfluidic extraction on panel 1 is benchmarked against the gold-standard protocol 
(benchtop plasma separation by double centrifugation and Qiagen miRNeasy protocol 
GS) as well as the bench-top adapted protocol (plasma separation by centrifugation and 
adapted nucleic acid isolation protocol AP).  The extraction of the panel of miRNAs 
including miR-126, miR-1913 and let7d and miR-122 was successful and qPCR showed 
levels comparable to the two bench protocols controls (Figure 24).  No significant signal 
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was detected for any of the respective miRNAs on our negative controls, confirming that 
there is no detectable contamination within the microfluidic cartridges or controls.  
 
Figure 23 Comparison of miRNA expression levels from gold standard bench protocol, adapted bench 
protocol and integrated microfluidic device from whole blood.  Whole blood from 6 healthy volunteers were 
processed by the microfluidic device and compared to standard RNA extraction from the gold standard bench 
protocol (GS) and adapted benchtop protocol (AP). qPCR of the panel of miRNAs in duplicate compared the yield 
from these benchtop protocol and the microfluidic device (MD).  (Data is expressed as the raw Cq values, mean ± 
SEM, n = 6) (no significant differences for each separate miRNA, Kruskal-Wallis ANOVA) 
 
Similar experiments were run during the second experimental phase.  This time, 
extractions from blood were run, per each sample (N=6), on both cartridge 9 and 11, 
and the QIAGEN bench protocol.  Results on the full panel of miRNAs are shown in 
Figure 25 A. We need to clarify that, for cartridge 11, protocol parameters were optimised 
with respect to the ones used in the experiment in the previous section, as described in 
the next Chapter.  Therefore, drying step was performed for 13 min and placing the heater 
above the membrane module with set temperature 90 °C, so as to guarantee complete 
removal of inhibitor compounds.  Data points were not included in this analysis when 
qPCR duplicates showed Cqs differing more than 5 Cqs. Results were very close among 
the three sample populations, with the bench gold standard performing statistically only 
0.7 Ct lower than MD2 and 1.4 Ct lower than MD1.  In spite of performing slightly worse 
in terms of Cts, MD1 results showed a much lower variance than MD2 (9.9 against 18.2, 
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with GS samples variance of 11.4).  This shows well in Figure 24B where we can notice 
a much tighter correlation between MD1 and GS than the one GS has with MD2.  
Compared to the data shown in 5.3.4, the much tighter fit to the trend-line shown by MD1 
must be attributed to the enhanced drying conditions used for this test (e.g. comparing 
results in Figure 21 and Figure 24).  Specifically, R2 passed from 0.56 to 0.85, in spite of 
running the tests with whole blood instead of extracted plasma, which could increase test 
variability (for MD2, R2 passed from 0.86 to 0.7 when using whole blood).  As data shown 
for miR1913 and miR126 were close across all samples to the negative control (deionised 
water), they were not used for the trend analyses.  As the bench treated samples suffered 
the same issue, we reckon a PCR optimisation would be required to increase higher 
sensitivity on these biomarkers.   
 
Figure 24 Direct comparison of miRNA extraction with cartridge 11 and 9, benchmarked against the gold 
standard bench protocol..  A) Whole blood from 6 healthy volunteers were processed by the two microfluidic 
devices (MD1=cartridge 11, MD2=cartridge 9) and compared to standard RNA extraction from the gold standard 
bench protocol (GS) (Data is expressed as the raw Cq values, mean ± SEM, n = 6)).  As negative control (ctrl) we 
used deionised water.  B) Correlation between Cqs obtained with microfluidic and bench extraction. Data points were 
not included in this analysis when qPCR duplicates showed Cqs differing more than 5 Cqs or Within 2 Cqs from 
negative control. 
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5.2.7 Eluate s tabi l i ty:  microfluidics  vs  gold s tandard  
Finally, we tested the stability of the miRNAs eluates obtained for extractions from blood 
from both the microfluidics (cartridge 9) and the gold standard isolation processes.  
Figure 25 shows the results obtained from the QIAGEN gold standard extraction (GS) 
and the microfluidic device (MD), performing qPCR both within 2 hours from the 
extraction and leaving the eluates for 48h, a time lapse approximately corresponding to 
delivering the samples to an analysis lab, on the bench.  No statistical difference was 
found among the populations, indicating that the microfluidic process stabilises miRNAs 
as well as the bench protocol.  Further testing would be necessary to generalise this 
finding on a wider miRNA panel and for different time lengths.  In addition, optimising 
qPCR to obtain lower Cqs would make quantification more precise.  Nonetheless, we 
consider this an interesting proof of concept on the stability of eluates obtained with our 
method. 
 
Figure 25 Comparison of miRNA expression levels from gold standard bench protocol and integrated 
microfluidic cartridge from whole blood in terms of overall levels and stability. Whole blood from 6 healthy 
volunteers were processed by the microfluidic cartridge and compared to standard RNA extraction from the gold 
standard QIAgen miRNAeasy bench protocol (GS) adapter bench protocol (AP) and microfluidic cartridge (MD). 
qPCR of the panel of miRNAs in duplicate compared the yield from these benchtop protocol and the microfluidic 
cartridge after the extraction and 48h later leaving the elution on the bench.  (Data is expressed as the raw Cq values, 
mean ± SEM, n = 6) (no significant differences for each separate miRNA, Kruskal-Wallis ANOVA). 
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5.2.8 Prel iminary tes ts  for  future work  
 
Figure 26 Exiqon miRCURY validation against QIAGEN miRNEASY. Whole blood from 9 healthy volunteers 
were processed through double centrifugation to extract plasma, miRNAs were either extracted by QIAGEN 
miRNEASY (N=6) or Exiqon miRCURY (N=3), as from the material and method section of this chapter. This 
comparison is only a preliminar comparison, tests were not paired and quantification was not performed on the same 
qPCR plate. 
As discussed in Chapter 3, this thesis does not focus on the development of new isolation 
methods, but on the adaptation of existing protocols for microfluidics purposes, and their 
implementation within disposable, user friendly cartridges.  It follows that part of the 
research process must involve testing on new extraction protocols. As shown in Figure 
26, preliminary work on a reduced miRNA panel (including miR16-5p, miR21-3p and 
miR451a) on plasma extracted from fresh blood from healthy volunteers (N=3), indicates 
that Exiqon miRCURY protocol (as described in the material and method section 5.1.2) 
might be a much more efficient tool than QIAGEN miRNEASY, for miRNAs isolation.  
For more reliable results, tests should be repeated with paired samples and a wider 
miRNAs panel, nonetheless the gap between the two sets of data is wide enough to 
assume the conclusions of a further analysis will not be qualitatively different.  
 
5.3 Conclusions and final remarks 
Delays in sample preparation after blood draw, resulting in platelet activation and 
haemolysis, can affect the quality of miRNA extracted, thus leading to biased and 
inconclusive analysis.  This was confirmed in section 5.2.1 on a seven miRNAs panel by 
testing samples with a 48h time delay in sample processing.  The differential effect of 
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aging observed indicates, not only that comparing samples isolated at different time 
points might be misleading, but that comparison is not straightforward if they are not 
processed quickly, even when samples are isolated at the same moment.  This clearly 
indicates the need for fast sample processing at the point of care.   
Our proposed solution is an integrated, self-contained and automated platform to deploy 
at the point-of-care, able to perform sample preparation without cumbersome equipment 
and trained staff.  We showed in section 5.2.2 that our microfluidic BPS chip is able to 
deliver plasma with the same miRNA quality as double centrifugation from several 
millilitres of blood, without the need of a centrifuge and batch processing, allowing for 
easy integration in a microfluidic workflow.  In the following sections two microfluidic 
cartridges for miRNA extractions have been benchmarked against the adapted protocols 
mirroring the same chemistry and the gold standard bench protocols.  The two adapted 
protocols were reproducibly integrated within two models of microfluidic cartridges 
(described in 3.2.1 and 3.2.2 respectively), for semi-automated miRNA extraction both 
from double centrifuged plasma and whole blood diluted 1:1 in PBS.  The disposable 
microfluidic cartridges, manufactured in-house, were shown to have no miRNA 
contamination and the addition of colourings (to ease visualisation of reagents through 
the various stages of the platform integration) had no effect on detected miRNA levels.  
The microfluidic extractions showed performances very close to the bench protocols (as 
from section 5.2.4 and 5.2.6) without involving manual steps and the overall 
performances were not far from the Qiagen RNeasy.  In spite their different chemistry, 
the two protocols implemented within the microfluidic format showed similar results.  
The more complex protocol involved in the extraction process of cartridge 11 did not 
enhance extraction efficiency, nonetheless, the lower variance obtained among the 
samples treated with this cartridge indicates a more reliable protocol.  
Recent preliminary tests, indicated that Exiqon kit miRCURY might be a more powerful 
tool for the extraction of miRNA than the other protocols.  As we showed the possibility 
to rapidly adapt the design of our microfluidic cartridge to implement different protocols, 
we cannot exclude, in the future, the implementation of the Exiqon protocol within our 
microfluidic workflow.  The proposed microfluidic process, as shown in here, is semi-
automated and required an operator to input the commands on a laptop.  Nonetheless, this 
can be easily automated from start (whole blood) to finish (microRNA eluate), therefore 
alleviating any human errors compared to the manual conventional bench protocol.  
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Some of the problems spotted during the study, such as the inhibitors contamination, were 
tackled in the work described in the next chapter, which deals with the optimisation of 
the extraction protocol. 
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CHAPTER 6: CFDNA: EXTRACTION OPTIMISATION 
In this chapter is described the optimisation of the microfluidic extraction protocol 
relatively to the cfDNA yield in the eluates.  It is important to notice that there are several 
differences between cfDNA and miRNA, not limited only to their chemical structure.  For 
example, as mentioned in Chapter 2, cfDNA has an average size of 166 bp, against the 
19-25 bp for miRNA.  Therefore, the optimisation of the extraction protocol for one of 
these biomarkers will not necessarily reflect in a higher yield for the extraction of the 
other. 
6.1 Material & Methods 
6.1.1 Cartr idge choice  
As a first step, it was necessary to determine which one of the cartridges described in 
Chapter 3, and characterised for miRNA extraction in Chapter 5, was the most suitable 
for cfDNA extraction.  Therefore, we analysed the eluates obtained using the same plasma 
samples and processing them through both cartridges. This test was only preliminary 
(N=2) but, as expected, cartridge 11, which implements a protocol developed on purpose 
for the extraction of cfDNA, gave results 1.9±0.5 times higher in terms of cfDNA 
concentration in the eluates (using qPCR on LINE primer, data not shown).  
6.1.2 Optimisat ion parameters  choice  
Once the cartridge to optimise had been chosen it was necessary to select which 
parameters to use for the optimisation.  During the first part of the tests which are shown 
in Chapter 5, PCR inhibition problems were encountered when working with cartridge 
11.  PCR inhibition can generally be attributed to protein contamination, due to an 
ineffective washing step, or presence of ethanol or other compounds (contained in 
chaotropic agents and washing buffers) in the eluate, due to ineffective drying before the 
elution step. In our case, we attributed inhibition to the difficulties of drying the thick, 
Econospin membranes in a microfluidic format.  Therefore, the parameter selections had 
to fall on those affecting the drying step. 
An efficient drying step is fundamental, not only to guarantee the absence of PCR 
inhibitors, but also to ensure the correct elution of the NAs adsorbed on the membrane.  
Indeed, any traces of ethanol, or any other compound which acts as a chaotropic agent, 
such as the washing buffers, within the membrane, would otherwise mix with the elution 
buffer reducing its solvating power. 
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Drying must be effective but also fast, so as to have a short protocol, compatible with 
POC applications.  Our drying strategy is establishing a continuous airflow at a high flow 
rate through the membrane.  Several parameters can be changed to affect the drying step, 
such as airflow rate, drying step duration, temperature of the process.  Among these I 
decided to fix the airflow rate to the maximum allowed by the syringe pump providing 
the compressed air, as the aim of the process is to be as quick as possible, and to change 
temperature and drying time. 
The membranes to dry are, in the case of cartridge 11, Econospin membranes (Epoch Life 
Sciences).  These membranes were considered the most suitable for the adsorption 
module of this cartridge, as they were shown to perform as well as the gold standard 
QIAGEN membranes, when used with the same protocol (See Figure 27A), for a tenth of 
the price.  
As from the schematic in Figure 27B, each of these membranes is actually composed of 
four single layers stacked together (named sub-layer thereafter).  Therefore, we decided 
to perform the tests both with adsorption modules containing the full four-layer stack, or 
a single sub-layer. 
Although it is obvious that a higher number of sub-layers should lead to a higher NA 
yield, it is important to notice that this advantage might be neglectable, in the case most 
of the NAs contained in the sample were absorbed in the first few sub-layers.  In addition, 
in the microfluidic format, after the elution step, a considerable volume of eluate is 
retained within the membrane.  This volume is larger when a higher number of sub-layers 
are present, which can potentially lead to a reduction in the overall NA yield at the end 
of the extraction.  In the next section, we will discuss steps taken to determine the optimal 
number of sublayers to implement within the microfluidic device. 
 
Figure 27 Econospin membranes (Epoch Life Sciences) A) Comparison on paired samples between QIAGEN and 
Econospin membranes extraction efficiency using the QIAGEN circulating nucleic acids kit; qPCR on LINE gave no 
significant differences between the extractions efficiency of the two membranes. B) simplified schematics of the 
four-membrane stack which composes each Econospin column etraction module.  
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6.1.3 Blood col lect ion and preparat ion  
In this module, four blood samples were obtained by healthy volunteers through the 
Scottish National Blood Transfusion Service.  The blood was spun down at 1,600 g for 
10 mins to remove cells, supernatant was collected in fresh tubes and spun again at 12,000 
g for 10 mins to remove cell debris.  Supernatant was collected and the four samples were 
pooled together to obtain 8 ml of plasma.  This was sub-divided in 20 aliquots of 400 l.  
6.1.4.  Microfluidic operat ion  
The drying tests were performed using a specifically designed chip containing only the 
membrane module plus one inlet and one outlet, connected to external tubes by threaded 
connections (Epigem ltd, UK).  So as to simulate the procedure within cartridge 11, the 
mirroring adapted bench protocol was chosen (details in 2.2.2).  Briefly, to the 400 l 
plasma sample were added 40 l Proteinase K, 400 l Lyse buffer and 5.6 l carrier RNA.  
The mixture was vortexed for 10 s and then incubated for 10 mins.  Following the 
incubation, the mixture was flushed through the membrane and washed with 200 l 
washing buffer WB1, 200 l washing buffer WB2 and 200 l ethanol.  The system was 
then dried following the specific conditions to be tested.  Finally, 65 l of elution buffer 
were injected on the membrane, incubated for 20 s and pushed by an airflow to a 
collection tube.  
For all samples, the maximum air flow rate obtainable with our syringe pump (610 ml/h) 
was used.  Drying time ranged between 3 and 13 min and tests were performed at room 
temperature or using our heater module (see 3.4.1) with set temperature 90°C.  
Additionally, we tested both modules including a single membrane, and modules 
including the complete set in which 4 membranes are stacked together. 
6.1.5 PCR 
Due to its abundance in plasma, characterisation was performed using qPCR primer 
sequences for LINE (Long interspersed nuclear elements) with amplicon size 90 bp; 
forward - 5’-TGCCGCAATAAACATACGTG -3’,  
reverse - 5’-GACCCAGCCATCCCATTAC-3’.   
PCR was performed on all the eluates using 2x Power SYBR® Green PCR Master Mix 
(Thermo Fisher Scientific) to amplify target with LINE primers final concentration 
200nM.  To allow for quantification a standard curve was created using a series of 5 serial 
dilutions of Human Genomic DNA.  Thermal cycling conditions were 600 s at 95°C 
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followed by cycling for 40 times, 15 s at 95°C and 60 s at 60°C.  Samples were amplified 
in duplicates using Mx3005P qPCR system (Agilent).  
 
6.2 Results and discussion 
6.2.1 Influence of  drying t ime and drying temperature on the f inal 
concentrat ion of  cfDNA  
 
Drying tests: one membrane 
 
Figure 28 Drying effect on cfDNA adsorption on a single membrane.  Pooled plasma from healthy volunteers was 
subdivided in 400 l samples which were processed following the extraction protocol (see 6.1.4) through individual 
microfluidic membrane modules including a single membrane. Drying airflow was 610 ml/h for all samples, drying 
time ranged between 3 and 13 min. Tests were performed at room temperature (RT) or using a heater with set 
temperature 90°C. qPCR results were converted into cfDNA ng/l using a standard curve run together with the 
samples. 
In Figure 28 is shown the qPCR quantification of the eluates obtained drying in different 
conditions a single silica membrane embedded within a microfluidic device.  In spite of 
the fact that the initial sample was the same, the critical effect of drying time resulted in 
no cfDNA recovery for drying shorter than 7 minutes for the room temperature drying 
(RT) and 5 minutes for the 90°C drying tests. After this, a plateau is reached and further 
drying does not result in any improvement in cfDNA yield. This indicates that even small 
amount of liquid on the membrane can have a powerful effect in inhibiting qPCR or the 
elution efficiency, and even small residues can make the difference. As expected, 
increasing the temperature resulted in shorter drying time. All experiments were run only 
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once for test condition, due to the high volume of pooled plasma required in order to 
process all specimens with the same starting sample.  
Drying test: four-membrane stack 
 
Figure 29 Drying effect on cfDNA adsorption on a four membane stack. Pooled plasma from healthy volunteers 
was subdivided in 400 l samples which were processed following the extraction protocol (see 6.1.4) through 
individual microfluidic membrane modules inlcuding a four-membrane stack. Drying airflow was 610 ml/h for all 
samples, drying time ranged between 3 and 13 min. Tests were performed at room temperature (RT) or using a heater 
with set temperature 90°C. qPCR results were converted into cfDNA ng/l using a standard curve run together with 
the samples. 
As shown in Figure 29, the same drying conditions applied to the single membrane device 
(room temperature and 90°C, drying time ranging from 3 to 13 minutes) were applied to 
a device including a four-membrane stack.  No cfDNA was detected for any drying time 
when drying at room temperature.  On the other hand, operating at 90°C for times longer 
than 9 minutes, a detectable amount of cfDNA was found, with levels about four times 
higher than the ones observed in the single membrane device.  This discredits the 
hypothesis made in 6.1 which most NAs might be adsorbed by the first sub-layers.  On 
the contrary, it seems to indicate that the adsorption on the membrane brings close to the 
saturation of the active sites.  Nonetheless, more data would be necessary for a precise 
quantification on the phenomenon that would lead to clear conclusions.  For now, we will 
limit our analysis to the fact that a 4 sub-layer module leads to higher yields than a single 
sub-layer one. The presence of 4 membranes makes, as expected, the device harder to 
dry, and without any heating this would be impossible in a reasonable time, compatible 
with point of care applications. 
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6.2.2 Eluate  retent ion  
In this module, the influence of the number of membrane on the final CNAs yield is 
investigated.  If on one hand a higher number of membranes results in a higher CNAs 
concentration in the eluate, in a seemingly linear fashion, on the other it also entails a 
lower volume of eluate.  This is true for both bench protocols and microfluidic 
applications.  Although, for our microfluidic system where it is necessary to force the 
eluate out of the membrane module using only an air flow, the problem has even more 
relevance.  Looking at the differences of both mechanical set-ups, during centrifugation, 
the force is applied directly to the fluid.  In the microfluidic extraction, it is the air flow 
pushing the fluid out of the membrane.  As the membrane is disk shaped, with air inlet 
and outlet placed at the centre of the disk, the airflow profile along the area will not be 
even.  Peripheral areas will experience a slower airflow and fluid might be stagnating 
around this areas.  In addition, the formation of preferential air passage through the 
membrane areas already dried will make this effect even more prominent.  
According to our data (N=2) (Figure 31), the eluate volume obtained with our 
microfluidic device decreases linearly with the number of membranes stacked in the 
extraction module following the equation:  𝑉𝑒 = 𝑉𝑖 − 12.67 ∗ 𝑁𝑚  (With Ve= final eluate 
volume [l], Vi= inlet elution buffer volume, in this case 65 l, and Nm= number of 
membranes in the adsorption module).  Volumes were measured using a 200 l pipette 
(Sigma Aldrich) 
 
Figure 30 Elution volume vs number of membranes stacked in the extraction module. cfDNA was performed on 
modules including 1,2 or 4 membrane sub-layers and eluate volume was measured with a 200 l pipette (N=2) 
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The straight fitting line in Figure 30 can be used, together with the line fitting the cfDNA 
concentration (CcfDNA [ng/l]) vs membrane number plot obtainable from the data shown 
in 6.2 (𝐶𝑐𝑓𝐷𝑁𝐴 = 0.24 ∗ 𝑁𝑚 − 0.15), for a useful calculation.  Indeed, multiplying the 
two equations representing how volume and concentration change with the membrane 
number, we obtain the equation indicating the total amount of CNAs recovered within the 
eluate versus membrane number.  This equation is plotted in Figure 31.   
 
 
Figure 31 Total cfDNA contained in the eluate vs number of membranes stacked within the extraction module. 
This curve was obtained by multiplying the equation of the line fitting data on the eluate volume vs number of 
membranes and the equation of the line fitting data on cfDNAs concentration vs number of membranes. 
These equations can be useful when choosing the adsorption module to adopt according 
to the application for which the cfDNA extraction is required.  For the qPCR amplification 
of a specific sequence, a concentrated sample might be the most suitable to analyse, 
resulting in lower detection limits and faster amplification.  In this case, working with a 
four membranes stack would be the preferential choice.  For other applications, such as 
NGS, where the total amount of nucleic acids in the sample is more important, our 
simplified equation indicates it would be preferable to work with an extraction module 
including two or three membranes stacked together.  
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6.3 Conclusions and final remarks 
In this chapter, dedicated to the optimisation of the cfDNA extraction protocol, I only 
dealt with a small part of the extraction module system.  The effect of the number of 
membranes to be stacked within the module, of the drying time and of the drying 
temperature, was studied in regard to the cfDNA concentration in the final eluate and the 
total volume of eluate recovered.  The tests performed in that respect demonstrated that 
the drying step plays a fundamental role in the process and if it is not thoroughly 
accomplished this leads to a totally ineffective elution, resulting in no cfDNA 
amplification in the samples.  The four-layer stack performed nearly four times better 
than the single membrane module, which seems to indicate the saturation of the active 
sites in the extraction module.  This four-layer module required a 13 min drying step at 
90°C, against 7 or 5 mins for the single membrane module, at room temperature or 90°C 
respectively.  For a drying time up to 13 minutes, drying at room temperature was found 
to be completely ineffective for the four-layer module.  The objective of this work is to 
produce a device for the fast extraction of CNAs, therefore I did not investigate longer 
drying times.  Finally, as the eluate volume decreases sensibly with membrane number, 
our calculations showed that operating with two membrane modules might be more 
performing than four-membrane modules in terms of total cfDNA amount recovered.  
This finding can be useful when the total amount of cfDNA is more relevant than its 
concentration, such as in sequencing or genotyping.  Our optimisation did not go beyond 
this point, although several other parameters may deserve attention in future work.  
Among these parameters, (i) the reagent chambers shape (ii) mixing strategy to enhance 
sample homogeneity before the adsorption step, and (iii) the washing step to optimise the 
wash buffer volumes and type are the ones which will be addressed in priority.  Shaping 
the membrane module so as to better fit the purpose of microfluidic extraction, e.g. having 
a tubular membrane, in which the same adsorption volume is distributed over a lower 
cross section, would ensure a more uniform drying and an easier elution step, resulting in 
a faster process.   
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CHAPTER 7: CONCLUSIONS/RELEVANCE STATEMENT 
 
Circulating nucleic acids (CNAs) hold great promises as diagnostic and prognostic 
biomarkers and could play a game changing role in the personalised treatment of several 
clinical conditions, including cancer.  One of the technical bottlenecks to overcome before 
the clinical implementation of CNAs-related technologies lies in sample preparation.  In 
this thesis, I have designed, manufactured and tested an integrated system for the sample 
preparation of CNAs from whole blood, in one single step and without the need of bulky 
equipment or trained staff. 
In Chapter 3, I described the design of the disposable cartridge and of the portable 
automation platform.  Several generation of cartridges were developed along my PhD, 
overcoming multiple issues, mostly related to fluid control, air-gaps removal, reagent 
mixing, minimisation in the use of external pieces of equipment (e.g. syringe pumps) and 
need for actuators.  In this thesis, I have only presented two of these designs.   
Chapter 4 describes the custom bonding method which allowed for the fast prototyping 
and small-scale manufacturing of the disposable cartridges, which greatly eased our 
research.  This method is currently used in our lab by all the researchers working on 
PMMA devices.  
Chapter 5 and Chapter 6 discuss the performances of the microfluidic system on the 
extraction of miRNA and cfDNA respectively.  This work demonstrates the successful 
integration of an existing blood-plasma extraction module within a nucleic acid extraction 
cartridge, achieved during this PhD project.  As shown in Chapter 5 and 6, the device 
performs well compared to the gold standards used in biological laboratories, which 
require several manual steps and cumbersome equipment.  The biological validation 
performed proved the effective implementation of two protocols with different chemistry 
within our microfluidic format.  Although several examples can be found in literature 
about NA extraction from blood in microfluidic devices, this is the first time a continuous 
blood plasma separation, from several millilitres of blood, is coupled with the extraction 
system.  Until now, plasma extraction was either performed off-chip or skipped, 
proceeding directly to cell lysis for genomic material extractions.  Those devices 
including plasma extraction did so by means of an integrated filter, not suitable for high 
volume operation and therefore for CNAs extraction.  Most of the current technology 
which could perform the same operation is based on bulky pipetting robots, not suitable 
for close to patient extraction and cost ineffective.   
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In spite of current limitations, the technology offers tested solutions to the problem of 
rapid and robust blood sample preparation for CNA-based tests.  The introduction of 
automated CNAs extraction tools will enable the standardisation of the sample 
preparation step in academic and industrial settings.  
Future work will go back to the study of the physical phenomena that rule the extraction 
process within the cartridge, so as to enhance the overall performances. These phenomena 
include the fluid mechanics of the mixing steps, thermodynamics and kinetics ruling the 
reactive steps and adsorption-desorption of CNAs on the membrane and the thermal 
transfer between the heater and the cartridge. Several steps need to be performed before 
the commercial availability of the device described.  In terms of product development, 
the future challenges are in the translation of the prototypes to high volume manufacturing 
set-ups and the stabilisation of reagent storage within the cartridges.  At the moment, the 
cartridges are filled manually a few minutes before sample processing and a PEEK 
connector is used to connect the cartridge with valves, inlet and outlet tubing.  Strategies 
to safely store the reagents within the cartridges, potentially for long periods, need to be 
thoroughly researched, although some steps have already been performed, including the 
implementation of blister pouches within the disposable cartridges.  Contact between 
samples and reagents with any of the non-disposable part of the platform needs to be 
totally avoided.  This includes valves and any external tubing.   
The automation platform will maintain its current characteristics of portability, small 
footprint and fast process, but work will focus in developing it into a more user-friendly 
instrument.  Instead of requiring to be controlled externally through a laptop, the 
automated protocol will be processed from the platform itself and cartridge replacement 
will be as simple as changing capsule in a coffee machine. As it is possible to implement 
protocols with different chemistry just making small adjustments to the microfluidic 
design, future work will test the advantages of different approaches, including 
commercially available protocols, such as the Exiqon miRCURY kit, and the 
development of custom methods, optimised purposely for our scopes. 
This future work will be explored within a phase I High Growth Spin Off grant funded 
by Scottish Enterprise (Start October 2017).  
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